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4 INTRODUCTION 
4.1 Cancer 
Multicellular organisms are composed of individual cells that are all derived from the 
fertilized egg, but which have differentiated according to a strict developmental programme, 
giving rise to a variety of specialized cell types. Most of these carry a complete organismic 
genome encoding far more information than any one of these cells will ever require. This 
endows the cells with versatility and the vital possibility to adapt to the ever changing needs 
of the organism as a whole, for instance by retaining the ability to proliferate and participate 
in tissue morphogenesis in response to injury. However, it also poses a danger to the 
organism, as the individual cells may erroneously gain access to information that should 
normally be denied to them. Specifically, the genomic sequences are vulnerable to somatic 
mutations and epigenetic changes which in some cases can change the behaviour of the cell.  
 
When such genomic alterations occur that result in a changed pattern of growth, favouring 
cell division and disfavouring cell death, a neoplasm can arise. Neoplasia literally means ‘new 
growth’ and can be used interchangeably with tumour, a Latin term meaning ‘swelling’. As 
long as a tumour respects the normal boundaries of the tissue of origin, it is said to be benign. 
However, upon the acquisition of additional genomic changes, a tumour can progress to 
invade and destroy neighbouring tissue structures and spread to distant sites where it can 
establish new tumours termed metastases. These are the common characteristics of malignant 
tumours, collectively referred to as cancers.  
 
4.1.1 The hallmarks of cancer 
It has long been suggested that tumour development proceeds via a process adhering to the 
principles of Darwinian selection, in which a succession of genetic changes conferring growth 
advantages are selected for, resulting in the progressive development of malignant traits [1]. 
In 2000 D. Hanahan and R. A. Weinberg published a seminal paper titled “The Hallmarks of 
Cancer”, suggesting a collection of six such traits or capabilities that are shared by most and 
perhaps all types of human cancers, and which should thus be considered the cornerstones of 
selective pressures acting upon a developing tumour [2]. These capabilities are self-
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sufficiency in growth signals, insensitivity 
to anti-growth signals, evasion of apoptosis, 
limitless replicative potential, sustained 
angiogenesis, and tissue invasion and 
metastasis (Figure 1). Later, the evasion of 
immune surveillance has been suggested as 
an additional hallmark [3]. 
 
Self-sufficiency in growth signals 
Normal cells usually exist in a quiescent 
state requiring mitogenic growth signals 
from their surroundings to reenter the cell 
cycle. These signals can be provided as 
diffusible growth factors (GFs), by 
extracellular matrix components, or by 
neighbouring cells, and are generally 
transmitted into the cell by transmembrane receptors, often belonging to the tyrosine kinase 
receptor family. Self-sufficiency in these signals can be achieved through autocrine supply of 
GFs, overexpression of receptors, or alterations in components of downstream cytoplasmic 
signalling [2]. 
 
Insensitivity to anti-growth signals 
The quiescent state of resting cells is not only maintained by the absence of mitogenic signals, 
but also by the presence of signals actively repressing progression through the cell cycle. Such 
signals are transmitted to the cell through transmembrane receptors paralleling the situation 
for growth signals, and the cellular response is often funnelled through effects of inhibitors of 
the cell cycle machinery such as the retinoblastoma protein (pRB). Insensitivity to these 
signals can be achieved through downregulation of receptors, direct inactivating mutations of 
RB, or mutations of components of the cell cycle machinery [2]. 
 
Evasion of apoptosis 
Cell proliferation is balanced by cell death in normal homeostatic tissues. As a safeguard 
against untimely proliferation induced by the activation of oncogenes, the cell’s innate 
response is the activation of apoptosis. This commonly occurs through p53-dependent 
Figure 1. The hallmarks of cancer as suggested by 
Hanahan and Weinberg. Adapted from [2]. 
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activation of the so-called intrinsic apoptotic pathway (see section 4.3.2), and inactivation of 
this pathway through direct p53 mutation or deregulation of upstream or downstream p53 
signalling is thought to be an almost universal occurrence in tumour cells [4].  
 
Limitless replicative potential 
The number of replicative cycles a cell can encounter is normally limited by the erosion of 
telomeres associated with every replication cycle, resulting in the inability to protect the ends 
of chromosomal DNA after 60-70 doublings. The maintenance of telomeres in tumour cells 
can be achieved by the expression of the telomerase reverse transcriptase (TERT), whose 
activity is normally limited to a very select subset of somatic cells such as stem cells [5]. In 
addition, about 10% of tumours can engage an alternative strategy to maintain telomeres, 
termed ‘alternative lengthening of telomeres’ (ALT) [6;7]. 
 
Sustained angiogenesis 
The diffusion capacity of nutrients, metabolites and gases limits the distance from a vascular 
capillary at which a cell can survive to approximately 100 μm. Thus, an expanding tissue 
mass must be able to support the ingrowth of new vessels if it is to exceed a certain size. The 
activation of this so-called angiogenic switch can be accomplished by increased expression 
and secretion of soluble factors which can bind to receptors on endothelial cells stimulating 
the sprouting of novel vessels. Examples include vascular endothelial growth factor (VEGF) 
and fibroblast growth factors (FGFs). Additionally, the secretion of inhibitory factors can be 
downregulated [2].  
 
Tissue invasion and metastasis 
The ability of cancer cells to grow not only in an expansive manner, but to expand growth 
beyond its natural boundaries, thereby infiltrating neighbouring structures, is a defining 
characteristic of a malignant tumour. This allows cancer cells to enter into the blood stream 
(intravasate), be transported to distant tissues where it can lodge in microvessels, and in some 
cases extravasate and successfully form new colonies of cancer cells. These distant metastases 
are responsible for the vast majority of cancer-related deaths [8]. However, this hallmark 
stands out from the other five in that it is not intuitively apparent why such a capability should 
be selected for. Recent evidence supports the notion that metastatic dissemination indeed does 
not depend on the acquisition of additional genetic alterations, but rather is an inadvertent 
side-effect of primary tumour formation. In particular for carcinomas, i.e. malignant tumours 
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arising from epithelial tissues, a process termed the ‘epithelial-mesenchymal transition’ 
(EMT) is suggested to be crucial. EMT is a developmentally programmed process, involving 
the activation of a specific set of transcription factors, enabling epithelial cells to transiently 
enter a mesenchymal state allowing it to cross the basal lamina and invade the extracellular 
matrix of the underlying stroma. It is envisioned that tumour-associated stroma can supply 
tumour cells with heterotypic signals activating EMT, thus enabling invasion, intravasation 
and consequent dissemination of cancer cells. The successful survival and proliferation of 
these cells at new locations resulting in the formation of macroscopic metastases, is thought to 
be a very rare event when compared to the number of tumour cells that originally disseminate, 
and the mechanisms governing such colonization are currently unresolved (reviewed in [9]). 
 
Additional hallmark: Evasion of immune surveillance 
In addition to the six hallmarks of cancer originally suggested by Hanahan and Weinberg, a 
seventh hallmark, evasion of immune surveillance, has later been suggested [3]. It is clear that 
our immune system has evolved to employ numerous strategies to suppress cancer 
development, and consequently cancer cells will have to select for properties that allow them 
to evade this immune surveillance if the cancer is to succeed. The interplay between tumour 
cells and the cells of the innate and adaptive immune system is highly complex. However, 
three main strategies have been suggested to be employed by cancer cells to reduce the 
pressure imposed by the immune system. First, cancer cells can ‘hide’ from the T 
lymphocyte-mediated response by downregulating their expression of human leucocyte 
antigen (HLA) type I molecules. Secondly, cancer cells can actively repress the induction of 
the extrinsic apoptotic pathway involved in some forms of T lymphocyte-mediated cancer cell 
killing. Thirdly, cancer cells can induce an immune subversion, i.e. the active suppression of 
the immune response (reviewed in [3]).  
 
4.1.2 The nature of genetic perturbations in cancer cells 
Through comprehensive investigation into signalling pathways involved in the development 
of the hallmarks outlined above, numerous oncogenes and tumour suppressor genes have been 
identified and characterized. Some of these are found mutated frequently, examples of which 
include PI3K (phosphoinositide 3-kinase), RAS, TP53 (tumour protein p53), PTEN 
(phosphatase and tensin homologue), RB, and CDKN2A (cyclin-dependent kinase inhibitor 
2A, encoding p16INK4a and p14ARF) [10]. When large-scale sequencing of multiple cancer 
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genomes became available, there was considerable expectation that novel high-frequency 
mutations would be discovered, providing insight into new pathways important for tumour 
development. However, such studies have failed to identify previously unrecognized 
commonly mutated genes. Rather they conclude that every tumour harbours a complex 
combination of low-frequency mutations that drive the tumour phenotype [11-16]. In other 
words, even though the genetic changes driving the tumour phenotype might result in a 
relatively limited number of common functional hallmarks, the genetic changes themselves 
display tremendous complexity and heterogeneity. This has led to the definition of cancer as 
“a complex collection of distinct genetic diseases united by common hallmarks” [10].  
 
4.1.3 The tumour microenvironment 
The genetic and phenotypic changes described above, all refer to the primary tumour cells per 
se. It has, however, become increasingly acknowledged that the tumour stroma plays a key 
role in supporting tumour growth. This stroma consists of extracellular matrix as well as 
various non-transformed cells such as fibroblasts, myofibroblasts, leukocytes, myoepithelial 
and endothelial cells [17].  
 
Figure 2. The tumour microenvironment. The cancer cells are surrounded by a microenvironment comprised 
of endothelial cells from blood and lymphatic vessels, stromal fibroblasts, and several bone marrow-derived cells 
(BMDCs) including macrophages, myeloid-derived suppressor cells (MDSCs), TIE2-expressing monocytes 
(TEMs) and mesenchymal stem cells (MSCs). Adapted from [18]. 
  12 
A normal stromal environment has been shown to exert an inhibitory role on tumour growth, 
but evidence suggests that heterotypic interactions between the transformed cells and the 
surrounding stroma induce substantial gene expression and epigenetic changes in the latter 
part, leading to phenotypic changes better suited to support the tumour [10;19]. In addition, 
there is evidence that tumour cells can recruit bone marrow (BM)-derived mesenchymal cells 
and haematopoietic cells to the tumour site, which subsequently establish as an integral part of 
the tumour stroma [20;21]. This novel microenvironmental niche created by the tumour cells 
not only serves as a more permissive neighbourhood, but is thought to play an active role 
throughout cancer initiation, progression and metastasis through the action of secreted factors 
and cell-cell interactions. 
 
4.2 Cell proliferation 
Most cells in a multicellular organism at a given time exist in a quiescent state, requiring 
specific stimulation of growth signals to enter a proliferative state. These signals act on 
components of the cell cycle, which describe the distinct stages a cell passes through to 
prepare for and execute cell division. Originally, cell division was divided into two stages: 
mitosis (M) and interphase. Later the interphase stage of cell division was divided into three 
distinct phases: the gap 1 (G1) phase in which the cell prepares for DNA synthesis, the 
synthesis (S) phase in which DNA is replicated, and the gap 2 (G2) phase in which the cell 
prepares for mitosis [22]. The progression through the phases of the cell cycle can mainly be 
attributed to the action of two classes of proteins, the cyclins and the cyclin-dependent kinases 
(CDKs), whereas negative regulation is provided by various cyclin-dependent kinase 
inhibitors (CKIs). 
 
4.2.1 Cell cycle progression 
CDKs are serine/threonine protein kinases, expressed at relatively stable levels throughout the 
cell cycle. Their activation requires the binding of cyclins that confer both substrate 
specificity and regulation of the CDK enzymatic acitivty [23]. The cyclin levels rise and fall 
in a coordinated manner throughout the cell cycle (Figure 3). This leads to periodical 
activation of the CDKs, laying the grounds for the ordered induction of downstream events 
associated with progression through the different cell cycle phases. The human genome 
contains 13 loci encoding CDKs and 25 loci encoding cyclins [24]. However, only subsets of 
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these are directly involved in driving the cell cycle, including the interphase CDK2, CDK4 
and CDK6; the mitotic CDK1; and ten cyclins belonging to four different classes termed A-, 
B-, D- and E-type cyclins. 
 
 
Figure 3. The fluctuation of cyclins during the cell cycle. The figure depicts how D-type cyclins are expressed 
in a mitogen-dependent manner. This initiates signalling resulting in the sequential and transient expression of E-
, A- and B-type cyclins in restricted phases of the cell cycle. Adapted from [25]. 
 
 
The entrance of a cell into the G1 phase of the cell cycle is marked by the induction of D-type 
cyclins. Transcriptional induction of these cyclins occurs in response to several mitogenic 
stimuli [26-32]. Anti-proliferative stimuli on the other hand, can repress their expression [33-
37]. In addition, levels of D-type cyclins are under post-transcriptional control, with 
regulation of their degradation through the ubiquitin/proteasome pathway partly depending on 
phosphorylation events imposed by glycogen synthase kinase-3β (GSK-3β) [38-42]. Once 
induced, D-type cyclins bind to and activate CDK4 and CDK6. One of the targets of CDK4/6-
cyclin D is pRB, which upon partial phosphorylation releases members of the transcription 
factor family E2F, leading to transcription of E2F-responsive genes required for further 
propagation through the cell cycle [43;44]. Amongst the earliest E2F-induced genes are E-
type cyclins [45]. This enables activation of CDK2 by cyclin E in late G1 phase, resulting in 
further pRB phosphorylaton [45;46]. The resulting hyperphosphorylation of pRB defines the 
so-called restriction point (R) at which the cell does not need further stimulation by mitogenic 
signals to complete its cell cycle. During late G1/early S phase, E2F activity induces 
transcription of A-type cyclins, enabling the formation of CDK2-cyclin A complexes which 
play an active role in DNA synthesis through phosphorylation of proteins involved in DNA 
replication such as cell division cycle 6 (CDC6) [47;48]. Towards the end of interphase, 
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cyclin A levels increase further, allowing its association with CDK1, and this complex is 
thought to be essential for the initiation of prophase, marking the G2/M phase transition [49]. 
Following the nuclear envelope breakdown, cyclin A is degraded, and this facilitates the 
formation of CDK1-cyclin B complexes which actively participate in and complete mitosis 
[24] (Figure 4). 
 
Figure 4. The cell cycle stages. The various stages of interphase and mitosis are shown with the site of activity 
of regulatory CDK-cyclin complexes indicated. G0 phase represents a resting/quiescent phase entered by the cell 
upon lack of mitogenic signals or the presence of anti-mitogenic signals. Cells in G0 account for the major part 
of the non-growing, non-proliferating cells in mammals. Adapted from [50]. 
 
The cell cycle model outlined above represents the so-called ‘classical model’, in which the 
basic concept is that each phase is driven by specific CDK-cyclin complexes. This model has 
recently been challenged by numerous systematic knock out (KO) studies in mice, 
demonstrating that CDK2, CDK4 and CDK6 are redundant for cell cycle progression in most 
cell types, as their function can generally be replaced by CDK1 [51]. CDK1 on the other 
hand, is absolutely required to drive the embryonic cell division, as its elimination prevents 
embryos from developing beyond the two cell stage [51]. A similar situation has been 
demonstrated for cyclins, with cyclin A2 and B1 emerging as the most non-redundant family 
members (reviewed in [23;52]). While these studies have revealed previously unrecognized 
redundancy in cell cycle regulation, the general principle of the classical model is still thought 
to be valid in most cell types in the presence of the full complement of CDK and cyclin 
family members. However, as deletion models have demonstrated, different CDKs and 
cyclins can have tissue- or cell-specific functions in adult tissues [23]. 
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4.2.2 Cell cycle checkpoints 
As already illustrated by figure 4, the cell cycle is organized much like a timer that triggers 
the events of the cell cycle in a set sequence. The CDK-cyclin complexes can be viewed as 
biochemical switches in this timer, ensuring the timely activation of events. Upon this basic 
programme, a number of checkpoints are imposed that can turn the switches on or off 
according to the state of the cell.  
 
 
Figure 5. The cell cycle control system. The figure illustrates some of the crucial steps in the progression 
through and regulation of the cell cycle. Major check points are indicated with thick arrows. (APC/C: anaphase-
promoting complex/cyclosome). Adapted from [53]. 
 
Examples of biochemical events providing such modulation of CDK-cyclin activity are 
mentioned in section 4.2.3. There are many ways of defining cell cycle checkpoints; however, 
in its simplest sense it can be divided into three major regulatory transitions. The first is the 
already mentioned restriction point at which mitotic and anti-proliferative signals are 
integrated to decide whether the cell shall indeed start replicating its DNA. The second is the 
G2/M checkpoint in which the cell ensures that DNA replication is complete before 
committing to mitosis. The third is the metaphase-to-anaphase transition in which the cell 
ensures that all chromosomes are correctly aligned and attached to the spindle before the cell 
proceeds to cytokinesis [53]. In addition to the sensing of events intrinsic to the progression of 
the cell cycle, there are multiple points at which the cell cycle can arrest in response to DNA 
damage, ensuring time for the damage to be repaired before further propagation through the 
cycle. DNA damage halts the cell cycle primarily during G1 phase, at the G1/S transition, or 
at the G2/M transition (Figure 5) and will be described in more detail in sections 4.4.3.2 and 
4.5.3.2. 
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4.2.3 Regulation of CDK activity 
As has already been mentioned, CDK activation requires the availability and binding of a 
proper cyclin. In addition, CDK activity is regulated by post-translational modifications 
(PTMs) and CKIs. 
 
Post-translational modifications 
Full activation of a CDK-cyclin complex requires phosphorylation on specific threonine 
residues: T161 in CDK1, T160 in CDK2 and T172 in CDK4 [54;55]. Such activating 
phosphorylation is ensured by the enzyme CDK-activating kinase (CAK) [56]. Other kinases, 
such as WEE1 and myelin transcription factor 1 (MYT1) catalyze phosphorylation of 
threonine and tyrosine residues resulting in inhibition of CDK-cyclin complexes even in the 
presence of activating phosphorlyation [57-60]. Inhibitory phosphorylation of CDKs is 
assumed to be constitutive, suggesting that the regulation lies in the activity of the CDC25 
family of phosphatases, which can specifically remove these phosphate groups [61-63].  
 
Cyclin-dependent kinase inhibitors 
There are two main families of cell cycle inhibitors: the INK4 (inhibitor of CDK4) family 
(p15INK4b, p16INK4a, p18INK4c, and p19INK4d), and the Cip/Kip (CDK-interacting protein/Kinase 
inhibitory protein) family (p21Cip1, p27Kip1, and p57Kip2) [64]. Members of the INK4 family 
specifically inactivate the G1-phase CDKs by complexing with CDK4 and CDK6 prior to 
their association with D-like cyclins, thereby preventing CDK-cyclin complex formation [65]. 
This blocks pRB phosphorylation and E2F release, resulting in G1 arrest. Members of the 
Cip/Kip family can inhibit the already formed CDK-cyclin complex. They generally display 
high affinity for G1- and S-phase complexes, but can additionally inactivate the M-phase 
complex CDK1-cyclin B [66-69].  
 
The expression of CKIs varies according to extrinsic and intrinsic cell signals. For instance, 
the CDKN1A (cyclin-dependent kinase inhibitor 1A) locus encoding p21Cip1, is under the 
transcriptional control of p53 [70]. p53 is positioned as an integrator of several stress sensing 
signalling pathways in the cell, being activated in response to DNA damage (see section 
4.4.3.1). The resulting transcription of p21Cip1 arrests the cell in G1, allowing time for DNA 
repair [71]. In addition, p21 Cip1 is able to induce G2- and S-phase arrest [72-74], and has been 
implicated in terminal differentiation [75] and senescence [76]. An example of cell cycle 
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inhibition resulting from extrinsic anti-proliferative signalling is the expression and activation 
of p15INK4b and p27Kip1 in response to binding of transforming growth factor β (TGF-β) to its 
receptor [77;78].  
 
There exists an intimate interplay between CDK-cyclin complexes and CKIs. One example is 
provided by CDK4/6-cyclin D complexes which, in addition to facilitating E2F-mediated 
cyclin E transcription, also ensures titration of p21Cip1 and p27Kip1 from the CDK2-cyclin E 
complexes, thereby relieving their inhibition (reviewed in [79;80]). In response, active CDK2-
cyclin E phosphorylates p27Kip1, priming it for degradation and thus further amplifying the 
CDK2 activity necessary for the G1/S transition [81].  
 
4.3 Apoptosis 
In 1842 Carl Vogt published his work on the developmental history of the common midwife 
toad (“Untersuchungen über die Entwiklungsgeschichte der Geburtshelferkrœte [Alytes 
obstetricians]”). This probably constitutes the first mention of naturally occurring cell death. 
During the next 120 years, cell death other than damage-induced necrosis received little 
attention. The study of the phenomenon then started to gain some pace, with the realisation 
that cell death can be a programmed, normal morphogenic event in the development of 
multicellular organisms [82;83]. Further morphological characterization by light microscopy 
led to the distinction between coagulative necrosis and so-called shrinkage necrosis in 1965, 
both phenomena being observed in parallel in the ischemic liver [84].  
 
In the following years, the distinction between these two forms of ‘necrosis’ was described in 
further detail using electron microscopy, preparing the grounds for a paper by J. F. Kerr, A. 
H. Wyllie and A. R. Currie published in British Journal of Cancer in 1972 [85] in which the 
term apoptosis was coined. Here, recent advances by their and other research groups 
describing a new mode of cellular death with ultrastructural features consistent with an active 
and controlled phenomenon is described, culminating in the important conclusion that it 
represents a “basic biological phenomenon with wide-ranging implications in tissue kinetics”. 
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Figure 6. Illustration of the apoptotic process in vivo.  The figure illustrates the separation of the apoptotic 
cell from its surrounding cells followed by condensation, fragmentation and subsequent engulfment by 
neighbouring cells. Adapted from [85]. 
 
Due to the associations of the term ‘necrosis’ with cell death imposed by noxious agents, the 
authors did not favour the continued use of ‘shrinkage necrosis’ to describe a process which 
was conceived as essential in the normal development and physiology of multicellular 
organisms. The word ‘apoptosis’ was therefore proposed. The word is taken from Greek, 
originally describing the ‘dropping off’ or ‘falling off’ of petals from flowers, or leaves from 
trees. In the context of a multicellular organism, this parallels the separation of the dying cell 
from the surrounding cells, which is followed by its condensation, fragmentation, and 
phagocyttic engulfment by neighbouring cells (see illustration from the original publication, 
figure 6). The authors conclude that apoptosis is “well suited to a role in tissue homeostasis” 
and refer to experiments demonstrating the occurrence of significant levels of apoptosis in 
healthy tissues, during embryogenesis, teratogenesis, atrophy/involution, and in growing 
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malignant neoplasms. Until this point the deregulation of mitosis had received much attention 
when seeking to explain the mechanistic basis for tumour development, but importantly the 
authors now postulated that deregulation of apoptosis might be equally important.  
 
4.3.1 The signalling pathways involved in apoptosis  
Several years passed between this important definition of apoptosis on the basis of 
electronmicroscopic features and the unravelling of its molecular basis. In 1980 A. H. Wyllie 
provided the first report of the association between the observed chromatin condensation and 
activation of an endogenous endonuclease, resulting in internucleosomal double-strand 
cleavage of DNA, producing the characteristic laddering of DNA upon agarose 
electrophoresis [86].  
 
Four years later, the B cell leukaemia/lymphoma 2 (BCL-2) gene was identified based on its 
position at the break point of the t(14;18) translocation commonly found in follicular 
lymphoma and occasionally in acute lymphoblastic leukaemia (ALL) [87;88]. Because this 
translocation placed BCL-2 in close association with the enhancer region of the human μ 
chain gene, it was immediately hypothesized that this would lead to an increase in BCL-2 
protein expression that might be directly involved in B cell oncogenesis. In 1988 the first 
report that gave experimental support to this hypothesis was published, showing that BCL-2 
could cooperate with cellular myelocytomatosis oncogene (c-myc) to promote proliferation of 
B cell precursors, some of which became tumourigenic [89]. Importantly, this paper also 
showed that if indeed BCL-2 was to qualify as a proto-oncogene, it would stand out from 
other proto-oncogenes known until then, as it seemed to provide a survival advantage rather 
than a drive for proliferation. This was soon confirmed by several papers from S. J. 
Korsmeyer’s group, reporting survival advantages in the absence of growth advantage in cells 
overexpressing BCL-2 [90-92]. The same group could also show that BCL-2 localizes to the 
inner mitochondrial membrane [93]. Eventually, BCL-2 turned out to be the first identified 
member of a large family of proteins characterized by the presence of BCL-2 homology (BH) 
domains. This group consists of both pro- and anti-apoptotic members, and plays a pivotal 
role in the regulation and execution of the intrinsic apoptotic pathway. 
 
In parallel with the unravelling of the function of BCL-2 emanating from work on human and 
murine systems, studies of the genetic control of apoptosis in the nematode Caenorhabditis 
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elegans (C. elegans) provided important clues to other crucial components of mammalian 
apoptosis. In 1992, a C. elegans homologue to BCL-2 was identified with the discovery of the 
gene ced-9 (cell death abnormal) which acted to inhibit apoptosis [94]. However, already in 
1986, two other genes; ced-3 and ced-4 were shown to be crucial for developmental apoptosis 
in C. elegans [95]. Seven years later, ced-3 was cloned, and the predicted Ced-3 protein was 
found to show similarity to the already known mammalian interleukin-1β (IL-1β) -converting 
enzyme (ICE) and Nedd-2 [96]. ICE had an already identified function as a cysteine protease, 
responsible for cleaving and activating IL-1β. Consequently it was proposed that Ced-3 may 
act as a cysteine protease in the initiation of programmed cell death in C. elegans, and that 
cysteine proteases also function in programmed cell death in mammals. Within three years, a 
total of ten human homologues had been identified, and subsequently termed cysteine-aspartic 
proteases (caspases) [97]. It was soon confirmed that many of the caspases indeed played a 
central role in apoptosis in humans.  
 
As opposed to the case for Ced-3, no human homologue for the putative Ced-4 protein was 
known at the time of the cloning of ced-4 in 1992 [98]. In 1997, the human homologue, 
termed apoptotic protease activating factor-1 (APAF-1) was cloned, and it was concurrently 
demonstrated that APAF-1 binds cytochrome c [99]. Shortly before this discovery, the release 
of cytochrome c from the mitochondrial intermembrane space to the cytosol had been 
identified as a crucial event in the induction of the apoptotic programme [100]. In the 
subsequent year, it was found that cytochrome c release was linked to caspase-3 activation 
[101], and that cytochrome c release could be inhibited by BCL-2 [102;103]. This contributed 
to a more coherent outline of the mammalian apoptotic pathway as we know it today. Finally, 
in 1998 the gene product of egl-1, a gene identified in egg-laying abnormal C. elegans 15 
years earlier [104], was cloned. The resulting protein, Egl-1 was shown to act in a 
proapoptotic manner, interacting physically with Ced-9, and to contain a region similar to the 
BH3-domain found in known pro-apoptotic members of the BCL-2 family in humans [105]. 
Consequently, the following sequence of events was proposed for the apoptotic process in C. 
elegans: Egl-1 can activate apoptosis by binding to and directly inhibiting the activity of Ced-
9, thus releasing the cell death activator Ced-4 from an inhibitory Ced-9/Ced-4-containing 
complex. This model has since been acknowledged as the general outline of C. elegans 
apoptosis, and the homologies of this highly conserved process in the nematode and 
mammals, can be represented in a simplified manner as demonstrated in figure 7. 
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Figure 7. The homologies of the highly conserved process of apoptosis. The figure shows the parallel 
function of the homologous proteins in the apoptotic process in C. elegans and the intrinsic apoptotic pathway in 
mammals. Modified from [106]. 
 
 
The mammalian pathway outlined above, corresponds to the intrinsic/mitochondrial apoptotic 
pathway. In addition, there exists an extrinsic apoptotic pathway elicited by the binding of 
ligands to a subset of receptors belonging to the tumour necrosis factor (TNF) superfamily. 
The activation of these so-called death receptors initiate a cascade of events either 
culminating directly in caspase-3 activation, or resulting more indirectly in caspase activation 
through effects on the mitochondrial apoptotic machinery (Figure 8) (revewed in [107]).  
 
 
 
Figure 8. Overview of mammalian 
apoptotic pathways. 1) The extrinsic 
pathway. Binding of ligands to death 
receptors leads via adaptor proteins to 
the activation of caspase-8, which can 
either activate effector caspases directly 
or activate the intrinsic pathway through 
cleavage of the BCL-2 protein BID. 2) 
The intrinsic pathway. Cellular stress 
leads to increased activity of the pro-
apoptotic members of the BCL-2 family 
(BH3-only proteins), and this facilitates 
permeabilization of the outer 
mitochondrial membrane by BAX and 
BAK. Released cytochrome c joins 
APAF-1 and procaspase-9 to form the 
apoptosome, resulting in activated 
caspase-9 which can further activate 
effector caspases. 3) The granzyme B 
pathway. Cytotoxic T lymphocytes and 
natural killer cells can induce apoptosis 
in target cells by releasing the pore 
forming protein perforin and granzyme 
B. Upon entry into the cell, granzyme B 
can either activate caspase-3 directly or 
activate the intrinsic apoptotic pathway 
through BID cleavage. Modified from 
[108]. 
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4.3.2 The intrinsic apoptotic pathway 
The intrinsic apoptotic pathway is initiated by cellular stressors such as increased intracellular 
reactive oxygen species, DNA damage, unfolded proteins, and deprivation of growth factors 
[109]. In this pathway members of the BCL-2 family are crucial regulators of the 
mitochondrial membrane integrity. Upon permeabilizaton, cytochrome c is released into the 
cytosol, permitting activation of the initiator caspase-9 on the scaffold protein APAF-1. 
Caspase-9 then further cleaves and activates the effector caspases, caspase-3 and caspase-7, 
which directly mediate the development of an apoptotic phenotype resulting in the demolition 
of the cell (Figure 8).  
 
4.3.2.1 The BCL-2 family 
The BCL-2 family is characterized by the presence of BH domains and comprises three 
functionally distinct subfamilies (Figure 9). The anti-apoptotic subfamily is made up of the 
originally described BCL-2 protein, in 
addition to BCL-XL, BCL-W, MCL-1, BCL-
2A1 (A1), and BCL-B. They contain four 
BH domains, and most of them also a 
transmembrane (TM) domain. The pro-
apoptotic members are divided into two 
subfamilies. The first consists of BAX, BAK, 
and the little-studied BOK. These proteins 
contain three BH domains and share 
significant homology with members of the 
anti-apoptotic subfamily. The second pro-
apoptotic subfamily is termed BH3-only 
proteins and comprises BIK, HRK, BIM, 
BAD, BID, PUMA, NOXA, and BMF. As 
the name implies, these proteins only contain 
one BH domain, the BH3. Apart from this 
domain, they share little homology with 
members of the other subfamilies or 
members within their own subfamily 
(reviewed in [108]).  
Figure 9. The BCL-2 protein family. A schematic 
overview of the members of the three subfamilies of 
BCL-2 proteins. (BH: BCL-2 homology domains, 
TM: transmembrane domain). Adapted from [108].  
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The simplified version of how these three subfamilies exert their control over the intrinsic 
apoptotic pathway is that upon activation by a stress signal, the BH3-only proteins insert their 
BH3 domain, an amphipathic α-helix, into a hydrophobic groove on the anti-apoptotic 
members. This releases pro-apoptotic members from inhibition, subsequently resulting in the 
insertion of BAX and/or BAK oligomers in the outer mitochondrial membrane (OMM) with 
consequent permeabilization. This general order of events with BH3-only proteins acting 
upstream of BAX and BAK is firmly established, as BH3-only proteins cannot induce 
apoptosis in cells lacking both BAX and BAK [110;111]. It is also clear that BH3-only 
proteins can bind and inhibit members of the anti-apoptotic subfamily, and that there exists 
differential affinity between members of these subfamilies. BIM, PUMA, and tBID can bind 
to all anti-apoptotic BCL-2 proteins, whereas NOXA binds only MCL-1 and A1, and BAD 
binds only BCL-2, BCL-XL, and BCL-W (Figure 10) [112]. 
 
 
Figure 10. Selective inhibitory capacity of BH3-only proteins. The promiscuous inhibitors BIM, PUMA and 
tBID can inhibit all anti-apoptotic BCL-2 family members, whereas BAD and NOXA exhibit selective 
inhibition. Adapted from [113]. 
 
4.3.2.1.1 Activation of BAX and BAK 
The exact mechanism by which BH3-only proteins activate BAX and BAK is still a subject of 
debate. In healthy cells, BAX exisits predominantly as a cytosolic monomer [114] with its 
BH3 domain buried, a conformation that precludes its association with other BCL-2 class 
members [115]. Upon a death stimulus, BAX then translocates to intracellular membranes, 
including OMM [114;116], where it assembles into high molecular weight oligomers [117]. 
In contrast to BAX, BAK, with its BH3 domain buried [118], is constitutively localized at 
OMM [119]. Two competing models termed the ‘direct activation model’ and the ‘indirect 
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activation model’ have been proposed to explain how the anti-apoptotic BH3-only members 
of the BCL-2 family regulate the activation and polymerization of BAX and BAK. 
 
The direct activation model 
In this model, the BH3-only members are 
further subdivided into ‘activators’ and 
‘sensitizers’. The ‘activators’ include BIM, 
tBID, and possibly PUMA and are proposed 
to bind directly to BAX and BAK to induce a 
conformational change, thereby unveiling 
their BH3 domain and promoting their 
activation. The role of the ‘sensitizers’ is to 
bind anti-apoptotic members, thereby 
displacing and releasing any bound 
‘activators’. This model thus implies that 
certain BH3-only members can bind directly 
to BAX and BAK, as have been demonstrated 
in some experimental settings [120-124]. The 
reason why BIM, tBID, and PUMA are the 
most potent apoptosis-inducers in the BH3-
only group can in this model be explained by 
the fact that they hold the role as ‘activators’ 
(Figure 11). Although not a BCL-2 family 
protein, cytoplasmic p53 has also been given a 
possible role in this model, with a dual 
function both as an ‘activator’ and as a 
‘sensitizer’ [125].  
 
The indirect activation model 
According to this model, no direct interaction 
between BH3-only proteins and BAX or BAK 
is required. The conformational state in which 
BAX and BAK have their BH3-domain buried 
is termed ‘unprimed’, and upon a hitherto 
Figure 11. The direct activation model. A 
schematic outline of the direct activation 
model in which BH3-only proteins are divided 
into sensitizers and activators. Adapted from 
[126]. 
Figure 12. The indirect activation model. A 
schematic outline of the indirect activation model 
in which BH3-only proteins are divided into 
selective and promiscuous inhibitors of the anti-
apoptotic BCL-2 subfamily members. Adapted 
from [126]. 
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unknown signal supplied by an apoptotic stimulus, their conformation change into a ‘primed’ 
state exposing their BH3-domains. This enables the oligomerization of BAX and BAK; 
however, such oligomerization will initially be inhibited through BH3-domain-mediated 
interaction with anti-apoptotic members of the BCL-2 family [127-130]. BH3-only members 
induced by the apoptotic stimulus then subsequently displace members of the anti-apoptotic 
subfamily, thereby releasing BAX and BAK from their inhibition. The reason why BIM, 
tBID, and PUMA are the most potent apoptosis-inducers in the BH3-only group, can in this 
model be explained by their promiscuous nature, i.e. they can engage and inhibit all members 
of the anti-apoptotic subfamily (Figure 12).  
 
The permeabilization of the outer mitochondrial membrane 
Exactly how the conformationally changed BAX and BAK proceed to oligomerize is not 
certain. It has been demonstrated that exposure of the BH3-domain in BAX can lead to 
homodimerization [131], and models proposed both by advocates of the ‘direct’ and the 
‘indirect’ model, seem to envisage a higher order assembly of such dimers through an as yet 
unidentified interaction surface which can lead to the formation of large oligomer structures 
(Figures 13 and 14). 
 
 
 
 
Figure 13. Activation of BAX oligomerization according to the ‘direct activation model’. The figure shows 
how a BH3-only activator protein is thought to induce conformational change in BAX through a ‘hit-and-run’ 
mechanism, enabling homodimerization of BAX. This in turn is thought to facilitate higher order 
oligomerization of BAX dimers. Adapted from [132]. 
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Figure 14. Activation of BAX and BAK oligomerization according to the ‘indirect activation model’. The 
figure shows how BAX and BAK are thought to change from an unprimed to a primed configuration upon an 
apoptotic stimulus. The primed forms are kept in check by binding to anti-apoptotic members of the BCL-2 
family until displaced by BH3-only proteins. This enables homodimerization of BAK and BAX, facilitating 
higher order oligomerization of dimers. Adapted from [113].  
 
 
4.3.2.2 The formation of the apoptosome 
APAF-1 is a multidomain protein with three functional regions: an N-terminal caspase 
recruitment domain (CARD), a nucleotide-binding and oligomerization domain (NOD/NB-
ARC), and a C-terminal string of WD40 repeats. The function of CARD is to bind 
procaspase-9 by homotypic interaction, and the WD40 repeats bind cytochrome c [133]. In 
the absence of cytochrome c, APAF-1 exists in a monomeric form. However, upon binding of 
 
 
Figure 15. The structure of APAF-1 and the formation of the apoptosome. (a) The structure of APAF-1 with 
CARD, NB-ARC (also called NOD) and WD40 repeats. (b) The stepwise formation of the apoptosome upon 
cytochrome c release. Adapted from [133]. 
  27 
cytochrome c, an intrinsic ATPase in the NOD hydrolyses bound ATP or dATP (hereafter 
commonly referred to as (d)ATP)  to (d)ADP, resulting in a conformational change of APAF-
1. It is thought that (d)ADP – (d)ATP exchange is then necessary to enable the monomers to 
polymerize into an heptameric wheel-like structure which constitutes the functional 
apoptosome [133]. In this structure, the seven CARDs constitute the centre of the wheel, 
located in close proximity to each other (Figure 15). This proximity is thought to be crucial 
for activation of procaspase-9 which now has access to the CARDs of the apopotosome. 
 
4.3.2.3 The caspase family 
As previously mentioned, the term caspase is derived from cystein aspartate specific protease. 
It refers to a conserved cystein side chain of the enzyme which is critical for catalysis, and a 
stringent specificity for cleaving protein 
substrates containing aspartate, a rare 
specificity among proteases. All caspases 
have an almost identical primary specificity 
pocket which is perfectly shaped to 
accommodate an aspartate side chain [134]. 
The caspases identified in humans are 
schematically depicted in figure 16. 
Common to all caspases is that they are 
produced as inactive precursors termed 
zymogens. These display very low catalytic 
activity, which is kept in check by regulatory 
molecules. The N-terminal prodomain varies 
in length and motif. The long prodomains 
consist of protein-protein interaction 
domains termed CARD or death-effector 
domain (DED) which mediate recruitment of 
these zymogens to specific signalling 
complexes displaying similar interaction 
domains. The zymogens are further made up 
of a large and a small subunit, and the 
cleavage between these subunits typically 
Figure 16. The caspase family. The figure gives a 
schematic overview of the structure and function of 
known human caspases (12-S* is the common 
truncated catalytically inactive form of caspase-12, 
12-L* is the full length caspase-12 expressed in a 
subset of humans of African descent). Adapted from 
[108].  
  28 
generates the active caspase which exists as a heterotetramer composed of two heterodimers 
derived from two zymogens. As will be discussed below, the proteolytic processing is not 
obligatory for activation of all caspases. The mammalian caspases are primarily involved in 
apoptosis or inflammation. However, many of the caspases with clearly defined roles in 
apoptosis or inflammation may have additional roles in other cellular processes (reviewed in 
[135]). The apoptotic caspases can be subdivided into initiator and effector caspases. 
 
The initiator caspases 
The initiator caspases (caspase-2, -8, -9, and -10) are characterized by long N-terminal 
prodomains that recruit them to signalling complexes, thus linking upstream signalling to 
downstream caspase-mediated effects through cleavage and activation of effector caspases. 
Caspase-8 is an essential initiator caspase of the extrinsic apoptotic pathway [136], whereas 
the possible physiological roles of caspases-2 and -10 are still a matter of debate [108]. 
 
Caspase-9 is a key component of the intrinsic apoptotic pathway. Via its N-terminal CARD, 
procaspase-9 binds to APAF-1-CARD in the centre of the septameric wheel structure of the 
apoptosome. Procaspase-9 does not need proteolytic cleavage to activate its catalytic site. As 
opposed to most other procaspases which exist as inactive homodimers before cleavage, 
procaspase-9 exists as an inactive monomer and its proteolytic site is activated by 
dimerization [137]. The function of the apoptosome is therefore to create a platform on which 
the CARD of individual APAF-1 proteins are brought in close proximity and can recruit 
several procaspase-9 molecules. There is evidence to suggest that this facilitation of local 
concentration is sufficient to promote dimerization, an event termed ‘induced-proximity 
activation’ of procaspase-9 (reviewed in [138]). However, it has also been argued that an 
additional interface between the apoptosome and procaspase-9 is involved in inducing a 
conformational change of procaspase-9 which facilitates its dimerization. This is termed the 
‘induced conformation model’ (reviewed in [138]). Irrespective of how dimerization is 
facilitated, it leads to internal proteolysis between the large and small subunit as a secondary 
event, resulting in partial stabilization of the activated dimers [139]. casp9 KO mice display 
embryonic or perinatal lethalily depending on the strain of mice [140;141]. The most 
prominent phenotypic feature is hyperplasia of the brain which is shown to result from 
decreased apoptosis, and mouse embryonal fibroblasts (MEFs) from casp9-null mice show 
resistance to apoptosis induced by irradiation as well as cytotoxic drugs. However, 
haematopoietic cells display a more varied sensitivity to apoptotic stimuli, suggesting that the 
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requirement for caspase-9 in the intrinsic apoptotic pathway might vary according to cell type 
and insult [140;141].  
 
The effector caspases 
Caspase-3 is regarded as the main effector caspase responsible for the cleaving the majority of 
cellular substrates associated with apoptosis. It is activated by proteolytic cleavage by 
caspase-9, -8, or -10, but is not a substrate for caspase-2 [142]. casp3 KO mice have a very 
similar phenotype as casp9 KO mice in some genetic backgrounds [143;144], but show 
normal development in others [145], suggesting it might be redundant for most developmental 
cell death. Cells derived from casp3-null animals are defect in DNA fragmentation and 
chromatin condensation when exposed to cytotoxic agents, but most cells eventually die 
exhibiting the other typical morphological hallmarks of apoptosis [144]. 
 
Caspase-7 is structurally similar to caspase-3, is activated by the same initiator caspases, and 
has similar substrate specificity [106]. However, casp7 KO mice develop normally, and cells 
derived from these animals retain sensitivity to apoptosis [145]. casp7/casp3 double KO mice, 
on the other hand, die perinatally, suggesting that caspase-3 can compensate for caspase-7 
[145]. 
 
Although structurally similar to caspase-7 and -3, caspase-6 has different substrate specificity 
[146]. casp6 KO mice develop normally [147], and it is not established that caspase-6 plays a 
role in apoptosis, although it is often found classified as an apoptotic effector caspase. 
 
4.3.2.4 Caspase substrates 
The consensus substrate specificity sequence of caspases is found in a wide array of proteins, 
and many of these can be shown to be cleaved by caspases in vitro. However, only a few 
proteins have been shown to be caspase substrates in vivo with established relevance to the 
apoptotic process. It is therefore thought that many of the assumed substrates are either 
innocent bystanders or are not actually cleaved at all in vivo [134]. Some of the established 
substrates of intiator caspases have already been mentioned, such as caspase-3 and -7, and 
BID. In addition, pRB is cleaved in its C-terminal region in a conserved caspase cleavage site 
during apoptosis, and this cleavage is necessary for TNFR1-induced but not DNA damage-
induced apoptosis to proceed [148]. Caspase-3 cleaves ICAD, an inhibitor/chaperone of CAD, 
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the nuclease responsible for double-strand cleavages during apoptosis. This allows CAD to 
dimerize, forming the catalytically competent form [149-151].  Poly(ADP-ribose) polymerase 
(PARP) is a substrate of caspase-3 and -7. PARP normally catalyses poly(ADP-ribose) 
ligation to acceptor proteins in response to DNA damage, and its cleavage prevents this action 
[152]. Finally, caspase-9 is itself a substrate for caspase cleavage at two distinct sites in the 
interchain linker region. The first cut is catalyzed by itself, creating a novel N-terminal 
epitope which is essential for the binding of caspase-9 to its inhibitor X-linked inhibitor of 
apoptosis protein (XIAP) [153]. This is assumed to function as a temporary brake on the 
apoptotic process. The second cut is mediated by the effector caspases and creates yet another 
N-terminal epitope which renders caspase-9 resistant to XIAP inhibition. By releasing 
caspase-9 from inhibition, this cleavage event creates a positive feedback loop whereby 
effector caspases increase the proteolytic potential of caspase-9 [134]. 
 
4.3.3 Defining apoptosis 
When cell death through apoptosis was defined morphologically in 1972, it was contrasted to 
the only defined mode of cell death at the time, namely necrosis. Necrosis was viewed as an 
accidental death in a physiological sense, induced by overwhelming noxious stimuli that 
resulted in a more or less uncontrolled destruction of the cell. Apoptosis, on the other hand, 
could either be part of a normal physiological process or a result of noxious stimuli. However, 
the resulting process in the cell was conceived as orderly, controlled and purposeful, clearing 
the dying cell without trace by preparing it for phagocytosis by neighbouring cells. More 
recently, accumulating evidence has suggested the existence of a more complex picture of cell 
death. Consequently, a Nomenclature Committee on Cell Death has been established with the 
aim of critically evaluating names describing distinct modalities of cell death, and formulating 
recommendations on their definition and use. In their updated recommendations from 2009 
[154], they suggest strict definitions of when a cell can be considered ‘dead’. In the absence 
of a specific biochemical event shown to define a ‘point-of-no-return’ in the cell death 
process, the following morphological definitions are still recommended: 1) the cell has lost 
the integrity of its plasma membrane, as defined by the incorporation of vital dyes in vitro; 2) 
the cell, including its nucleus, has undergone complete fragmentation into discrete bodies; 
and/or 3) its corpse (or its fragments) has been engulfed by an adjacent cell in vivo.  
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The committee defines four distinct modalities of cell death (Table 1). In addition, they 
describe tentative definitions of ‘atypical cell death modalities’ including mitotic catastrophe, 
anoikis, excitotoxicity, Wallerian degeneration, paraptosis, pyroptosis, pyronecrosis, and 
entosis. What characterizes these atypical modalities is that they display morphological or 
biochemical features of one or more of the established modes of cell death. Consequently, it is 
not currently clear whether they can be said to represent truly novel and distinct modes of cell 
death. 
 
 
Table 1. The four defined modes of cell death. The Nomenclature Committee on Cell Death’s definition of 
apoptosis, autophagy, cornification, and necrosis based on accepted morphological features. Adapted from [154]. 
 
With respect to apoptosis, the committee stresses that morphological criteria still apply as the 
only defining features, and that ‘apoptosis’ hides a major degree of biochemical and 
functional heterogeneity. Although numerous studies have demonstrated that apoptosis is 
associated with several biochemical criteria, including DNA framgentation and caspase 
activation, a number of reports indicate that these changes are not always required for the 
execution of the cell death programme after typical apoptotic stimuli. For instance, inhibition 
of caspase activation has been shown to be insufficient to prevent cell death (reviewed in 
[155]). As already mentioned in section 4.3.2.3, caspase-3 activation may be necessary for the 
development of some of the typical morphological and biochemical signs of apoptosis such as 
chromatin condensation and DNA fragmentation. Therefore, inhibition of caspase activity can 
prevent the appearance of some of the apoptotic features, and delay but often not inhibit cell 
death (reviewed in [156]). In conclusion, the absence of caspase activity and DNA 
fragmentation cannot exclude ongoing apoptosis-like cell death. However, due to the 
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morphological definition of apoptosis, and the role played by effector caspases in the 
formation of some of the morphological traits, it may be argued that in the strictest sense 
classical apoptosis is caspase-dependent. G. Kroemer and S. J. Martin have suggested 
dividing the relationship between caspase activation and cell death as illustrated in figure 17 
[155].  
 
Figure 17. The relationship between caspase dependence and effect of caspase inhibiton on cell death. The 
figure illustrates how dependence on caspase activation can differ between cell types and between death stimuli. 
Effects of caspase inhibition will consequently have different effects on whether cell death can still occur, and on 
the morphological features of the resulting cell death. Adapted from [155].  
 
Having discussed all the possible pitfalls of attempts to correlate measurements of 
biochemical markers to the occurrence of apoptosis, the Nomenclature Committee on Cell 
Death, ends their most recent report by discussing whether the present morphology-based 
strict definition of different forms of cell death is indeed expedient. Firstly, they argue that 
much of the work performed to delineate the biochemical pathways involved in cell death has 
been performed in vitro on immortalized cell lines. In intact tissues, however, dying cells are 
usually engulfed well before signs of advanced apopotosis become detectable. It may 
therefore still be acceptable to consider caspase activation and/or DNA fragmentation 
sufficient to diagnose apoptotic dell death in vivo. Secondly, as there are numerous examples 
of cell death displaying mixed features of apoptosis and necrosis or autophagy, it may not be 
meaningful to operate with clear-cut and absolute distinctions based on historical 
morphological criteria. Thirdly, they argue that it would be preferable to replace the 
morphological aspects with biochemical/functional criteria. As there does not seem to exist 
perfect correlations between morphology and biochemistry in this field, the committee 
anticipates that the morphological terms will eventually be displaced by biochemical 
definitions, probably resulting in a more differentiated classification of cell death. However, 
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they argue that such classification will only become meaningful once it can have a predictive 
impact, that is to predict possibilities to pharmacologically/genetically modulate cell death 
and/or predict consequences of cell death in vivo [154]. 
 
4.4 The DNA damage response 
Maintenance of genomic integrity is a fundamental feature of life. As a result, several distinct 
surveillance mechanisms, collectively termed the DNA damage response (DDR) machinery, 
have evolved to detect and initiate appropriate responses to diverse genotoxic insults. These 
insults are in part imposed from the environment, examples of which include ultraviolet (UV) 
and ionizing radiation (IR) as well as various chemicals. In addition, reactive oxygen species 
(ROS) are constantly produced inside the cell as a result of normal metabolic processes. The 
DDR machinery components are hierarchically organized into sensors, transducers and 
effectors. Upon recognition of a lesion, these pathways will initiate DNA repair processes 
(reviewed in [157-159]). If a lesion is complex, the DDR machinery also ensures delay in cell 
cycle progression through activation of cell cycle checkpoints to allow time for repair 
(reviewed in [160;161]). In the case of extensive lesions or failure to repair, the DDR 
machinery can activate pathways that will eliminate the cell from the proliferative pool by 
inducing senescence or cell death (reviewed in [162-164]), thereby avoiding the fixation of 
potentially deleterious mutations.  
 
4.4.1 DDR sensors 
Different types of DNA damage attract different sets of damage-sensing proteins. With 
respect to DNA double strand breaks (DSBs) it is assumed that the earliest events probably 
involve alterations in chromatin structure [165-167]. Through mechanisms that are still poorly 
understood, this recruits a mediator complex consisting of Mre11, Rad50, and Nbs1 (MRN) 
and also results in the phosphorylation of variant H2A histones (H2AX) [168] in the vicinity 
of the DSB. These two events act as a signal amplifier that recruits additional signalling 
molecules to the lesion, amongst them the crucial upstream transducer kinase ataxia 
telangiectasia mutated (ATM) [169]. In addition to the MRN complex, a heterodimeric 
complex consisting of Ku70 and Ku86 subunits binds to the free DSB ends [170;171]. 
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An example of another type of sensor complex is provided by the exposure of stretches of 
single stranded DNA (ssDNA). This can result from replication fork stalling during S phase 
due to the continued unwinding of the DNA template by helicases, but is also thought to be a 
secondary event in DSBs associated with the endonuclease and/or exonuclease activity of 
Mre11/CtIP complexes [172;173]. Stretches of ssDNA are rapidly coated by replication 
protein A (RPA) [174], an event that attracts the upstream transducer kinase ATR (ATM- and 
Rad3-related) through binding of its regulatory subunit ATR-interacting protein (ATRIP) 
[175].  
 
4.4.2 Activation of kinase transducers  
ATM-CHK2 
ATM is a PI3K-related kinase that normally exists as an inactive multimer, being activated 
upon dissociation into monomers [176]. It is known that interaction with the MRN complex 
plays an important role in its efficient and rapid activation, but the molecular details of this 
process are not fully understood. Activation of intermolecular autophosphorylation on S1981 
is thought to be an essential event [176], and in addition autophosphorylation on S367 and 
S1893 might be of importance [177]. More recently, it has been reported that acetylation of 
K3016 by the acetyl transferase Tat-interacting protein 60 (TIP60) might be crucial to ATM 
activation [178;179]. Both phosphorylation and acetylation events of ATM occur within 
minutes of the induction of DNA DSBs [176;178;179], 
allowing for swift kinase activity towards an array of 
ATM substrates. 
 
A central ATM target is the checkpoint kinase 2 
(CHK2) which is phosphorylated in an ATM-
dependent manner on T68 [180-182]. This event is 
probably not sufficient for full CHK2 activation; 
however, it is thought to trigger additional 
autophosphorylation events on T383 and T387, 
ultimately resulting in CHK2 activation [180;183] 
(Figure 18). Additionally, ATM can activate the stress 
response signalling complex p38MAPK/MK2 
Figure 18. Activation of kinase 
transducers involved in DNA double-
strand break signalling. 
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(mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 
2), which has been demonstrated to play a role in DNA damage-induced cell cycle arrest 
[184].  
 
ATR-CHK1 
ATR, like ATM, is a PI3K-related kinase, but the 
events leading up to its activation are less well 
characterized than for ATM. They are thought to 
involve ATR-ATRIP interaction with another DNA-
associated complex composed of Rad9-Rad1-Hus1 
(9-1-1) and DNA topoisomerase 2-binding protein 1 
(TopBP1) [185;186]. Activated ATR recruits a 
mediator protein called claspin to the site of damage, 
which enables the phosphorylation on S317 and 
S345 of the main ATR downstream kinase 
checkpoint kinase 1 (CHK1), resulting in its 
activation [187] (Figure 19). Similar to ATM, ATR 
can also activate p38MAPK/MK2.  
 
DNA-PKsc 
A third PI3K-related kinase recruited to sites of DNA damage is DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs). DNA-PKcs is recruited to the site of damage through 
binding to the Ku heterodimer, which also activates the kinase activity of DNA-PKcs 
(reviewed in [188]). 
 
4.4.3 DDR effector proteins and outcomes 
4.4.3.1 p53 activation 
DDR activation leads to accumulation and activation of the tumour suppressor p53, a protein 
that plays an important role in several of the DNA damage-induced effector pathways, 
including DNA repair, cell cycle arrest, senescence and apoptosis. The p53 signalling 
involved in the execution of these pathways will be explained in more detail in the section on 
Figure 19. Activation of kinase 
transducers involved in single-
stranded DNA signalling. 
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p53 (see section 4.5.3), whereas this paragraph mainly will focus on the mechanistic 
background for p53 activation upon DDR signalling.  
 
p53 is a direct substrate for ATM, with ATM activation resulting in rapid phosphorylation of 
p53 on S15 [189;190]. ATR is thought to maintain S15 phosphorylation at later stages during 
the DDR [191]. S15 phosphorylation has been proposed to be a prerequisite for subsequent 
T18 phosphorylation by casein kinase 1 (CK1) [192] which has been demonstrated to 
negatively affect p53 binding to its negative regulator HDM2 (see section 4.5.2.1.1) [193]. 
CHK1 and CHK2 can further phosphorylate p53 on S20 [194;195]. Whether phosphorylation 
of S15 and S20 contributes to p53 accumulation through effects on HDM2 binding is 
currently debated. Alternatively, they have been suggested to contribute to increased p53 
transcriptional activity [189;196-198]. ATM has also been indirectly implicated in 
phosphrylation of p53 on S46 [199;200], and in its dephosphorylation at S376 [201].  
 
In addition to effects on the p53 phosphorylation status, the DDR machinery contributes to 
DNA damage-induced p53 accumulation by acting on two of the crucial negative p53 
regulators: HDM2 and HDMX (see sections 4.5.2.1.1 and 4.5.2.2.1). ATM directly 
phosphorylates HDM2 on S395, an event that impairs nuclear export and degradation of p53 
[202;203]. ATM also indirectly affects HDM2 through activation of the tyrosine kinase c-
ABL (Abelson murine leukemia) which binds to and phosphorylates HDM2 on Y394, 
impairing the inhibition of p53 [204-206]. Finally, ATR can phosphorylate HDM2 on S407, 
resulting in reduced HDM2-dependent export of p53 to the cytoplasm [207]. With regards to 
HDMX, ATM directly phosphorylates it on S403, and this contributes to its DNA damage-
induced ubiquitination and degradation [208].  
 
Figure 20. Activation of p53 by DDR. The figure illustrates some of the key events involved in DNA damage-
induced activation of the ATM-CHK2 and ATR-CHK1 signalling pathways, and how they converge to activate 
p53 through direct and indirect effects. Adapted from [209]. 
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4.4.3.2 p53-independent DDR outcomes 
DNA repair 
ATM and ATR have been shown to directly affect the activity of several players in the DNA 
repair machinery through their kinase activity. Examples include the DNA helicase Bloom 
syndrome protein 1 (BLM1), breast cancer associated gene 1 (BRCA1), histone H2AX, the 
replication fork associated mini chromosome maintenance (MCM) complex, as well as the 
MRN complex itself [210]. In addition, DNA-PKcs plays a direct role in non-homologous end 
joining (NHEJ) in response to DSBs (reviewed in [211]). 
 
Cell cycle arrest 
With respect to p53-independent DDR-induced cell cycle arrest, both the ATM-CHK2 and 
ATR-CHK1 pathways converge to inactivate CDC25 family members (Figure 21).  
 
 
 
Figure 21. Pathways involved in p53-independent DNA damage-induced cell cycle checkpoints. The figure 
summarizes the various pathways involved in DDR kinase-induced inhibition of CDK-cyclin complexes. 
Adapted from [184]. 
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As mentioned in section 4.2.3, CDC25 is a family of CDK-directed phosphatases, 
contributing to CDK activation through removal of inhibitory phosphate groups. CDC25A is 
an important substrate for CHK1 and possibly CHK2. Phosphorylation on S76 primes it for 
ubiquitination and subsequent proteasomal degradation [212], which can contribute to both a 
p53-independent G1 arrest [213], S-phase delay [214], and G2 arrest [215]. At the G2/M 
boundary CDC25B plays an important role in the activation of CDK1 which upon binding to 
cyclin B can further activate CDC25C, creating a positive feedback loop [216]. CDC25C can 
be phosphorylated by both CHK1 and CHK2 on S216, creating a binding site for 14-3-3 
proteins [217-219], probably resulting in functional inactivation of the phosphatase by 
cytoplasmatic sequestration [220;221]. Similarly, CDC25B is functionally inactivated by 
phosphorylation on S309 and S323 mediated by CHK1, CHK2 or p38MAPK/MK2 [184;222]. 
Additionally, CHK1 can phosphorylate WEE1 on S624 and thereby activate its function as an 
inhibitory CDK kinase [223;224]. 
 
4.4.4 Consequences of deregulated DDR 
There are several diseases that result from germline mutations of components of the various 
DDR pathways. Depending on the exact role of the defect component, these diseases display 
phenotypes typically involving developmental defects, severe immunodeficiency, 
neurodegeneration, premature ageing, or cancer predisposition, and thus illustrate the 
importance of high fidelity genome maintenance for normal development and health [161]. 
One striking example is provided by mutations of the ATM gene, resulting in the autosomal 
recessive disorder ataxia-telangiectasia (A-T). Obvious clinical signs of the disease are 
cerebellar ataxia and oculocutaneous telangiectasias, which provided the disease with its 
name long before the mutated gene was recognized and termed accordingly. The ataxia is 
caused by progressive neurodegeneration principally affecting the Purkinje cells of the 
cerebellar cortex, which is probably caused by defective responses to DNA DSBs. In addition, 
the disease is characterized by immunodeficiency caused by the lack of resolution of DNA 
DSBs generated during V(D)J recombination, a process vital for generating the versatile 
repertoire of T cell receptors and immunoglobulin chains (see section 4.6.1). Both T and B 
lymphocyte precursors in these patients have a high frequency of abnormal hybrid joins which 
has occurred during inversion rearrangements, and this also predisposes them to develop 
lymphoid neoplasias. As expected, they also exhibit hypersensitivity to ionizing radiation (for 
a comprehensive review on A-T and ATM function, see [225]). 
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Although it is becoming increasingly clear that germline mutations and genetic 
polymorphisms play an important role in cancer predisposition, most of the accumulated 
changes driving the malignant phenotype in a fully developed cancer are the result of somatic 
mutations. Cancer cells generally display increased mutational frequencies and chromosomal 
aberrations indicating severe attenuation of the processes normally involved in ensuring the 
fidelity of the genome. Indeed, aberrations of the ATM-CHK2-p53 cascade and other DDR 
components are almost universal features of cancer cells. The selective forces driving such a 
DDR-defective phenotype are not yet completely delineated. However, emerging candidates 
are two anti-cancer barriers involving the DDR machinery: oncogene-induced DNA 
replication stress and telomere shortening. Both of these processes converge on DNA damage 
signalling and are proposed to be of major importance for the selection of mutations in the 
DDR pathway during carcinogenesis (reviewed in [161]). 
 
4.5 p53 
The discovery of p53 is attributed to two publications from 1979. First, D. P. Lane and L. V. 
Crawford reported a 53 kDa host protein which co-precipitated with the Simian virus 40 
(SV40) large T antigen [226]. Soon after, D. I. Linzer and A. J. Levine reproduced this 
finding, and could also report that this protein could be found in uninfected carcinoma cells, 
implicating it as a tumour antigen independent of SV40-infection [227]. However, almost 
simultaneously the group of L. J. Old reported that antisera raised against a chemically 
induced mouse sarcoma recognized a 53 kDa protein in transformed, but not untransformed 
cells. In this report the name ‘p53’ appeared for the first time [228].  
 
For several years after its discovery, p53 was regarded as a probable oncoprotein, as it was 
found overexpressed in many virally transformed cells and cell lines derived from human 
tumours [229;230]. This notion was strengthened when the mouse p53 cDNA was cloned in 
1984 [231], as cells co-transfected with plasmids harbouring this p53 cDNA and the activated 
ras oncogene underwent transformation [232;233]. However, it later became clear that these 
initial p53 cDNAs contained mutations, and that wild type (wt) p53 was not able to cooperate 
with an activated ras gene to transform cells. Rather, wt p53 was found to suppress ras 
mediated transformation [234;235]. Analysis of tumour materials from cancers of various 
sites, showed frequent occurrence of mutations in the TP53 gene, and in accordance with 
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Knudson’s two-hit hypothesis for tumour suppressor gene inactivation, it was found that in 
many cases the non-mutated allele was lost [236]. In 1990, inherited TP53 mutations were 
found to cause the familial Li-Fraumeni syndrome, characterized by a diversity of childhood 
and adult tumours [237;238]. In 1992 TP53 KO mice were bred, and found to be viable and 
developmentally normal, but susceptible to spontaneous tumours [239]. Collectively, these 
findings firmly placed TP53 not as a proto-oncogene, but as a tumour suppressor gene.  
 
Simultaneously, functional studies shed light on how p53 could exert its function as a tumour 
suppressor, with the findings that wt p53 was induced upon DNA-damaging treatment and 
mediated subsequent cell cycle arrest and apoptosis [240-243]. Based on these findings, it was 
nicked-named ‘The guardian of the genome’ [244], a term which can still be regarded to grasp 
the essence of its function. Mechanistic studies into how p53 could exert its effects revealed 
that p53 was a sequence-specific transcription factor [245-249], and in 1994 the crystal 
structure of the p53 core domain interacting with DNA was solved [250]. 
 
4.5.1 An overview of p53 structure and function 
p53 structure 
The p53 protein consists of 393 amino acids, and is commonly divided into three functional 
domains: the N-terminal domain, the central core and the C-terminal domain (Figure 22).  
 
 
 
Figure 22. Outline of the p53 protein with its functional domains. The N-terminal part consists of a 
transactivation domain (TAD) and a Src homology 3-like (SH3) domain. The central core contains the DNA-
binding domain (DBD), whereas the C-terminal end contains nuclear localization signals (NLS), a 
tetramerization domain, nuclear export signals (NES), and a regulatory domain. Adapted from [251]. 
 
 
The N-terminal domain contains the transactivation domain (TAD) which is required for 
transcriptional activation. The TAD also contains the interaction site with p53’s negative 
regulator HDM2 (see section 4.5.2.1.1). The Src homology (SH3) domain is a proline-rich 
domain required for the interaction with SIN3, protecting p53 from degradation. The central 
core contains the sequence-specific DNA binding domain (DBD), and the interaction sites for 
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most of the p53 interacting proteins. The C-terminal domain contains nuclear localization 
signals (NLS) and nuclear export signals (NES) in addition to a tetramerization domain 
required for the oligomerization of p53 monomers. The end of the C-terminal domain (C-
terminal regulatory domain) has a high content of basic amino acids thought to play a role in 
regulating the core DBD [252]. 
 
p53 transcriptional activity 
p53 is a sequence-specific transcription factor with a target response element (RE) sequence 
composed of two 10-base decamers and a spacer as shown in figure 23. p53 binds this 
sequence as a dimer of dimers, in which each p53 subunit contacts three nucleotides of the 
RRRCW or WGYYY pentamer. This results in conformational changes both of p53 and of 
the target DNA. Additionally, it has become clear that p53 can also bind to and activate 
transcription of genes with non-canonical REs, such as half sites, three-quarter sites, and 
tetrameric REs. Approximately 150 p53 REs have so far been validated [253]. However, 
genome-wide approaches suggest this could be a gross underestimate of the real number of 
genes that might be regulated by p53 [254]. In addition, recent evidence indicates that p53 
also controls the transcription of several miRNAs such as the miR-34 family (reviewed in 
[255;256]) and miR-192, -194 and -215 [257-259].  
 
 
Figure 23. The accepted consensus sequence for p53 binding. The figure illustrates the accepted double 
decamer consensus sequence for p53 bindng (R=purine, Y=pyrimidine, W=A or T, spacer < 3), with listed trans 
and cis acting factors that have been shown to affect binding and initiation of transcription. Adapted from [253]. 
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p53 has also been shown to act as a transcriptional repressor. Less is known about the cis 
element requirements in these cases, and many downregulated genes have proposed target 
sequences that differ from the p53 binding consensus [260;261]. However, recent data 
indicate that a specific dinucleotide core combination within the CWWG consensus motif 
could be a key factor in determining whether p53 transcriptionally activates or represses a 
target gene, thereby identifying approximately 25% of the validated p53 REs to be repressive 
[262]. 
 
p53 non-transcriptional effects 
The physiological role of p53 as a transcription factor is well established. However, as early 
as in the mid 1990’s, reports indicated that non-transcriptional effects of p53 might also be of 
importance. Key findings were that trans-activation deficient mutants of p53 were able to 
induce apoptosis [263], and that p53-dependent apoptosis could proceed in the absence of 
RNA and protein synthesis [264]. These findings have later been confirmed and elaborated, 
and further indications of the importance of transcription independent effects of p53 on 
apoptosis have accumulated (reviewed in [265;266]). In addition p53 has been shown to have 
transcription-independent effects on autophagy and DNA repair [267;268]. 
 
4.5.2 The regulation of p53 
The cell can regulate p53 function at several levels. Two well-established levels of regulation 
are the control of p53 expression and p53 transcriptional activity. In addition, it has recently 
become clear that p53 can be expressed as several different isoforms, adding further 
complexity to the regulation of its function. The latter topic will not be discussed in further 
detail here (for a recent comprehensive review, see [269]). 
 
4.5.2.1 Regulation of p53 expression 
To explain how p53 accumulates after genotoxic stress, the main focus has been on post-
translational mechanisms, which certainly plays an essential role through stabilization of the 
otherwise labile p53 protein. However, there are also studies indicating a contribution of 
regulation on a transcriptional and post-transcriptional level. 
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Transcriptional regulation 
In 1995, a study concluded that genotoxic insult imposed by different agents lead to an 
increase in p53 mRNA levels caused by increased activity at a novel promoter element, 
termed the p53 core promoter [270]. Although a κB motif partly overlapped with this element, 
nuclear factor kappa B (NF-κB) was not found to play a role in this process. This was later 
challenged by another report, stating that NF-κB could indeed contribute to the regulation of 
p53 gene expression after exposure to daunorubicin [271]. More recently, it was reported that 
p53 itself is involved in a positive feedback loop whereby DNA damage-induced p53 or p73 
can bind to a p53 RE half-site, located at −121 to −112 (relative to the first transcription 
initiation site), to augment p53 transcription. By silencing p53 and p73, a significant 
suppression of TP53 transcription was observed both under normal and stressed conditions 
[272]. 
 
Post-transcriptional regulation 
There have been several reports on regulation of p53 mRNA translation through different 
mechanisms. In 1995, it was reported that p53 itself could bind the 5’ untranslated region 
(UTR) of p53 mRNA and inhibit its translation, forming a negative feedback loop [273]. In 
more recent years, it has been demonstrated that HDM2 can bind p53 mRNA through its 
RING domain, promoting its translation. Moreover, cancer-derived single silent point 
mutations could weaken this interaction, providing a means of these mutations to suppress 
p53 levels [274]. Another report implicated HDM2 in a more indirect manner by showing that 
the ribosomal protein L26 can bind p53 mRNA and augment its translation. HDM2 was 
shown to bind L26 and prime it for degradation through ubiquitination in addition to 
attenuating its affinity to p53 mRNA. This was shown to contribute to the low p53 levels in 
unstressed cells. In response to genotoxic stress, the inhibitory effect of HDM2 on L26 was 
attenuated, enabling rapid increase in p53 synthesis [275]. Yet another report focused on two 
internal ribosome entry sites (IRESs) in p53 mRNA which can direct the translation of p53 
and its N-truncated isoform ΔN-p53. A polypyrimidine tract-binding protein (PTB) was 
shown to bind to both IRESs but with differential affinity augmenting translation of the 
respective isoforms. Upon doxorubicin treatment, PTB translocated to the cytoplasm 
facilitating p53 mRNA translation and possibly contributing to the coordinated expression of 
the two isoforms [276].  
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MicroRNAs might also play a role in the post-transcriptional regulation of p53 as miR-125b 
can bind to a microRNA RE in the 3’UTR of p53 mRNA, leading to repression of p53 protein 
levels [277]. Finally, p53 mRNA stability has been shown to be regulated by a natural 
antisense transcript of p53 termed Wrap53 (WD40-encoding RNA antisense to p53). This 
transcript targets the 5’ UTR of p53 mRNA leading to its stabilization, and was found to both 
maintain basal p53 mRNA levels and to play a role in stabilizing p53 mRNA in response to 
DNA damage [278]. 
 
Post-translational regulation 
Notwithstanding the existence of mechanisms involved in modulation of TP53 transcription 
as well as p53 mRNA stability and translation, regulation of p53 protein stability appears to 
constitute the major mechanism dictating p53 protein levels. Under unstressed conditions, p53 
is a labile protein with a half-life of less than 30 minutes. However, upon the receival of stress 
signals, the half-life of p53 is dramatically increased, allowing for accumulation of the 
protein. Key to regulation of p53 protein stability is the rate of proteasomal degradation 
controlled by p53 ubiquitination levels [279;280], an event that is under the control of E3 
ubiquitin ligases. 
 
4.5.2.1.1 HDM2 
A central component in the p53 regulatory circuit is the HDM2 protein. The murine double 
minute 2 (mdm2) gene was identified in 1987 as one of three genes located on 
extrachromosomal amplifications in the spontaneously transformed murine cell line 3T3-DM 
[281]. The Mdm2 protein, termed HDM2 in humans, was later shown to bind to and inhibit 
p53 [282;283], and was soon recognized as a major negative regulator of p53. Indeed, 
mdm2−/− mice display early embryonic lethality which can be rescued upon concomitant 
Trp53 (transformation related protein 53) deletion [284;285], underscoring the importance of 
Mdm2-mediated regulation of p53, at least during embryogenesis. The negative regulatory 
effect of HDM2 on p53 has been ascribed partly to its ability to act as an E3 ubiquitin ligase 
for p53 [286], thus promoting its degradation [287;288], and partly to its function as an 
inhibitor of p53 transcriptional activity [289;290]. In vivo models, however, challenge the 
importance of HDM2 as a p53 transcriptional inhibitor, and favour the role as a p53 E3 
ubiquitin ligase as its major physiological asset [291-293].  
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It has long been assumed that the accumulation of p53 after genotoxic stress is caused at least 
in part by the dissociation of the p53-HDM2 complex, leading to reduction in p53 
ubiquitination and proteasomal degradation. Whether this is a universal mechanism of DNA 
damage-induced p53 stabilization, or whether additional factors are involved, is still a matter 
of debate [294]. Changes in HDM2-dependent ubiquitination of p53 can, in theory, be caused 
by modulation of its interaction with p53, its enzymatic activity, or its protein levels. There is 
evidence that regulation occurs at all these three levels. 
 
Modulation of HDM2 – p53 interaction 
Due to the proximity between residues 18-26 of p53 known to be essential for HDM2 
binding, and several N-terminal serines and threonines shown to be phosphorylated upon 
DNA damage, it was hypothesized that N-terminal p53 phosphorylation might play a role in 
p53 activation by disturbing the p53-HDM2 interaction. In particular the ATM-target site S15 
and the CHK2-target site S20 of p53 have been in focus, and early reports indicated that 
phosphorylation of these sites might indeed reduce the affinity of p53 for HDM2 [295-297]. 
However, these results were soon disputed, with a series of in vitro studies showing little or 
no effect of phosphorylation of p53 on S15 and S20, but instead pointing to T18 
phosphorylation as a new candidate for disruption of the p53-HDM2 complex 
[192;193;298;299]. Phosphorylation of S15 might still be of significance as one study has 
indicated it as a prerequisite for T18 phosphorylation to take place [192]. The importance of 
these PTMs has further been investigated in mutant mice that express p53 with 
phosphorylation-deficient serine to alanine substitutions at S18 and S23 (equivalent to human 
S15 and S20, respectively). The phenotypes of mice with S18A, or S23A, or the double 
mutation S18,23A are generally mild, although some apoptotic defects have been observed 
[300-304]. Importantly, however, p53 protein stability after DNA damage is either not, or 
only marginally, affected by these mutations, supporting the above-mentioned in vitro studies 
that question the role of S15 and S20 phosphorylation in modulation of p53-HDM2 
interaction. Mouse models investigating the effects of the human T18 equivalent are yet to be 
reported. Based on these and other studies, it has been suggested that p53 N-terminal 
phosphorylation might play a role under certain conditions and/or in certain tissues, but that 
p53 stabilization in vivo requires a far more sophisticated regulatory network than can be 
provided by p53 phosphorylation alone [305].  
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In addition to phosphorylation, acetylation of p53 has recently received attention as a mode of 
post-translational modification that affects p53-HDM2 interaction. p53 acetylation levels are 
markedly enhanced upon cellular stress. CREB binding protein (CBP)/p300 can acetylate the 
six C-terminal lysines of p53 [306]. In addition, two acetylation sites located in the DBD have 
been described, and it was demonstrated that acetylation of these eight different residues 
prevents the interaction of p53 with HDM2 [307]. Furthermore, as lysine acteylation and 
ubiquitination are mutually exclusive, acetylation of p53 on its C-terminal lysines has the 
additional effect of blocking some of the major p53 ubiquitination sites targeted by HDM2 
[308-310].  
 
The interaction between HDM2 and p53 can also be modulated by HDM2-interacting 
proteins. The CDKN2A locus gives rise to two unrelated proteins through the use of 
alternative reading frames: p16INK4a and p14ARF. p14ARF is a predominantly nucleolar protein 
which is induced upon activation of oncogenes and serves as an important negative regulator 
of HDM2. This effect has partly been attributed to the ability of p14ARF to interfere with p53-
HDM2 interaction by binding to and sequestering HDM2 into the nucleoli [311], and partly to 
its ability to directly inhibit the E3 ubiquitin ligase activity of HDM2 [312;313]. In addition, 
p14ARF can modulate the activity of other p53 ubiquitin ligases, such as ARF-BP1 [314]. 
Although it is not entirely clear which of these mechanisms of action of p14ARF that plays the 
most important role in a given cellular context, p14ARF has been convincingly shown to play 
an important role in p53 regulation [305]. As opposed to p14ARF, the transcription factor Yin 
Yang 1 (YY1) can enhance the interaction between HDM2 and p53 [315]. 
 
Modulation of HDM2 E3 ubiquitin ligase activity 
Similar to p53, HDM2 is the target of PTMs. HDM2 harbours several phosphorylation and 
acetylation sites, and modification of these sites appears to mainly affect its enzymatic 
activity as an E3 ubiquitin ligase. Phosphorylation of HDM2 on S166 and S186 residues 
promotes its activity, whereas phosphorylation on S395 and Y394 as well as acetylation 
events mediated by CBP/p300 inhibit its activity [316-318]. The enzymatic activity of HDM2 
can also be modulated by interacting proteins like p14ARF, as well as several ribosomal 
proteins such as L5, L11 and L23 [319-322].  
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Modulation of HDM2 levels 
HDM2 is a relatively labile protein under unstressed conditions [323]. It is targeted for 
proteasomal degradation through ubiquitination, and has been suggested to be subject to 
autoubiquitination. However, mutations abolishing HDM2 E3 ligase activity do not affect 
HDM2 stability, indicating the need for alternative E3 ligases [293]. HDM2 ubiquitination is 
conteracted by the deubiquitinating enzyme HAUSP (herpesvirus associated ubiquitin specific 
protease) [324;325]. DNA damage induces phosphorylation of HDM2, resulting in HAUSP 
dissociation, accelerating HDM2 proteasomal degradation [208;323]. The consequent HDM2 
destabilization has been demonstrated to be necessary for p53 activation [326]. This DNA 
damage-induced reduction in HDM2 levels is transient, as the increased p53 activity that 
follows leads to increased transcription of the HDM2 gene [327]. Thus, in relation to the 
DNA-damage response, HDM2 levels are tightly regulated by multiple factors both at a 
transcriptional and post-translational level. The HDM2-related protein HDMX has also been 
suggested to affect HDM2 stability, but this role of HDMX remains controversial [328].   
 
4.5.2.1.2 Other p53 E3 ubiquitin ligases 
In addition to HDM2, other E3 ubiquitin ligases capable of targeting p53 have been identified. 
These include PIRH2, COP1 (constitutively photomorphogenic 1), and ARF-BP1/Mule 
(ARF-binding protein 1/MCL-1 ubiquitin ligase E3) [314;329-331]. Like HDM2, PIRH2 and 
COP1 are both p53 target genes and can therefore be part of a negative feedback loop 
involving p53. It is presently unclear exactly what role E3 ligases other than HDM2 play in 
regulating p53 levels in different cellular contexts. As many of the recently discovered p53 
isoforms lacks the binding site for HDM2, it has been suggested that these ligases might play 
an important role in the differential regulation of p53 isoform levels [279]. 
  
4.5.2.2 Regulation of p53 transcriptional activity 
Early on in the studies of p53 transcriptional activity, it was envisioned that for p53 to bind to 
promoter regions in DNA in a sequence-specific manner, a stress signal resulting in a 
multitude of post-translational modifications was required. This view has later been 
challenged by observations that a significant portion of p53 is bound to DNA in unstressed 
cells [332;333], and that p53 is present at the promoters of its transcriptional targets during 
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normal homeostasis [334;335]. Recently, a model has been proposed in which p53 activation 
can be divided into three steps [305] (Figure 24).  
 
 
Figure 24. Three-step model for p53 activation in response to stress. (Ac=acetylation; P=phosphorylation; 
Me=methylation; N8=neddylation; S=sumoylation). Adapted from [305]. 
 
The first step involves stabilization of the otherwise labile p53 protein with subsequent 
accumulation through processes discussed above. This allows for increased amounts of p53 to 
bind DNA, but its transcriptional activity is actively repressed by HDMX (see below) and 
possibly HDM2. The second step involves anti-repression through removal of these repressors 
due to post-translational modifications of p53 and its repressors, enabling select activation of 
p53 target genes. The third step involves further post-translational modifications of p53 and 
recruitment of co-factors which direct the final cellular outcome through promoter-specific 
activation. 
 
4.5.2.2.1 HDMX 
The HDMX protein is structurally related to HDM2, with a strictly conserved p53 binding 
domain [336]. It also contains a conserved RING finger domain, but is not able to act as an E3 
ubiquitin ligase towards p53. Rather, this domain is though to be important for the interaction 
with HDM2 [337;338]. Transgenic mice models have shown that MdmX (the mouse 
equivalent of HDMX) acts in vivo as an essential, non-redundant, negative regulator of p53 
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during embryonic development [339-341], and similarly HDMX is assumed to be a crucial  
regulator of p53 in a variety of cellular settings. The mechanistic details underlying this 
regulatory effect still remain to be fully elucidated. HDMX has been implicated as a possible 
regulator of p53 protein stability, but recent evidence has cast doubts on such a role. 
Currently, it is thought that HDMX does not participate in the regulation of p53 stability 
independently of HDM2. Whether it does so in an HDM2-dependent manner remains unclear 
(reviewed in [328]). While the importance of HDMX as a regulator of p53 stability appears to 
be loosing ground, there is accumulating evidence that HDMX is a crucial negative regulator 
of p53 transcriptional activity [294;342;343]. 
 
Transcriptional repression by HDMX and HDM2 
HDMX has been demonstrated to interact with p53 at the promoters of specific p53 target 
genes [307], resulting in inhibition of their transcriptional activation. However, the 
mechanistic details of how the repression is performed are unresolved. HDMX has been 
shown to decrease p300-mediated acetylation of p53 [344;345], and this might contribute to 
its repressive effect. Like HDMX, HDM2 can form a protein complex with p53 at the 
promoters of its target genes [307;346;347]. The possible role of HDM2 as a transcriptional 
repressor of p53 is, however, still controversial [291-293].  
 
Anti-repression 
The release of p53 from repression by HDMX and HDM2 may occur by two different 
mechanisms. One involves the stress-induced phosphorylation and acetylation of p53 that 
alleviate its interaction with HDMX and HDM2. The other is brought about by post-
translational modifications of HDMX and HDM2. Phosphorylation of HDMX inhibitis its 
associtation with HAUSP, resulting in its accelerated turnover [208;323;348]. Similarly, post-
translational modifications of HDM2 have been shown to result in increased HDM2 
degradation [305]. It should be noted that although anti-repression of p53 might be sufficient 
to activate p53-dependent transcription at a select set of highly responsive targets, it is thought 
to be insufficient to induce many of the p53 targets involved in apoptosis [305]. 
 
Promoter-specific activation 
To activate gene expression patterns involved in particular p53-driven cellular outcomes, it is 
envisioned that particular combinations of post-translational modifications involving 
acetylation, methylation, sumoylation, and neddylation, as well as recruitment of specific co-
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factors might act as a barcode guiding the select activation of target genes [305]. For instance, 
acetylation of p53 is not required for transcription of HDM2 or PIRH2 involved in feedback 
and promotion of cell survival. Partial acetylation is sufficient for transcription of CDKN1A 
and GADD45 (growth arrest and DNA damage 45) involved in transient growth arrest and 
DNA repair, whereas specific acetylation is required for transcription of pro-apoptotic genes 
[305]. As an example of the latter, acetylation at K120 occurs after DNA damage or activation 
of p14AFR, and is essential for transcription of PUMA and BAX [349;350].  
 
The ASPP (ankyrin-repeat-, SH3-domain- and proline-rich-region-containing proteins) family 
represents an example of co-factors that influence the promoter specificity of p53. This family 
consists of two pro-apoptotic members ASPP1 and ASPP2, and one anti-apoptotic member 
iASPP (reviewed in [351]). ASPP1 and ASPP2 promote binding of p53 to pro-apoptotic 
target genes such as BAX, PUMA and PIG3 (p53-inducible gene 3) [352;353], whereas iASPP 
prevents the transcriptional activity of p53 bound to pro-apoptotic promoters [354].  
 
4.5.3 Biological functions of p53 
The p53 network is normally ‘off’. It is activated only when cells are stressed or damaged 
[355]. Genes shown to be regulated by p53 can be grouped into various biological activities 
such as apoptosis, cell cycle regulation, senescence, energy metabolism, DNA metabolism, 
angiogenesis, immune response, cell differentiation, motility and migration, cell-cell 
communication, and most recently stem cell control (reviewed in [253;356;357]). Among 
these, only apoptosis and senescence have been directly implicated in mediating the effect of 
p53 as a tumour suppressor, and these will be discussed in more detail below. 
 
4.5.3.1 Apoptosis 
p53 can act at multiple levels of both the intrinsic and extrinsic apoptotic pathways through 
induction of pro-apoptotic and suppression of anti-apoptotic target genes. In addition it can 
contribute to the execution of apoptosis through non-transcriptional mechanisms.  
 
Transcription-dependent induction of apoptosis 
p53 induces the transcription of a vast number of genes involved in the positive regulation and 
execution of apoptosis. These include members of the BCL-2 family (BAX, BID, PUMA, and 
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NOXA), components of the core apoptotic machinery (APAF-1, caspase-8, and caspase-6), 
components of the extrinsic apoptotic pathway (DR5, FAS, TNFSF10, TNFSF6), and other 
less-defined factors (AEN, p53AIP, PERP, and PIG3). In addition, p53 can contribute to the 
transrepression of anti-apoptotic factors such as BCL-2, survivin, ARC, and gelactin-3 [358]. 
The relative relevance of these and other factors to the apoptotic response unleashed by p53 
activation in a given cellular setting is not determined and probably varies according to cell 
type and cellular context. Even though p53 activation clearly can contribute to the execution 
of apoptosis through the extrinsic pathway, it is generally assumed that cells that have 
engaged p53-dependent apoptosis typically follow the intrinsic apoptotic pathway [359].  
 
Of the above mentioned p53 target genes, PUMA (p53 up-regulated modulator of apoptosis) 
has recently received much attention as an important mediator of p53-induced apoptosis, as it 
in many instances seems to be able to account for virtually all the pro-apoptotic activity of 
p53. PUMA is highly conserved between human and mouse [360], and is also conserved and 
serves similar functions in more distant vertebrates such as zebrafish [361]. No PUMA 
homologue has been identified in lower eukaryotes, but the BH3-only protein Egl-1 might be 
its functional counterpart in C. elegans [362]. PUMA is normally expressed at very low levels 
[360], but is rapidly induced upon stress. This induction seems to depend solely upon 
transcriptional activation of PUMA. Although the PUMA gene promoter has binding sites for 
multiple transcription factors, studies have indicated that p53 and the p53 binding sites in the 
PUMA promoter are indispensable for its induction by DNA damage [360;363]. PUMA has 
been shown to be essential for p53-dependent apoptosis in a number of cell culture systems 
[363-367]. In mice, Puma is induced in a p53-dependent fashion in tissues such as neurons, 
thymocytes, haematopoietic cells, spleen and intestinal crypts, and Puma KO mice are highly 
protected from ionizing radiation (IR)-induced apoptosis in all of these tissues [368-371]. 
These apoptotic defects resemble those observed in Trp53 KO mice [243;372]. Furthermore, 
the p53-dependent PUMA induction has been demonstrated to be the major mechanism 
resulting in IR-induced apoptosis in hematopoietic and intestinal stem cells and progenitor 
cells, contributing significantly to the resulting tissue injury [371;373]. Collectively, these 
findings place PUMA as an essential mediator of p53-dependent apoptosis.  
 
Transcription-independent induction of apoptosis 
A fraction of stress-stabilized p53 rapidly translocates to the outer mitochondrial membrane 
[374;375] where it has been found to interact with several members of the BCL-2 family. By 
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interacting with and neutralizing BCL-XL and BCL-2, it can act analogously to a sensitizer 
BH3-only protein [376;377]. Further it can act analogously to an activator BH3-only protein 
by binding to BAK and thereby relieving it from MCL-1 inhibition [376;378], and by 
activating BAX through transient interaction [125]. Even though this mitochondrial action of 
p53 can proceed independently of its nuclear action, there are also suggestions that the two 
pathways might cooperate, with p53-induced PUMA being able to release cytoplasmic p53 
that is sequestered by BCL-XL, thereby allowing it to migrate to the mitochondrion [365]. 
Indications of the in vivo relevance of these findings come from whole body IR of mice. In 
radiosensitive organs, there is a rapid translocation of p53 to the mitochondria that triggers an 
early wave of apoptosis which is subsequently followed by PUMA induction and a second 
wave of apoptosis. Lack of p53 accumulation at the mitochondria after IR correlates with cell 
cycle arrest and the complete absence of apoptosis [379]. 
 
4.5.3.2 Cell cycle arrest and senescence 
Whereas cell cycle arrest is a reversible process, senescence is by definition a cellular state of 
irreversible growth arrest. Senescence was originally described in relation to the observed 
limited proliferation potential of normal cells experiencing accumulating telomere erosion 
with increasing cell divisions. Such erosion will beyond a critical limit trigger a DNA damage 
response with subsequent activation of p53, resulting in growth arrest [380;381]. p53-induced 
senescence can also be initiated by non-telomeric signals such as oncogene activation [382] 
and DNA damage caused by other events than telomere shortening [383;384].  
 
Central p53 target genes implicated in cell cycle arrest are CDKN1A (encoding p21Cip1), 
GADD45 and 14-3-3 [385]. p21Cip1 is an inhibitor of CDK2-cyclin E activity, whereas 
GADD45 and 14-3-3 inhibit CDK1 activity. In addition, p53 can repress the expression of 
cell cycle progression genes such as CDK4 and CCNE2 (encoding cyclin E2), as well as cell 
cycle phosphatases such as CDC25A and CDC25C [386-388]. The induction of p21Cip1 is also 
important in p53-induced senescence, but the factors determining the cell’s decision between 
transient and permanent cell cycle arrest remain elusive. One possible mechanism is that the 
resolution of DNA damage by successful repair will inhibit p53 – p21Cip1 signalling, whereas 
irreparable/sustained DNA lesions or other stimuli leading to sustained p53 and p21Cip1 
activation will maintain a senescent phenotype [162]. Compared to the relatively well-defined 
sequence of events involved in p53-mediated apoptosis and cell cycle arrest, the details in 
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p53-mediated senescence are only partially understood. Beyond the need for p21Cip1 
induction, MIC-1 (macrophage inhibitory cytokine-1) has been identified as a p53-responsive 
gene involved in senescence. MIC-1 is a cytokine of the TGF-β family which might propagate 
a senescence programme by autocrine or paracrine induction [389]. Also, p53 can stabilize 
PAI-1 (plasminogen activator inhibitor-1) mRNA through direct binding [390], thereby 
facilitating increased translation of PAI-1, an established marker of senescent cells [391;392].  
 
4.5.4 p53 and cancer 
Even though p53 has formally been recognized as a tumour suppressor for many years, 
several aspects regarding how this task is being performed are still unresolved. This is perhaps 
not surprising taking into account all the different stimuli that can elicit a p53 response, the 
vast number of genes that can be regulated by such activation, and the many biological 
endpoints that can ensue (Figure 25). What is known is that there is strong selection against 
the p53 pathway in almost all cancers, irrespective of cell type or the underlying oncogenic 
mechanism [4]. Examples of questions that are yet unanswered are: how p53 discriminates 
between normal and tumour cells; what signals drive selection for loss of p53 function in 
cancers; when during tumourigenesis p53 is crucially triggered; and which of the many 
biological functions of p53 are required to forestall tumourigenesis [4]. 
 
Figure 25. A simplified view of p53 signalling. The figure provides an overview of the various stress factors 
that affect the p53-HDM2 feedback loop leading to accumulation of p53, with consequent transcriptional and 
non-transcriptional downstream events leading to different outcomes for the cell depending on the severity of 
stress. Adapted from [393]. 
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4.5.4.1 Transformation-related activation of p53 
With regards to the signalling pathways involved in activating p53 in response to malignant 
transformation, there have been two leading and contesting theories. The first is the activation 
of p14ARF in response to activated oncogenes, the second is activation of the DDR pathways.  
 
p14ARF 
p14ARF is activated specifically in response to oncogenic signalling [394]. This is a persistent 
and obligate feature of tumour cells and could therefore be regarded a tumour-specific p53-
activating pathway. Several mouse models have recently provided support for an essential 
role for p14ARF (p19ARF in mice) in p53-mediated tumour suppression, seemingly at the 
expense of a possible role of the DNA damage pathway. G. I. Evan’s group developed mice in 
which the endogenous Trp53 was substituted with an inducible p53 (p53ERTAM induced by 
the administration of 4-OHT) [395]. Mice were divided into two groups, having their p53 
activated or not during whole body IR. The p53 status during irradiation did not affect the 
occurrence of lymphoma in these mice. Activating p53 a while after exposure to IR, on the 
other hand, did confer protection, but this was dependent on the presence of p19AFR. An 
inverse approach was employed by L.A. Donehower’s group, using mice in which a timed 
excision of the Trp53 gene could be performed, also demonstrating that the p53 status at the 
time of IR had no impact on tumourigenesis [396]. Yet a different approach utilized by J. 
Serrano’s group yielded a similar conclusion. They used ‘super-p53’ mice harbouring an extra 
transgenic copy of Trp53. These mice showed superior tumour suppression compared to their 
diploid counterparts, but this protection was lost in an Arf-deficient background [397]. Even 
though these studies provide compelling evidence for the in vivo role of ARF and seemingly 
cast strong doubts on the possible role of DNA damage signalling, two matters of concern 
have been raised as to their generalizability and interpretation. First, there is the matter of 
difference between mice and men. Mice lacking p19ARF are highly tumour prone [398], and 
spontaneous inactivation of Cdkn2aARF is common during tumour progression [399-401]. In 
humans, tumour-related mutations at the CDKN2A locus target mainly p16INK4A and not 
p14ARF [402;403], raising the possibility that p14ARF might play a more central tumour-
suppressive role in mice than in humans. Second, it can be argued that the effect of short-
lived, intense DNA damage induced by IR cannot necessarily be compared to the more 
prolonged and sustained activation of DNA-damage pathways that have been observed in 
different stages of tumourigenesis.  
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DDR pathways 
Many studies support the notion that DNA damage checkpoints respond to oncogene 
activation. Analyses of early-stage human tumours show that cells in the earliest precursor 
lesions show constitutive activation of DNA damage signalling pathways in the absence of 
signs of chromosomal instability or TP53 mutation [404-408]. This is in contrast to highly 
proliferative normal tissues, suggesting that it is a tumour-specific phenomenon. Experimental 
models have also supported these findings, demonstrating that checkpoint proteins are 
activated upon controlled increase of oncogene expression in cultured cells [406], and during 
induction of hyperplasia in human skin xenografts [408]. Signs of DNA damage signalling are 
also found in more developed and malignant tumours, but they are often lost in advanced 
tumours, suggesting perhaps a selective pressure to eliminate components of this pathway. 
Mechanistically, it is proposed that oncogenes, leading to untimely activation of CDKs, might 
lead to impaired or inappropriately activated origins of replication resulting in DNA 
replication stress. In support of the notion that oncogene-induced DNA damage is replication-
associated, studies have demonstrated that if replication is enforced through the expression of 
cyclin E or H-Ras, the markers of DNA damage do not appear if the cells are blocked from 
entering S phase [404;405].  
 
4.5.4.2 Outcomes in p53-mediated tumour suppression 
As previously mentioned, the long list of biological outcomes affected by p53 signalling 
contains several candidates that might be implicated in p53-mediated tumour suppression. 
However, thus far apoptosis and senescence are the only outcomes that have directly been 
shown to contribute to this function of p53, and the relative importance of the two probably 
partly depends on the cell type giving rise to a given tumour. For instance, lymphocytes are 
known to be very prone to undergo p53-dependent apoptosis, and upon reactivation of p53 in 
mice with Eμ-myc-driven lymphomas, rapid and extensive tumour regression due to apoptosis 
has been described [409-411]. In models of murine sarcomas and hepatocellular carcinomas, 
on the other hand, p53 restoration induced senescence with consequent tumour regression due 
to immune clearance [411;412].  
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4.5.4.3 Modes of p53 inactivation in cancer 
 
p53 mutations 
Somatic TP53 mutations are common in most human cancers, ranging from 5 to 80% 
depending on type, stage, and aetiology of tumours [413]. Figure 26 shows the prevalence of 
TP53 mutations according to tumour site. As mentioned previously, the erroneous use of 
cDNA from mutant p53 for in vitro transfection studies in the 1980’s led to the misleading 
initial conclusion that TP53 was a proto-oncogene. On the positive side, however, it provided 
an early clue to the potential of mutant p53 to promote cancer. 
 
 TP53 stands out from most other classical tumour suppressor genes with respect to its 
spectrum of mutations in cancer material. Whereas the classical finding is biallelic 
inactivation by deletions or truncating mutations, TP53 most frequently (74%) presents with 
single monoallelic missense mutations resulting in the formation of a stable full-length 
protein, often found massively accumulated in cancer cells. The majority of these missense 
mutations are mapped to the DBD, usually resulting in the abrogation of sequence-specific 
DNA binding activity [414] (Figure 27).  
 
This has led to speculations that rather than resulting in mere ‘loss-of-function’, TP53 
mutations might contribute to cancer development through ‘gain-of-function’ or through 
dominant-negative effects on the remaining wt p53. Intense studies on the effects of TP53 
mutations both in vitro, in vivo in mouse models, and from clinical data has not yet clearly 
concluded how TP53 mutations exert their tumour-promoting effect (reviewed in [414]). This 
likely reflects a very complex picture in which ‘loss-of-function’, ‘gain-of-function’, and 
dominant-negative effects might all play a role, perhaps to varying extents depending on the 
type of TP53 mutation and the general genetic make-up of the specific tumour in question. In 
addition to questions regarding the functional role of TP53 mutations in tumour development, 
there has been considerable interest in possible effect of TP53 mutations on cancer prognosis 
and prediction of treatment response. Early studies using immune histochemistry, in which 
high levels of p53 in a tumour was interpreted as a sign of the presence of mutated TP53, 
yielded conflicting results. However, more recent studies based on gene sequencing, seem to 
suggest a general trend in which TP53 mutations are associated with poor overall and disease-
free survival, as well as with poor drug response [415]. 
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Figure 26. The prevalence of TP53 mutations by tumour site. The figure shows how the prevalence of TP53 
mutations differ greatly between cancers with the highest prevalence found in ovarian cancer and the lowest 
prevalence found in cervical cancer. Adapted from [416]. 
 
 
 
 
Figure 27. The type and location of cancer-related TP53 mutations. (a) The pie diagram shows the 
distribution of cancer related TP53 mutations according to the type of mutation, with missense mutations being 
most frequent. (b) The figure illustrates the location of cancer-related TP53 mutations with the vast majority 
occurring in the DNA binding domain (DBD), many of which localize to one of six mutational hot spots. 
Adapted from [414]. 
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Deregulation of wt p53 
In spite of the common occurrence of p53 mutations in human tumours, a high proportion still 
retains wt p53, and it is generally assumed that these tumours must employ strategies to keep 
their p53 activity in check. Examples of such strategies include HDM2 amplification and 
overexpression, suppression of p53 by viral products, and loss of p14ARF. 
 
HDM2 is found amplified in 10% of all cancers with the highest incidence of 67% in 
Hodgkin’s lymphoma. In addition, it is found overexpressed in the absence of amplification in 
many tumours (reviewed in [417]). Specifically, in paediatric ALL, the majority of which 
retain wt p53, overexpression of HDM2 is a common event [418]. 
 
One example of virus-induced deregulation of p53 is found in cervical cancer which is almost 
always associated with infection with one of several high-risk human papilloma viruses 
(HPV). High-risk HPVs encode a viral protein, E6 that recruits the cellular ubiquitin ligase 
E6-associated protein (E6AP), facilitating p53 polyubiquitination and proteasomal 
degradation [419-423]. Due to the strong association between development of cervical cancer 
and HPV infection, it is not surprising that cervical cancers have the lowest frequency of p53 
mutations when tumours are classified according to site (Figure 26). Other DNA viruses have 
also been shown to express proteins that can interfere with p53. Examples include SV40 
[424], adenovirus [425], and hepatitis B virus (HBV) [426-428]. HBV infection is a well-
established risk factor for hepatocellular carcinoma. SV40 infection can cause an array of 
rodent tumours, and traces of SV40 infection can be found in many human tumours. Whether 
there is a causal link is uncertain, but findings seem to implicate SV40 at least in the 
development of mesothelioma [429]. The retrovirus human T cell lymphotropic virus type 1 
(HTLV-1), has also been shown to interfere with p53 signalling [430;431], and this virus is a 
causative factor in the development of adult T cell leukaemia.  
 
Deletion of CDKN2A leads to the loss of p14ARF. This unleashes HDM2 activity, resulting in 
untimely p53 degradation. Such deletions are observed in cancers of various locations such as 
breast, brain and lung, and are especially frequent in the absence of TP53 mutation [355]. 
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Polymorphisms in the p53 pathway 
Inherited variations in genes of the p53 pathway can theoretically affect p53 levels or activity 
in response to transformation to influence cancer susceptibility, and later in response to DNA-
damaging treatment regimens, to affect therapy response and disease outcome.  
 
With respect to the TP53 locus itself, numerous single nucleotide polymorphisms (SNPs) and 
other sequence variations have been identified (reviewed in [432]). The best described is a 
non-synonymous SNP in the TP53 coding region at codon 72 located in the SH3 domain of 
p53, encoding either proline (p53-P72) or arginine (p53-R72). The current view is that p53-
R72 is more efficient than p53-P72 at inducing apoptosis and protecting stressed cells from 
neoplastic development. This has led to the hypothesis that individuals carrying the p53-R72 
allele might be protected against cancer relative to individuals carrying the p53-P72 allele. 
Several studies evaluating the effect of the codon 72 polymorphism on cancer susceptibility 
have indeed reported statistically significant differences. However, the size and design of 
these studies have been criticized, suggesting that much larger studies than those undertaken 
will have to be performed to ascertain a polymorphism-dependent cancer risk difference 
[432].  
 
In HDM2, a T to G SNP at nucleotide 309 in the first intron has been the most intensively 
characterized [252]. Within this intron lies an estrogen receptor-sensitive promoter/enhancer 
region for HDM2, and the G allele has been shown to increase the affinity to the transcription 
factor specificity protein 1 (SP1), resulting in increased transcription and expression of 
HDM2 [252]. Some clinical studies have demonstrated that the presence of the G allele is 
associated with lack of response to therapy, poorer survival and outcome in various cancers 
(reviewed in [433]). Regarding cancer susceptibility, several studies have demonstrated an 
earlier age of onset or an increased susceptibility to breast cancer in premenopausal women 
carrying the G allele [252;434;435], whereas other studies show no association [432]. Also, in 
patients with Li-Fraumeni syndrome, the G allele has been associated with accelerated tumour 
formation [252;436-438]. 
 
4.5.4.4 Prospects for p53 based therapy 
The principle of so-called ‘targeted cancer therapy’ has gained substantial interest with the 
expanding universe of known aberrations in cancer on the molecular level. The most 
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successful attempts thus far have been directed towards cell surface molecules which can be 
targeted by antibodies, or enzymes that can be targeted by small molecular enzyme inhibitors. 
A variety of such compounds are already in common clinical use. As p53 is neither a surface 
molecule nor an enzyme, the design of drugs aiming to target it has proven more difficult. 
Two main approaches have been attempted: the use of p53 gene therapy and the use of small 
molecular compounds with the ability to restore p53 activity.  
 
p53 gene therapy 
Regarding gene therapy, there have been two main approaches. The first is delivery of TP53 
via an adenoviral vector. One compound is already in clinical use against head and neck 
cancer in China [439], whereas another is in phase III clinical trials [440]. An alternative 
approach is the use an E1B-deficient lytic virus which can only replicate in p53-deficient 
cells, thus providing selective cytolysis to p53-deficient tumour cells [441]. This compound 
has yielded promising results in clinical trials [393].  
 
Small molecular modulators of p53 
Regarding small molecular compounds aiming to restore p53 activity, several different 
strategies have been employed to identify promising candidates. The mechanism of action of 
these compounds can be divided into three main categories: 1) reactivation of mutant p53, 2) 
activation of wt p53, and 3) cyclotherapy (for a recent comprehensive review, see [442]). One 
example of a compound capable of reactivating mutant p53 is PRIMA, which has been shown 
to interact with mutated p53, causing a change in conformation which can restore wt function 
[443]. Examples of compounds capable of activating wt p53 are nutlins, MI-219, RITA and 
tenovins. Nutlins and MI-219 are designed to bind to the p53-interacting surface on HDM2, 
thereby inhibiting p53 degradation [444;445]. RITA is a compound which has also been 
found to inhibit p53-HDM2 interaction; however, it appears to do so by binding p53 rather 
than HDM2 [446]. Tenovins are inhibitors of SIRT1 and SIRT2 deacetylases, preventing p53 
deacetylation and thereby promoting p53 stabilisation and transcriptional activity [447]. 
Whereas activation of p53 is potentially cytotoxic to tumour cells retaining wt p53, it can be 
used in a protective manner during treatment of tumours harbouring mutated p53. This is the 
principle behind the concept of cyclotherapy, in which normal cells are placed in a temporary 
cell cycle arrest by inducing p53 using non-genotoxic drugs such as nutlins. As the cancer 
cells harbouring mutated p53 would not be affected by this treatment, they continue cycling, 
and are rendered sensitive to treatment with mitotic inhibitors as opposed to the arrested 
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normal tissue [442]. In this way, the therapeutic window of the mitotic inhibitor is increased. 
The clinical potential for the use of small molecular modulators of p53 activity is yet to be 
determined, as the above-mentioned compounds are all still in the preclinical stages of 
investigation or in early clinical trials [442]. 
 
4.6 B lymphocytes 
B (bursal or bone marrow-derived) lymphocytes can be defined as “a population of cells that 
express clonally diverse cell surface immunoglobulin (Ig) receptors recognizing specific 
antigenic epitopes” [448]. Along with their close relatives, the T (thymus-derived) 
lymphocytes, they constitute the major players in our adaptive immune system, and their 
origin can be traced back to the evolution of adaptive immunity in jawed vertebrates more 
than 500 million years ago [449]. As implied by its name, the initial development of the B 
lymphocyte takes place in the BM, which is hence termed a primary lymphoid organ. The 
immature B lymphocyte is then released into the blood stream, and can upon encounter with 
an antigen undergo functional maturation in a secondary lymphoid organ such as a lymph 
node, the spleen or mucosa-associated lymphoid tissues (MALT). The antibody-secreting 
plasma cell represents the terminally differentiated B lymphocyte, and is the functional end-
point of B lymphocyte development.  
 
4.6.1 B lymphocyte development in the bone marrow 
The process of haematopoiesis starts with the haematopoietic stem cell (HSC) which is 
present within a population of BM cells expressing CD34 [450]. HCS gives rise to a 
lymphoid-restricted cell termed the common lymphoid progenitor (CLP). CLP is assumed to 
be CD7+CD10+, but the phenotype of this cell is not firmly established [451]. In addition to B 
and T lymphocytes, the CLP can give rise to natural killer cells (NK) and dendrittic cells (DC) 
(Figure 28). 
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Figure 28. Model for haematopoietic development from the haematopoietic stem cell. HSC: haematopoietic 
stem cell; CLP: common lymphoid progenitor; T: T lymphocyte; NK: natural killer cell; p/cDC: 
plasmacytoid/conventional dendritic cell; B: B lymphocyte; CMP: common myeloid progenitor; GMP: 
granulocyte monocyte progenitor; mo: monocyte; Gr: granulocyte; MEP: megakaryocyte erythrocyte progenitor. 
Adapted from [451]. 
 
The current consensus for the BM development of B lymphocytes is that the B lineage-
restricted cell pass through the following stages: early B, pro-B, large pre-BI, large pre-BII, 
small pre-BII, immature B, and mature B [451] (Figure 29). All B lineage-committed cells 
prior to immature B lymphocytes are commonly referred to as B cell precursors (BCPs) [452]. 
 
An important event during early B lymphocyte development is the formation of the B cell 
receptor (BCR). Crucial events are recombinations at the variable regions of the heavy (VH) 
and light (VL) chain Ig genes, which lay the basis for generation of primary antibody 
diversity. Each VL region is composed of many different long variable gene segments (V) and 
short joining gene segments (J). The VH region is similarly constructed, but with an additional 
diversity gene segment (D). By random recombination events termed V(D)J recombination, 
one of the many V and J gene segments of the light chain regions, and one V, D and J gene 
segment in the heavy chain region are combined. This results in a combinatorial 
  63 
diversification which greatly contributes to antibody diversity. The mechanistic background 
for V(D)J recombination lies in an enzymatic complex termed RAG which is transcriptionally 
switched on in two waves corresponding to VH and VL rearrangement during B lymphocyte 
development (Figure 29). RAG functions as an endonuclease, inserting double strand breaks 
at specific recombination signal sequences between the gene segments. It then initiates 
rejoining by recruiting enzymes involved in NHEJ. As NHEJ is an error prone process in 
which a variable number of nucleotides might be lost or inserted, this further contributes to 
the process of diversification of the VH and VL gene regions.  
 
Figure 29. Bone marrow stages of B lymphocyte development. Overview of the different stages of early B 
lymphocyte development with expression of cell surface markers, enzymes and the state of V(D)J 
rearrangement. Adapted from [451]. 
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As rearrangement of the VH locus completes in pro-B lymphocytes, the cells start producing 
their μ heavy chain, but it is not expressed on the cell surface until the large pre-BII stage. As 
the recombination at the VL locus is not completed in these cells, μ associates with a surrogate 
light chain, forming the pre-BCR. Pre-BCR probably signals through ligand-independent 
oligomerization [453], and the expression of pre-BCR with subsequent signalling events is a 
prerequisite for further B lymphocyte development [454]. At the small pre-BII stage, VL 
recombination completes, making possible the expression of the true BCR at the immature B 
stage. Initially, only surface IgM (sIgM) is expressed, but by alternative splicing events of the 
constant region of the heavy chain (CH), sIgD is later coexpressed, marking the development 
into a mature B lymphocyte.  
 
4.6.2 Functional maturation of B lymphocytes 
Immature B lymphocytes can respond to certain types of antigens such as lipopolysaccarides 
in a T lymphocyte-independent manner. This results in differentiation into an IgM-secreting 
plasma cell, eliciting a rapid but relatively low affinity antibody response [455]. Most mature 
B lymphocytes reside within secondary lymphoid organs where they encounter and respond to 
antigens presented by DCs in a T lymphocyte-dependent manner. Such antigenic stimulation 
results in proliferation and differentiation into IgM-secreting plasma cells. In addition, some 
of the stimulated cells will enter the germinal centre (GC) where they differentiate into a 
rapidly proliferating state termed centroblasts. In the GC, the processes of affinity maturation 
and class switching takes place, greatly increasing the potency of the antibody response 
towards the antigen in question.  
 
Affinity maturation is the result of an increased mutation rate occurring in the V region 
coding sequence, termed somatic hypermutation (SHM). Centroblasts undergo repeated 
cycles of SHM, and only those cells that subsequently express BCRs with increasingly better 
affinity for the presented antigen will receive survival stimuli, the remaining cells being 
removed by apoptosis. Thus a clonal selection of the B lymphocytes developing the most 
efficient antibody takes place. Class switching is a process in which the original IgM and IgD 
expression is replaced by IgA, IgE or IgG expression. As opposed to the change between IgM 
and IgD which is a result of alternative splicing of transcripts from unaltered germline DNA, 
class switching involves genomic recombination, and is thus referred to as class switch 
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recombination (CSR). During CSR, specific switch sequences flanking the various C regions 
ensure the deletion of intervening DNA sequences. This results in the joining of the VDJ 
region to a new C region, encoding the α, ε or γ heavy chain instead of the μ or δ heavy chain. 
Due to functional differences between the different Ig heavy chains, class switching result in a 
more potent antibody response compared to what is initially achieved through IgM and IgD 
production. 
 
 
Figure 30. B lymphocyte development, activation and maturation. The figure summarizes the development 
of B lymphocytes in the bone marrow from the CLP to the immature B lymphocyte which is released into the 
circulation. There, it can be activated directly in response to certain antigens, or develop into a mature B 
lymphocyte residing in secondary lymphoid tissues. The mature B lymphocytes will upon encounter with an 
antigen partly give rise to plasma cells that produce the initial IgM response, and partly move to the germinal 
centre where they undergo affinity maturation by SHM and CSR, resulting in the delayed IgG/IgE/IgA response 
and the generation of memory cells providing long-term protection. Modified from [448]. 
 
Some of the B lymphocytes successfully surviving the process of clonal selection during a GC 
response will develop directly into effector cells in the form of Ig-secreting plasma cells. 
These plasma cells will secrete antibodies with increased affinity and altered biological effect 
towards the encountered antigen, and thus help booster the response towards the pathogen. 
Others will develop into memory cells expressing the refined antibody on their surface. These 
cells can survive in the body for prolonged periods of time, ensuring a rapid and efficient 
response to the same pathogen upon repeated exposure. Figure 30 summarizes some of the 
central events in B lymphocyte development, activation and maturation. 
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4.6.3 B lymphocyte malignancies 
The various stages of B lymphocyte development outlined in figure 30 have malignant 
counterparts reflecting the expansion of a dominant subclone. This results in the development 
of various types of leukaemias and lymphomas (Figure 31). 
 
 
Figure 31. Human B-lymphoid malignancies. The figure provides an overview of the different diseases with 
corresponding developmental stages of the cell of origin. CML-LBC: chronic myelocytic leukaemia-lymphoid 
blast crisis; other abbreviations are explained within the text. Adapted from [448]. 
 
The term leukaemia literally means ‘white blood’, and strictly speaking refers to a situation in 
which there is a highly increased amount of malignant white blood cells in the circulation in 
combination with suppressed erythropoiesis resulting in anaemia. The primary site of 
affection in many leukaemias such as ALL and chronic lymphocytic leukaemia (CLL) is the 
BM, with the expansion of transformed clones that are arrested at different stages of 
differentiation. In many cases of ALL, the spillover of leukaemic blasts into the peripheral 
circulation is quite low, and leukocytosis is therefore not an obligate finding in ALL. CLL 
cells on the other hand, phenotypically resemble later stages of B lymphocyte development 
and typically result in marked leukocytosis. The term lymphoma describes a solid lymphoid 
tumour mass. Lymphomas typically result from malignancies arising from developmental 
stages corresponding to B lymphocytes that reside in the secondary lymphoid tissues. The B 
lineage-derived lymphomas include small lymphocytic lymphoma (SLL), mantle cell 
lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), 
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Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Malignancies with phenotypes 
indicating a post-germinal centre origin, can present both as leukaemias as is the case for 
hairy cell leukaemia (HCL), and as solid tumours as is the case for marginal zone lymphoma 
(MZL), plasmablastic lymphoma (PL), multiple myeloma (MM), and Waldenström’s 
macroglobulimaemia (WM). Although applicable to most cases of lymphoid malignancies, 
the original strict distinction between leukaemias and lymphomas does not always reflect 
distinct stages of origin, but can in some cases merely reflect different stages of essentially the 
same disease. This is the case for leukaemia/lymphoma pairs such as CLL and SLL, ALL and 
lymphoblastic lymphoma, as well as Burkitt’s lymphoma/leukaemia. Figure 31 summarizes 
the different B-lymphoid malignancies according to their developmental stage. 
 
4.6.3.1 B cell precursor acute lymphoblastic leukaemia (BCP-ALL) 
ALL is the most common childhood cancer with approximately 200 new cases in the age 
group under 18 years being diagnosed in the Nordic countries every year. It has a peak 
incidence at 2 to 5 years of age, but also occurs, albeit with low incidence, in adults and the 
elderly. Both B and T lymphocyte precursors can give rise to ALL, but BCP-ALL is by far the 
most predominant subtype in all age groups.  
 
Biology 
Historically, ALL has been diagnosed and subgrouped according to the morphological 
appearance of the blasts in BM smears and biopsies. Typically, ALL blasts are small to 
intermediary in size with scanty cytoplasm, condensed nuclear chromatin and indistinct or 
absent nucleoli (Figure 32). However, less commonly blasts may be larger with finely 
dispersed chromatin and prominent nucleoli [456]. Reflecting the developmental stage of the 
cell of origin, BCP-ALL cells often express a variety of B lymphocyte-specific surface and 
cytoplasmatic antigens such as PAX-5, CD19, CD22, CD24, and CD79a. A large proportion 
also expresses CD10, CD34 and terminal deoxynucleotidyl transferase (TdT). Depending on 
their immunophenotype, BCP-ALLs can be classified into B-I (pro-B), B-II (common B), B-
III (pre-B), or B-III (pre-B/B) (Table 2). In addition to the immunophenotypic examination, 
cytogenetic characterization is used to subgroup BCP-ALLs, yielding further information 
about biological and pharmacological features that are important in risk stratification of the 
patients. The two most common genetic abnormalities in paediatric patients are 
hyperdiploidity and the t(12;21) translocation resulting in a TEL/AML1 fusion gene, both of 
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which are favourable prognostic markers. Unfavourable cytogenetic features include 
t(9;22)(q34;q11) (Philadelphia chromosome) resulting in the BCR/ABL fusion gene, 
t(4;11)(q21;q23) or t(19;11)(p13;q23) resulting in AF4/MLL or ENL/MML fusion genes 
respectively, and a hypodiploid karyotype [456].   
 
 
 
Figure 32. Common morphology of BCP-ALL. (A) Bone marrow smear showing small blasts with a high 
nuclear to cytoplasmic ratio, condensed nuclear chromatin and indistinct nucleoli. (B) Bone marrow biopsy 
showing the intense infiltration of the marrow cavity with ALL blasts. Adapted from [456]. 
 
 
 
 cyCD79 CD19 HLA-DR CD10 CD20 TdT cyIgM sIg 
B-I  
pro-B  
+ + + − − + − − 
B-II 
common-B 
+ + + + +/− + − − 
B-III  
pre-B 
+ + + + +/− + + − 
B-III  
pre-B/B 
+ + + + +/− + + + (κ/λ −) 
 
 
Table 2. Immunophenotypic classification of BCP-ALL. Based on criteria defined by the European Group for 
the Immunological Characterization of Leukemias (EGIL) [457;458]. 
 
 
Clinical presentation 
ALL often has an acute onset, although some patients present with a more insidious 
development of symptoms. Symptoms and signs reflect the blast burden and degree of BM 
replacement. Fever is common, and can either be a direct consequence of the leukaemia or of 
infections caused by neutropenia. Fatigue and lethargy result from anaemia, and bleeding 
diathesis from thrombocytopenia. Bone and joint pain are also very common and are a 
consequence of the expansion of the BM cavity. Frequently involved extramedullary sites of 
blast infiltration include lymph nodes, liver, spleen, and meninges. In addition, infiltration of 
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the orbital tissues, testes, tonsils and adenoids can be seen, all yielding symptoms and signs 
specific for the location of the leukaemic infiltrate. A peripheral blood count commonly 
reveals anaemia, thrombocytopenia and neutropenia. The total white blood cell count can be 
suppressed, normal, or elevated depending on the amount of blasts escaping to the peripheral 
circulation. Only about 15% of patients present with hyperleucocytosis, defined as more than 
100 x 109 cells/L [456].  
 
Treatment and outcome 
In general, treatment of BCP-ALL involves short-term intensive multimodal chemotherapy 
with high-dose methotrexate, cytarabine, cyclophosphamide, prednisolone or dexamethasone, 
vincristine, L-asparaginase, and/or an anthracyclin. This is followed by consolidation therapy 
with lower intensity regimens over several years. Radiation therapy can be used for localized 
treatment of central nervous system (CNS) or testicular involvement, or towards other 
localized infiltrates responding poorly to chemotherapy. Allogenic BM transplantation or 
high-dose chemotherapy with autologous stem cell support is used for certain patients.  
 
In the Nordic countries, paediatric BCP-ALL is treated according to a protocol developed by 
the Nordic Society of Paediatric Haematology and Oncology (NOPHO). As children are 
especially vulnerable to the long-term effects of chemotherapy and irradiation, and as the 
prognosis in terms of long-term survival is very good for a significant group of the patients, it 
is vital to achieve good risk stratification. This allows the standard risk group, encompassing 
more than 50% of all patients, to be treated according to relatively low-intensity protocols. 
This is expected to yield few and limited long-term side effects, whilst still keeping a cure rate 
of 90-95%. About 15% of the patients fall into a high-risk group needing treatment with a 
very intensive protocol to reduce their rate of treatment failure. The remaining intermediate-
risk patients are offered intensive therapy balanced against a need for acceptable short- and 
long-term side effects. CNS irradiation causes serious side effects in children both with 
regards to endocrine [459] and neurocognitive [460;461] function, as well as predisposing to 
secondary brain tumours [462]. The NOPHO ALL protocol from 2008 has therefore excluded 
this treatment modality altogether and replaced it with CNS-penetrating chemotherapy and 
intensified intrathecal therapy. Risk stratification of patients is initially performed at diagnosis 
based on white blood cell count and CNS involvement, and is later revised based on 
karyotype and treatment response, the latter reflected by BM minimal residual disease (MRD) 
and degree of clearance of CNS involvement [463]. Due to adaptation of therapy according to 
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risk stratification, improvements in supportive care, and optimization of existing 
chemotherapeutic drugs, survival rates after treatment for paediatric ALL has improved from 
less than 10% in the 1960s to 75-80% at present [456]. Figure 33 shows the development in 
event-free survival in different treatment eras in the Nordic countries.  
 
T im e from  d iagnosis  (years)
2 62 42 22 01 81 61 41 21 086420
P
ro
b
ab
ili
ty
1 ,0
0,9
0,8
0,7
0,6
0,5
0,4
0,3
0,2
0,1
0,0
S u rv iv al F un c tio n s
pEvent free survival
0.020.781571017ALL-2000
0.010.774221648ALL-92
0.020.7031093786-91
0.020.5634471981-85
SEpEFS 5 yEventsNEra
81-85
86-91
A LL-92
A LL-2000
U pdate M arch 2008  
Figure 33. Event-free survival of paediatric ALL in the Nordic countries. Adapted from [463]. 
 
Adult ALL patients generally have a poorer prognosis, with overall survival rates of 40-50% 
[464]. In Norway, these patients are treated with combinatorial chemotherapy regimens 
according to a protocol termed ‘Hammersmith-82’. Irradiation treatment is still employed 
against localized infiltrates and recurrence with CNS involvement, and BM transplantation is 
used more frequently than in paediatric patients [465]. 
 
4.6.4 Epstein-Barr virus infection 
The Epstein-Barr virus (EBV) is a member of the herpesvirus family of DNA viruses. 
Herpersviruses are ubiquitous in nature, but humans serve as the only natural host for EBV. 
Its discovery was facilitated by D. Burkitt, who in 1958 described a common cancer primarily 
affecting children in specific regions of Africa, which he postulated might be caused by a 
virus [466]. The disease was termed Burkitt’s lymphoma (BL), and in 1964 the virus was 
visualized by electron microscopy of a cell line established from BL, thus becoming the first 
virus clearly implicated in the development of a human tumour [467].  
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More than 90% or the human population are carriers of EBV. The virus is transmitted from 
host to host via saliva, and primary infection is thought to begin at the oropharyngeal 
epithelium with secondary infection of B lymphocytes trafficking in close proximity to these 
cells [468]. Most individuals are infected during the first decade of life, normally undergoing 
an asymptomatic infection. However, primary infection during adolescence or adulthood is 
often accompanied by a self-limiting lymphoproliferative disease known as infectious 
mononucleosis [469]. After the primary infection, EBV persists in a subset of circulating 
resting memory B lymphocytes with the viral genome existing in an episomal form at low 
copy numbers in the cell’s nucleus [468].  
 
4.6.4.1 In vitro EBV transformation of B lymphocytes 
Even though EBV may infect epithelial cells, T lymphocytes, macrophages, granulocytes, and 
NK cells [468], its preferential target is B lymphocytes. Attachment to the host cell is 
achieved through the binding of the viral envelope glycoproteins gp350 to CD21 [470] and 
gp42 to HLA class II molecules [471]. In vitro, EBV has the unique ability to transform 
resting B lymphocytes into permanent, latently infected lymphoblastoid cell lines (LCLs). 
EBV-transformed LCLs carry multiple copies of the viral episome, and constitutively express 
a limited set of viral gene products termed latent proteins [472]. The infection also changes 
the expression pattern of host genes yielding high levels of B lymphocyte activation markers 
and cell adhesion molecules that are usually absent or expressed at low levels in resting B 
lymphocytes This indicates that EBV-induced immortalization can be elicited through 
constitutive activation of the cellular pathways involved in driving physiological B 
lymphocyte proliferation [472].   
 
4.6.4.2 EBV-associated malignancies 
EBV has been associated with several types of B lymphoid lymphomas in addition to various 
carcinomas (reviewed in [468]). As opposed to what has been demonstrated for several other 
DNA viruses with oncogenic potential (see section 4.5.4.3), there is little evidence that EBV 
encodes viral proteins which inactivate tumour suppressors such as p53 or pRB. Indeed p53 
expression and function appear normal in LCLs. Rather, the evidence indicates that EBV 
subverts downstream parts of normal cell signalling pathways involved in cell growth [473]. 
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The EBV-associated lymphomas can be broadly divided into three groups: lymphomas in 
immunosuppressed patients, BL and HL. These are described briefly below. 
 
The T lymphocyte-directed immunosuppressive treatment given to patients after 
transplantations is associated with a greatly increased risk of lymphomas, also termed post-
transplant lymphoproliferative disease (PTLD). These are nearly always of B lymphocyte 
origin and EBV-positive [474]. Studies of V gene mutations and SHM indicate that the PTLD 
cells have a close relationship to centroblasts [475-477]. They express the full set of latent 
EBV genes seen in LCL, indicating that EBV plays an important role in driving the 
proliferation of the infected B lymphocytes in PTLD. Some lymphomas seen in highly 
immuncompromised AIDS patients show essentially the same phenotype [472]. 
  
BL can be divided into two groups, the high-incidence endemic form that affects children in 
areas of holoendemic malaria, and the low-incidence sporadic form seen in children in the 
developed world. In the former, EBV is present in all cases, whereas in the latter, EBV is 
present in about 15% of cases [472]. In the EBV-positive tumours, expression of EBV-
encoded genes is much more restricted than is the case for PTLD, so exactly how EBV 
contributes to the pathogenesis in BL is not clear. However, the phenotype of the transformed 
cells again points to centroblasts as being the cells of origin. Indeed, translocations of MYC 
into one of the immunoglobulin loci, resulting in constitutive activity, is a hallmark of BL, 
and the structure of chromosomal breakpoints strongly indicates that the translocations occur 
as an erroneous result of either CSR or SHM [478;479]. 
 
HL is characterized by atypical, large tumour cells known as Reed-Sternberg (RS) cells which 
typically constitute less than 1% of the tumour mass. EBV is detected in approximately 40% 
of cases of classical HL in the developed world, but nearly all cases in children from Latin 
America [480]. As for BL, only a restricted number of EBV-derived genes are expressed, and 
the role of EBV in the pathogenesis is not established. However, as for the other EBV-
associated lymphomas, genetic analysis of RS cells point to GC B lymphocytes as the cells of 
origin [469].  
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4.7 cAMP 
The cyclic ribonucleotide 3'-5'-cyclic adenosine monophosphate (cAMP), was originally 
identified in 1957 as a heat-stable factor produced in the presence of epinephrine and 
glucagon by cell-free liver homogenates, leading in turn to the formation of liver 
phosphorylase [481]. Soon after, this factor was shown to be identical to an adenine 
ribonucleotide, produced by degradation of ATP, initially thought to be a cyclic 
dianhydrodiadenylic acid [482], later corrected to be a monomeric cyclic phosphate [483].  
 
With time, cAMP has become recognized as a prototypical second messenger, being utilized 
as a signalling molecule in all domains and kingdoms of life [484]. In vertebrates, cAMP 
signalling is usually initiated through hormone or transmitter binding to G protein-coupled 
receptors (GPCRs). This leads to activation of the heterotrimeric G protein complex, in which 
the Gα subunit dissociates from the Gβγ subunits. The stimulatory form of Gα (Gαs) then 
activates an adenylyl cyclase (AC) which catalyzes the conversion of ATP to cAMP. The 
levels of cAMP are controlled by its rate of synthesis by AC and its rate of degradation by 
phosphodiesterases (PDEs). For a long time, the only known target of cAMP was protein 
kinase A (PKA). However, it has now become clear that cAMP can also stimulate the activity 
of Rap1-guanine nucleotide exchange factor proteins directly activated by cAMP (EPACs), 
and a subgroup of cyclic nucleotide-gated (CNG) ion channels. Another important realization 
has been that cAMP does not act by random diffusion from its site of synthesis to its effectors, 
but that cAMP signalling is organized into signalling units or signalosomes. In these 
signalosomes the GPCR, AC, PDE, PKA, PKA targets, and other factors are brought in close 
proximity, providing crucial spatiotemporal control of the many cAMP pathways. 
 
4.7.1 Regulation of cAMP levels 
4.7.1.1 G protein-coupled receptors   
GPCRs encompass the largest family of membrane proteins and mediate most cellular 
responses to hormones and neurotransmitters. In addition they play central roles in the 
transmission of sensory signals involved in vision, olfaction and taste [485]. Structurally, 
GPCRs are characterized by the presence of seven membrane-spanning α-helices separated by 
alternating intracellular and extracellular loop regions. These regions provide specificity to 
the GPCR function by linking the binding of given ligands to effects mediated by given G 
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protein subtypes as well as G protein-independent signalling. The heterotrimeric G proteins 
act as switches that turn on or off downstream signalling cascades in response to GPCR 
activation (Figure 34). They are composed of three subunits: α, β and γ, and are inactive in 
their heterotrimeric conformation in which Gα binds GDP and the constitutive Gβγ dimer. 
Activation of GPCRs induces a conformational change which permits G protein binding and 
catalyzes GDP release from Gα. This results in the formation of a stable, high affinity 
complex between the receptor and the G protein. Binding of GTP to Gα destabilizes the 
complex, leading to the release of Gα(GTP) and Gβγ, which can both bind to effectors in the 
cell, contributing to initiation of signalling cascades. The response is then terminated by the 
hydrolysis by Gα of GTP to GDP and subsequent reassociation of Gα(GDP) with Gβγ. This 
hydrolysis can be accelerated by regulators of G protein signalling (RGSs), which are multi-
functional, GTPase-accelerating proteins [486]. 
 
 
 
 
Figure 34. The G protein cycle. Heterotrimers of α(GDP), β and γ subunits are recruited to the activated GPCR 
(R*) upon binding of its ligand, resulting in GDP release. Subsequent binding of GTP to Gα causes dissociation 
of R*, Gα(GTP) and Gβγ. The G protein subunits can then activate various effectors (E) before the signal is 
terminated by the hydrolysis of GTP to GDP by Gα which may be catalyzed by RGSs. Adapted from [486]. 
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With regards to cAMP generation, two subgroups of Gα family members termed Gs 
(stimulatory G protein) and Gi (inhibitory G protein) are responsible for the regulation of AC 
activity upon GPCR activation (Table 3).  
 
  
Table 3. Gα protein classification. The table shows the classification of different members of the Gα protein 
family with corresponding effector molecules. Adapted from [487]. 
 
 
4.7.1.2 Adenylyl cyclases 
The generation of cAMP is universally catalyzed by members of the AC family. The catalytic 
mechanism of ACs is depicted in figure 35. 
 
 
Figure 35. The catalytic mechanism of cAMP generation by ACs. The substrate ATP is converted to a 
magnesium stabilized penta-covalent transition state in which the incoming and leaving groups are aligned, 
before completion of the reaction yielding cAMP and pyrophosphate. Modified from [484]. 
 
 
In mammals, nine transmembrane ACs (tmACs) and one soluble AC (sAC) have been 
identified. tmACs are directly regulated by GPCRs and heterotrimeric G proteins as described 
above (reviewed in [488]). In addition certain other proteins such as calmodulin, A-kinase 
anchoring proteins (AKAPs), Ric8a and Snapin can affect the activity of various tmAC 
isoforms through direct interaction (reviewed in [489]), and they are also subject to regulation 
ATP cAMP 
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by PTMs [490-492]. sAC on the other hand is regulated by bicarbonate [493] and calcium 
levels [494;495], and is insensitive to regulation by G proteins [496].  
4.7.1.3 Direct cAMP transfer through gap junctions 
In addition to the endogenous production of cAMP induced by activation of AC, cAMP can 
also be provided through transfer from neighbouring cells. As early as in the 1970s it was 
demonstrated that cAMP could move through junctional channels [497;498]. cAMP has 
subsequently been shown to be able to pass through gap junctions composed of different 
classes of connexins (Cx), but whether the permeability of these junctions allowes for 
delivery of sufficient amounts of cAMP to be physiologically relevant has been questioned. 
Recently, Cx43 was shown to yield particularly favourable permeability to cAMP, resulting in 
rapid delivery in sufficient quantity to trigger relevant intracellular responses [499]. 
Regarding the role of such cell-to-cell delivery of cAMP, it has also recently been 
demonstrated that naturally occurring T regulatory lymphocytes (T regs) harbour high levels 
of cAMP that can be delivered to responder T lymphocytes via gap junctions, and that this 
delivery is crucial to T reg-mediated T lymphocyte suppression [500]. 
 
4.7.1.4 Phosphodiesterases 
cAMP is a relatively stable molecule, and the only means of inactivating the cAMP signal 
within the cell is to actively degrade it [501]. The only known degradation route for cAMP is 
its conversion to 5’AMP by PDEs [502]. Mammalian PDEs comprise the products of 21 
genes which are categorized into 11 different families based on structural similarity. Members 
of the PDE5 and PDE6 families are cGMP-specific, whereas the remaining families are 
comprised of members that are either cAMP-specific or display dual specificity. Additional 
complexity arises from the use of alternative promoters and alternative splicing resulting in 
various transcripts from given subfamily genes [503]. All PDEs have a conserved C-terminal 
catalytic domain with 35 to 50% sequence homology, whereas the unique characteristics of 
each individual PDE variant are defined by protein domains located in the N-terminal part. 
The combination of unique tissue-specific expression patterns, gene regulation, enzymatic 
regulation by phosphorylation and interacting proteins, subcellular localization, and 
interaction with associated proteins, allows for complex and tight regulation of PDE activity 
[503]. In haematopoietic cells, PDE4 is the predominant PDE family. It is made out of four 
genes; 4A, 4B, 4C, and 4D which encode about 20 distinct isoform members [504]. PDE4A 
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expression is fundamentally ubiquitous [505;506], whereas PDE4B and PDE4D are the 
predominant isoforms in cells of the immune system [507;508]. 
 
4.7.2 cAMP effectors 
4.7.2.1 PKA 
PKA was discovered in 1968 as one of the first protein kinases [509]. The holoenzyme is a 
heterotetramer composed of two catalytic (C) subunits bound non-covalently to a regulatory 
(R) subunit dimer [510;511]. The enzymatic activity of the C subunit is kept in check by its 
sequestration by the R subunits, and its release is brought about by a conformational change 
in the R subunit precipitated by the binding of cAMP (reviewed in [511]). cAMP binds in a 
cooperative manner to two sites on each R subunit, and the binding of a total of four cAMP 
molecules results in the dissociation of the R dimer and the two C monomers [512]. The C 
monomers then act as serine/threonine kinases capable of phosphorylating a wide array of 
targets within the cell.  
 
There are four genes encoding different R subunits: RIα, RIβ, RIIα, and RIIβ, and three genes 
encoding different C subunits: Cα, Cβ, and Cγ (reviewed in [513]). Variants of PKA are 
divided into two main classes of isozymes: PKAI and PKAII, based solely on their content of 
RI or RII subunits, respectively. R isoforms are differentially expressed in tissues [514-516], 
and their subcellular distribution is also distinct [517-520]. PKAII is typically found in a 
particulate pattern in subcellular structures and compartments caused by its interaction with 
AKAPs. RI has low affinity for most AKAPs, and PKAI has largely been considered soluble 
and cytoplasmic; however, some RI-specific and dual-specific AKAPs capable of anchoring 
PKAI have been identified (reviewed in [521]). 
 
4.7.2.2 cAMP effectors other than PKA 
In addition to PKA, two other families of proteins contain a cAMP binding domain (CBD) 
allowing their activity to be regulated by cAMP: EPAC and CNG ion channels. EPACs were 
identified in 1998 [522;523], and shown to activate the Ras superfamily small GTPases RAP1 
and RAP2 in a cAMP-dependent manner. There are two EPAC isoforms, EPAC1 and 
EPAC2, of which EPAC1 is ubiquitously expressed whereas EPAC2 is more limited in its 
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tissue distribution [522;523]. They have later been shown to be involved in a wide variety of 
cAMP-regulated cellular functions such as cell adhesion, cell-cell junction, 
exocytosis/secretion, cell differentiation and proliferation, gene expression, apoptosis, cardiac 
hypertrophy and phagocytosis (reviewed in [524]). CNG ion channels are strictly ligand-gated 
channels whose opening requires the binding of cAMP or cGMP. They regulate the flux of 
Na+, K+ and Ca2+, and play an important role in the signal transduction pathways of vision and 
olfaction. In addition, cAMP and cGMP can facilitate opening of a second group of ion 
channels termed hyperpolarization-activated cyclic nucleotide-gated (HCN) channels by 
shifting their voltage dependence (reviewed in [525;526]).  
 
4.7.2.3 Transcriptional regulation by cAMP 
Some of the cAMP-dependent cellular effects are mediated through changes in gene 
transcription, many of which are a result of PKA-mediated phosphorylation and subsequent 
activation of a subgroup of transcription factors that contain basic region leucine zippers 
(bZIPs). PKA-activated bZIP-containing factors include cAMP response element binding 
protein (CREB), cAMP response element modulator (CREM), and activating transcription 
factor-1 (ATF-1) (reviewed in [527]). In addition, there is evidence that several genes can be 
regulated by cAMP in a PKA-independent manner, but it is presently not clear which 
transcription factors are involved in such PKA-independent, cAMP-responsive gene 
expression. There is some evidence of transcription factor activation downstream of EPAC 
activation. In addition, other guanine nucleotide exchange factors (GEFs) such as the PDZ-
domain containing GEF1 and 2 (PDZ-GEF1/2) are putative cAMP sensors that might be 
involved in PKA-independent transcriptional regulation (reviewed in [527]).  
  
4.7.3 cAMP signalosomes 
With the vast number of GPCRs capable of eliciting cAMP generation by ACs, and with the 
equally vast number of substrates of EPACs and PKAs, cAMP signalling needs to be 
carefully compartmentalized in order to obtain the necessary signal specificity. For PKA-
mediated effects, the existence of such cAMP signalosomes is firmly established, in which a 
given ligand binds to its GPCR which signals through associated G proteins to a neighbouring 
AC resulting in cAMP production. The synthesized cAMP will be restricted to a localized 
pool due to the existence of anchored PDEs in the vicinity of the AC, and this allows spatial 
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and temporal control of the cAMP signal. The signal is further delivered to a nearby PKA 
which is similarly anchored to subcellular structures by the means of AKAPs, thus eliciting 
the distinct biological outcome intended for the ligand in question (Figure 36). 
 
 
 
Figure 36. The cAMP signalosome. The figure illustrates the spatiotemporal control of cAMP signalling 
achieved by the close proximity of the signal input (GPCR), generator (AC), effector (PKA anchored by AKAP) 
and terminator (PDE). Adapted from [528]. 
 
The AKAPs constitute a family of structurally diverse proteins defined by their ability to bind 
the R subunit of PKA. In addition to their PKA-binding domain, all AKAPs contain a unique 
targeting domain directing the PKA/AKAP complex to defined subcellular structures, 
membranes or organelles. Many AKAPs also possess further domains enabling interaction 
with several other proteins involved in signal transduction, thus enabling them to form 
multivalent signal transduction complexes (reviewed in [521]).  
 
4.7.4 Biological effects of cAMP 
cAMP signalling contributes to the regulation of a wide array of biologically distinct cellular 
processes, examples of which include cardiovascular function, steroid biosynthesis, 
reproductive function, metabolism, exocytosis, and immune function (reviewed in [521]). In 
cells of the immune system, cAMP is well established as an important physiological signal 
transducer. On example is provided by the stimulation of the T cell receptor/CD3 complex 
resulting in transient formation of cAMP, which limits further activation of the cells [529] (for 
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a comprehensive recent review, see [530]). Lymphocytes possess GPCRs for catecholamines 
and prostaglandin E2 (PGE2), and engagement of these receptors by their respective ligands, 
has been shown to exert a growth-inhibitory effect mediated by the elevation of cAMP levels 
[531-534]. In addition to its many roles in normal cell physiology, distorted cAMP signalling 
has been suggested to be exploited by cancerous cells. 
 
4.7.4.1 cAMP signalling in cancer 
With the range and complexity of cAMP signalling in normal physiological processes 
outlined above, it comes as no surprise that the possible role of cAMP signalling in 
transformed cells has proven to be a complex issue. Indications of involvement of the 
different levels in the cAMP signalling cascade will be briefly discussed below. 
 
GPCRs 
Two well-described classes of GPCRs that can elicit a cAMP response are PGE2 receptors 
(EP receptors) and β-adrenergic receptors (β-ARs). Overexpression of cyclooxygenase 2 
(COX2), leading to augmented PGE2 production and EP signalling, has been implicated in the 
tumourigenesis of a wide variety of cancers (reviewed in [535]). However, EP signalling is 
complex, and increased cAMP levels have not been directly implicated in the tumour-
promoting properties of PGE2. With regards to β-AR signalling, murine models of ovarian 
cancer have demonstrated that exposure to chronic stress can promote tumourigenesis, and 
this effect has been directly associated with increased tissue catecholamines yielding 
increased β2-AR stimulation with subsequent activation of the cAMP-PKA pathway. Human 
studies have shown that increased β2-AR activity in breast cancer patients is associated with 
accelerated tumour growth. Conversely, males on β-blocker therapy have in some studies 
been shown to have a reduced risk of prostate cancer (reviewed in [536]). 
 
G proteins 
Activating mutations of Gαs resulting in constitutive AC activation is implicated in the 
pathogenesis of several endocrine tumours. The reason why cells of a subset of endocrine 
tissues are especially vulnerable to increased cAMP-PKA signalling is that CREB is involved 
in the transcription of specific primary response genes that initiate proliferation in these cells 
[537]. Growth hormone releasing hormone (GHRH) is produced in the hypophysis and 
stimulates growth hormone (GH)-producing cells in the pituitary gland, whereas thyroid 
  81 
stimulating hormone (TSH) is produced in the pituitary gland and stimulates thyroxine (T4)- 
and triiodothyronine (T3)-producing cells in the thyroid gland. Both GHRH and TSH are 
ligands of Gαs-coupled GPCRs. Specific point mutations of the αs subunits have been 
identified which result in abrogation of their intrinsic ATPase function and thus yield 
constitutive AC activation [538;539]. The mutationally activated forms of Gαs are commonly 
referred to as the gsp (Gs protein) oncogene, and occurs with high frequency in pituitary 
adenomas, thyroid adenomas and thyroid carcinomas [539;540].     
 
PDEs 
The possible role of PDEs in cancer has been particularly well studied in haematopoietic 
malignancies in which the PDE4 family plays the most prominent role in negative regulation 
of cAMP levels. Due to the anti-proliferative effect observed with cAMP in lymphoid cells, it 
has been hypothesized that transformed lymphoid cells would benefit from keeping their 
cAMP levels low by upregulating PDE activity, and that pharmacological inhibition of PDE 
could be a potential therapeutic strategy. PDE4 inhibition by theophylline or rolipram has 
been demonstrated to sensitize ALL and B-CLL cells to apoptosis in vitro when combined 
with corticosteroids or chlorambucil respectively. In DLBCL samples, high PDE4B 
expression has been shown to be correlated with poor prognosis, and it has thus been 
suggested that consequent suppression of cAMP levels might result in a growth or survival 
advantage in these tumours. However, this result should be interpreted with caution as PDE4B 
is a cAMP responsive gene, and it is thus possible that the causal relationship could be 
reversed with augmented PDE4B expression being a consequence of increased cAMP 
signalling (for an extensive review on PDEs in haematological malignancies, see [541]). 
 
cAMP levels 
There have been a few reports on enhanced cAMP levels in primary tumour samples 
[542;543]. However, these estimations of the cAMP content have been considered inaccurate 
due to inefficient separation of malignant cells of solid tumours from the surrounding stromal 
cells [543]. Regarding the effect of increased cAMP signalling in tumour-derived cell lines, 
the results are highly cell specific, with induction of growth arrest or apoptosis seen in some 
lymphoid and prostate cancer cell lines [541;544], and increased resistance to apoptosis-
inducing agents being observed in some cells of the myeloid lineage [545;546]. 
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PKA 
Several lines of evidence indicate that PKAI activity is associated with growth and 
proliferation, whereas PKAII activity is associated with differentiation and decreased 
proliferation [547;548]. In keeping with this, the RIα subunit has been found upregulated in a 
number of cell lines, as well as in primary tumour cells (reviewed in [549;550]). Additionally, 
there is evidence of an increased RI to RII ratio in human cancer tissues of different origins. 
Switching of this ratio has been suggested as a novel cancer treatment strategy, with the PKAI 
downregulator 8-Cl-cAMP as well as antisense RIα being tested in clinical trials [551]. 
 
AKAPs 
Polymorphic variants of AKAPs 10 and 13 have been found to be associated with increased 
familial breast cancer risk. As AKAP13 is an upstream effector of Ras homolog gene family 
member A (RhoA) signalling, it has been suggested that the polymorphic variant might result 
in constitutive RhoA activation. Regarding AKAP10, the polymorphism has been found to 
favour binding and activation of RIα, which could possibly contribute to a PKAI-skewed 
phenotype in these cells.  
 
CREB 
Several lines of evidence support a role for CREB in oncogenesis. In acute myeloid leukaemia 
(AML), CREB is an established proto-oncogene and is found overexpressed in the majority of 
patients. In clear cell sarcoma (CCS) CREB is translocated to the fusion oncoprotein Ewing’s 
sarcoma protein (EWS)-CREB, and in the process of immortalization of T lymphocytes with 
HTLV-1, CREB activation has been shown to be essential (reviewed in [552]). In addition, 
the tumour suppressor activity of LKB1 is in part mediated through inhibition of CREB 
activity. LKB1 is a serine/threonine kinase mutated in most cases of the inherited intestinal 
polyposis syndrome Peutz-Jegher’s syndrome (PJS), and constitutive activation of CREB has 
been demonstrated in samples from PJS patients [553]. 
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5 AIMS OF THE STUDY 
Previous studies in our laboratory have demonstrated that cAMP can inhibit proliferation of 
lymphoid cells by inducing both a G1 arrest [554;555] and an intra-S phase arrest [556]. In 
the latter paper it was also demonstrated that cAMP could profoundly attenuate the effect of S 
phase-specific cytotoxic drugs. This effect of cAMP could in large part be attributable to its 
ability to inhibit DNA replication, but prompted us to investigate whether cAMP could 
additionally exert a direct inhibitory effect on the DNA damage response (DDR).  
 
The overall aim of the present study was thus to explore the relation between cAMP levels 
and DDR in lymphoid cells, specifically aiming to: 
1) Unravel the effects of and mechanisms involved in cAMP-mediated regulation of DDRs. 
2) Elucidate the clinical relevance of cAMP in regulation of DDR by using BCP-ALL as a 
model system. 
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6 SUMMARY OF THE PAPERS 
 
PAPER I: 
Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL 
cells through abrogation of p53 accumulation. 
The aim of the present study was to explore whether cAMP could inhibit DNA damage-
induced cell death in lymphocytes through direct effects on the DDR machinery. The BCP-
ALL-derived cell line Reh was used as a model system, and DNA damage was induced by IR 
or cell cycle phase-independent cytotoxic drugs. We found that cAMP could profoundly 
inhibit the apoptotic cell death induced by DNA damage, and identified p53 as the most 
upstream component of the DDR pathway affected. The cAMP-induced reduction of DNA 
damage-mediated p53 accumulation was shown to be a prerequisite for the inhibitory effect of 
cAMP on apoptosis. The possible clinical relevance of our findings was underlined by our 
demonstration that cAMP was equally able to inhibit p53 accumulation and cell death in a 
small sample of primary BCP-ALL blasts that were treated with IR or DNA-damaging drugs 
commonly employed in conventional treatment of BCP-ALL. 
 
PAPER II: 
Activation of cAMP signalling interferes with stress-induced p53 accumulation in ALL-
derived cells by promoting the interaction between p53 and HDM2.  
In this paper we aimed to elucidate the mechanisms whereby cAMP prevented the DDR-
induced accumulation of p53 observed in paper I. We could show that cAMP inhibited p53 at 
the level of protein stability, and that this was caused by restoration of the levels of p53 
ubiquitination and consequent proteasomal degradation. The activity of the p53-directed E3 
ubiquitin ligase HDM2 was demonstrated to be necessary for the inhibitory effect of cAMP 
on p53 accumulation, and more specifically, cAMP was shown to promote the interaction 
between HDM2 and p53. 
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PAPER III: 
EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase.  
EBV infection is known to cause resistance of B lymphocytes to certain growth inhibitors. 
The aim of this paper was to examine whether EBV infection would affect the ability of 
cAMP to act as a growth inhibitor of B lymphocytes, and if so, to investigate the effect of 
EBV on cAMP-mediated inhibition of cell death induced by S phase-specific cytotoxic drugs. 
This study showed that although EBV infection rendered cells resistant to the inhibitory 
effects of the GPCR ligand isoprotenerol and the AC activator forskolin, it had no effect on 
the sensitivity of cells to growth inhibition induced by direct stimulation of PKA. 
Mechanistically, this was explained by defective AC activation with consequent pronounced 
inhibition of cAMP induction and PKA activation. The inability of forskolin to inhibit DNA 
replication and to induce S phase arrest in EBV-infected cells was also shown to render cells 
insensitive to the normal inhibitory effect of cAMP on cell death induced by the S phase-
specific DNA-damaging compound camptothecin.  
 
PAPER IV: 
Selective inhibition of cell death in malignant versus normal B cell precursors: 
Implications for cAMP in development and treatment of BCP-ALL.  
Based on our results from the BCP-ALL cell line Reh in papers I and II, we wished to explore 
whether cAMP-mediated suppression of the tumour suppressor p53 could have implications 
for development and treatment of BCP-ALL. To address this, we collected primary blasts 
from nine paediatric BCP-ALL patients and primary CD10+ BCPs from seven healthy 
volunteers. We could show that effects of cAMP on p53 levels and DNA damage-induced cell 
death previously described in Reh cells were reproduced in the primary BCP-ALL blasts, 
supporting the clinical relevance of our findings in the Reh cell line. In addition, cAMP 
provided BCP-ALL blasts with a pronounced protection against spontaneous cell death in 
culture. In contrast, the viability of normal BCPs was not enhanced by cAMP treatment, 
implying that the pro-survival effect of cAMP might be a malignancy-associated trait. We 
found no difference in the levels of total cellular cAMP between BCP-ALL blasts and normal 
BCPs, indicating that there is no selection for constitutively increased cAMP production 
during transformation. However, co-culturing BCP-ALL blasts with a BM-derived stromal 
cell layer could mimic the effect of cAMP on blast survival and p53 levels, suggesting that the 
leukaemic blasts might be provided with cAMP-mediated protective signals through their 
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interaction with the stromal cells. Finally, preliminary results suggest that abrogation of the 
cAMP signalling pathway through inhibition of PKA can augment the cytotoxic effect of 
DNA-damaging treatment, prompting further investigation into the possible clinical use of 
PKA inhibitors with the aim to potentiate conventional BCP-ALL treatment. 
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7 DISCUSSION 
7.1 Methodological considerations 
7.1.1 Cell systems 
A number of different cell systems have been used in this study: continuous cancer cell lines 
(Reh, EU-3, U2OS, MCF-7), immortalized normal cell lines (EBV-infected B lymphocytes, 
TK6 and WTK1 cells derived from the spontaneously transformed B lymphoblast cell line 
WI-L2, iMSC#3 cells which are hTERT immortalized BM-derived mesenchymal stroma 
cells), as well as primary cultures of cancer cells (BCP-ALL blasts) and normal cells (normal 
peripheral B and T lymphocytes, normal BCPs, BM-derived stromal cells). The cell systems 
that were used most extensively will be discussed in more detail below. 
 
7.1.1.1 Cell lines 
Since the first human cancer-derived cell line HeLa was established in 1951 (reviewed in 
[557]), cell lines have been invaluable tools in the study of human cell biology in general and 
cancer biology in particular. Continuously growing cell lines offer many advantages in cell 
research. They represent an almost unlimited supply of cells with relatively stable genotypes 
and phenotypes, thus avoiding the problem of interindividual variation. They also bypass the 
ethical issues associated with animal and human experiments [558]. However, cancer cell 
lines may not represent an optimal model for the study of human cancers. Cell lines are not 
easy to establish, and the cancers that yield successful cell lines tend to be fast growing, high 
stage, poorly differentiated, and often metastatic; reflecting the need for genetic changes that 
are often late events in cancer progression [558]. Therefore, although cancer cell lines have 
been demonstrated to be quite genetically stable and able to recapitulate the histopathology of 
the original tumour after subcutaneous injections, they cannot automatically be regarded as 
good models for the clinical spectrum of cancers at their site of origin [558].  
 
Several studies comparing the gene expression profile of cancer cell lines to that of primary 
normal and cancerous tissues from the same site of origin have been conducted. Expression 
patterns have been found to cluster according to the tissue of origin [559], but cell lines also 
tend to share large sets of signatures that can be said to be cell line-specific independent of the 
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tissue of origin [560]. Common to most of these gene expression studies is the finding that it 
is the lymphoma and leukaemia cell lines that most accurately model the gene expression 
pattern of their corresponding primary tumour [561] (reviewed in [562]). Cytogenetic 
aberrations producing pathophysiologically relevant fusion gene products are common 
occurrences in haematological malignancies, and it has been shown that key signatures are 
retained between primary cancer samples and cell lines with similar genetic aberrations 
[563;564]. These signatures probably reflect regulatory networks of importance for the 
transforming abilities of the primary genetic changes, and it is thus thought that lymphoma 
and leukaemia cell lines provide a relatively good model system to study the pathophysiology 
of their corresponding primary malignancies.  
 
Reh 
The Reh cell line was originally derived in 1973 from the peripheral blood of a 15 year old 
North African girl diagnosed with ALL at first relapse [565;565]. At the time, her disease was 
diagnosed as a ‘non-T, non-B ALL’. However, with the advent of immunophenotypic and 
cytogenetic classification, Reh was found to represent a BCP-ALL-derived cell line. 
Immunophenotypic traits include CD34−CD10+CD19+cyIgM−sIg−TdT+, providing the basis 
for its classification as stemming from a B-II (common-B) BCP-ALL [566]. Further, it is one 
of very few BCP-ALL cell lines harbouring the t(12;21)(p13;q22) translocation resulting in 
the expression of the TEL/AML1 fusion gene which is a common cytogenetic aberration 
occurring in approximately 25% of primary paediatric BCP-ALL specimens [567]. Evidence 
suggests that the TEL/AML1 fusion gene represents an initiating mutation that is necessary but 
insufficient for leukaemia development in this subgroup of BCP-ALL. It is thought to arise 
predominantly during faetal haematopoiesis at a rate that considerably exceeds that of overt 
clinical ALL, and the TEL/AML1-harbouring clones have been shown to expand and persist 
for more than a decade in a clinically covert state [568;569]. The exact function of the 
TEL/AML1 fusion protein in the leukaemogenic process is not definitely determined. 
However, AML1 has been shown to function as a DNA-binding transcriptional activator 
required for the expression of genes associated with normal haematopoiesis, and evidence 
suggest that TEL/AML1 might specifically repress AML1-dependent activation, possibly 
contributing to a differentiation block of early BCPs (reviewed in [569]). Additional genetic 
abnormalities in Reh include loss of 9p21.3 involving the p16INK4a/ARF locus, which is 
another common occurrence in paediatric BCP-ALL [570].  
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iMSC#3 
iMSC#3 is an immortalised BM-derived human mesenchymal stroma cell line generated by 
transduction with the pBabe-puro-hTert adenovirus [571]. It has been demonstrated to be non-
tumourigenic, have a normal karyotype, and maintain osteogenic and adipogenic potential as 
well as the ability to support B lymphocyte maturation [572]. We used this cell line to support 
the viability of primary BCP-ALL blasts in culture. In vivo, the bone marrow 
microenvironment (BMME) provides a far more complex supportive surrounding for normal 
and malignant BCPs, with osteoblasts, entothelial cells and BM stromal cells supplying them 
with a mulititude of both secreted and cell bound factors. However, the finding that iMSC#3 
could affect blast survival to a similar extent as primary BM stromal cell cultures, strongly 
suggests that this cell line provided the blasts with some of the crucial physiological stimuli 
normally provided by the BMME. 
 
7.1.1.2 Primary cell cultures 
BCP-ALL blasts 
Although leukaemic cell lines in general have been shown to provide relatively good models 
to study leukaemias, and Reh in particular has been shown to share many of the 
immunophenotypic and genetic traits commonly observed in paediatric BCP-ALL, we 
considered it important to examine whether we could reproduce the results from Reh cells in 
primary cancer material. To this end, we initiated a pilot study on primary BCP-ALL blasts 
isolated from paediatric patients at diagnosis. There are important limitations concerning the 
quantity and variety of experiments that can be performed on such material. Isolation of cells 
yields limited material with limited life span, and many useful tools in molecular biology such 
as transfection are virtually impossible to make use of in primary cells. These cultures 
therefore primarily served the purpose of confirming the validity of key findings from more 
elaborate molecular studies performed in Reh.  
 
BCP-ALL blasts were isolated from 1-3 ml of BM aspirate. Isolation of mononuclear cells 
(MNCs) was performed by density gradient centrifugation, and the proportion of BCP-ALL 
blasts in this population was evaluated by co-staining of CD10 and CD19 followed by FACS 
analysis. The yield of MNCs varied between 3 x 106 and 555 x 106 cells, probably reflecting 
both variations in the blast burden of the patients, and in the quality of the received BM 
aspirates. The proportion of CD10+CD19+ cells varied between 34 and 90%. Low relative 
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blast content was probably due to either partly conserved normal BM function or to admixture 
of peripheral blood during the sample collection. Contaminating cells were excluded from 
subsequent cell death measurements by subpopulation analysis of the CD19+ cells; however, 
they were not excluded from immunoblot analysis of p53 or measurement of total cellular 
cAMP levels. This represents a possible source of error in the interpretation of results from 
the latter two analyses. The proportion of contaminating cells could have been reduced by 
proceeding with additional selection procedures on the MNC-population in parallel to what 
was performed on normal BM samples. However, such selection was not carried our in order 
to minimize loss of cells.  
 
Normal BCPs 
Normal BCPs were isolated from 50-100 ml BM aspirates from healthy voluntary donors. 
Because normal BCPs account for only a minor portion of the MNCs from normal BM, we 
enriched for these cells by first depleting CD15+ cells to remove CD15+CD10+ granulocytes 
before proceeding to positive selection of CD10+ cells. The fraction of BCPs in the final 
population was assessed by CD19 staining and FACS analysis of the CD10-selected 
population. The final yield after CD10 selection varied between 0.3 x 106 and 6.1 x 106 cells, 
and the fraction of CD19+ cells within this population varied between 68 and 95%. As for 
BCP-ALL blasts, only the CD19+ cells were included in cell death analyses, whereas the total 
population of selected cells were included in the measurement of total cellular cAMP levels.  
 
It may be questioned whether the population of normal BCPs isolated for our experiments 
constitutes a true normal counterpart of the BCP-ALL blasts. CD10+ BCPs (used in cAMP 
measurements) encompass cells in all stages from CLP to immature B lymphocytes, and 
CD10+CD19+ BCPs (analyzed in cell death experiments) include cells in all stages from pro-
B to immature B lymphocytes (Figure 29). We did not conduct further immunophenotypic 
characterization of the normal BCP material, and can therefore not account for the relative 
contribution of distinct BCP cell subpopulations in the isolated BCPs. The BCP-ALL blasts 
used in our study are all classified into either B-II (common B) or B-III (pre-B) subtypes, and 
thus resemble relatively early stages of normal B lymphocyte development. To avoid 
additional reduction in cell yield, complicating the performance of assays, we did not perform 
further sorting of normal BCPs to obtain a cell population representing a more limited span of 
B lymphocyte development.  
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In addition, the concern of poor age matching of patient and healthy control groups can be 
raised. The use of properly matched control groups was not appropriate in our study, because 
it would have involved young children as donors of considerable volumes of BM. 
Considering the constrains imposed by practical and ethical considerations mentioned above, 
we believe that our choice of isolation method for normal BCPs resulted in a cell population 
representing an acceptable and relevant normal counterpart for BCP-ALL blasts. 
 
Bone marrow-derived stromal cell layers 
BM stroma is a term denoting cells anchored in the BM cavity and includes endothelial cells, 
reticular cells, fibroblasts, adipocytes, and macrophages. They grow readily in culture, 
forming adherent layers capable of supporting human myelo- and lymphopoiesis [573]. The 
stromal cell layers were prepared from methylcellulose-separated buffy coat layers of normal 
BM aspirates. Cells were grown in the presence of corticosteroids which ensure cellular 
heterogeneity as opposed to stroma grown in the absence of corticosteroids resulting in a 
morphogenically homogenous monolayer of BM-derived fibroblasts [573]. The cellular 
composition of the established stromal layers was not determined. The ability of the stromal 
layers to support blast survival diminished over time, and the cell layers were therefore used 
in experiments within one week after confluent growth was achieved.  
 
Ethical considerations 
There are several ethical concerns to consider when collecting material from patients and 
voluntary controls. In the case of our study, the patient material was collected concomitantly 
with diagnostic BM aspiration performed during general anaesthesia, thus representing no 
additional medical procedure for the children. The volume of donated BM was 1-3 ml, which 
by the involved paediatricians was considered not to cause any significant additional 
deterioration of the patient’s residual BM function. In spite of this, one should always be 
sensitive to the additional psychological burden imposed on parents and patients asked to 
participate in a scientific study during such a turbulent and disturbing phase of their lives. 
Regarding the healty donors, they were recruited amongst medical students on a voluntary 
basis. Aspiration of 50-100 ml of BM was performed from the posterior iliac crest under local 
anaesthesia. The procedure is experienced as painful but tolerable by volunteers, and is 
associated with minimal risk of serious complications. The collection of BM material from 
patients and healthy volunteers was approved by the Regional Ethics Committee of Norway, 
region Sør-Øst A, and recommended by Competent Authorities. 
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7.1.2 Modulation of cAMP levels and signalling 
7.1.2.1 Adenylyl cyclase activation by forskolin 
Forskolin is a diterpene compound with the ability to activate all tmACs [574;575] with the 
exception of tmAC IX [576;577]. It has no effect on sAC [496;578]. Independently of its 
effect on ACs, forskolin has been demonstrated to affect voltage-gated K+ channels [579] and 
glucose transporters [580]. Upon addition to cell culture, forskolin induces a rapid and 
pronounced elevation of cAMP levels. The effect on cAMP levels is transient, but in contrast 
to Gs-coupled GPCR stimulation in which cAMP return to base-line levels within 1-2 hours, 
cAMP in forskolin-treated cells does not completely return to preinduction levels (H. K. 
Blomhoff, unpublished results).  
 
7.1.2.2 cAMP analogues 
The cell-permeable synthetic cAMP analogue 8-(4-chlorophenylthio)-cAMP (8-CPT-cAMP) 
was used to exclude the possibility that the observed effects of forskolin could be due to AC-
independent signalling. As 8-CPT-cAMP is relatively PDE resistant, its use carries the similar 
risk to forskolin in inducing a supraphysiological cAMP response both in terms of amplitude 
and duration. 8-CPT-cAMP is a potent agonist of PKAs; however, it is also a potent EPAC 
agonist. Therefore, 8-CPT-cAMP is not suitable as a tool to discriminate between effects 
channelled throught these two groups of cAMP effector proteins. To distinguish between 
PKAs and EPACs as the likely cAMP effector in our experimental system, we made use of 
the EPAC-specific agonist 8-pCPT-2’-O-Me-cAMP [581], which due to methylation of the 
2’-ribose hydroxyl group, is an extremely poor PKA activator. 
 
7.1.3 DNA-damaging treatment 
DNA can be damaged in a number of ways in an experimental setting to study pathways that 
are involved in DDR signalling. The mode of action of the DNA-damaging agents used in the 
present study is briefly explained below. 
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7.1.3.1 Ionizing radiation 
IR consists of subatomic particles or electromagnetic waves that contain sufficient energy to 
detach electrons from atoms, thereby ionizing them. The source of IR used in our experiments 
was 137Cs, yielding high-energy electromagnetic waves termed γ rays. DNA damage by IR 
can result either from the direct ionization and subsequent deionization of the DNA molecule, 
or from ioization of surrounding water resulting in highly reactive free radicals that can react 
with DNA as a secondary event [582]. IR can cause many different types of DNA damage, 
such as single strand breaks (SSBs), DSBs, various types of base damage and DNA-protein 
crosslinks [582-584]. However, in terms of damage with lethal consequences for the cell, 
DNA DSBs are thought to be most important [583;584].  
 
7.1.3.2 Chemotherapeutic drugs 
Cell cycle phase-specific action  
Camptothecin is a cytotoxic alkaloid extracted from the plant Camptotheca acuminata. Its 
semisynthetic, water-soluble derivative Irinotecan is now in common use in the treatment of 
colorectal cancer. It is a topoisomerase I inhibitor, binding to the topoisomerase I-DNA 
complex, thus preventing religation of DNA SSBs in the DNA unwinding process during 
DNA replication. This results in DNA DSBs that are selectively imposed during the S phase 
of the cell cycle [585].  
 
Cell cycle phase non-specific action 
Doxorubicin and daunorubicin are anthracyclins that act by direct binding via intercalation 
between base pairs in the DNA helix. Doxorubicin is also a powerful iron chelator, and the 
iron-doxorubicin complex can bind DNA, producing free radicals that can act directly on the 
neighbouring DNA molecule. In addition, it can act as an inhibitor of topoisomerase II, thus 
inhibiting DNA repair. The end result is blockade of DNA and RNA synthesis and 
fragmentation of DNA [585].  
 
Cyclophosphamide is an alkylating agent of the nitrogen mustard type. It is metabolized and 
activated in the liver, and acts by alkylation and direct binding to DNA, resulting in DNA 
crosslinking. In addition, it similarly affects RNA, resulting in inhibition of protein synthesis 
[585]. Due to the need of metabolic activation, we have used the cyclophosphamide derivative 
4-hydroperoxycyclophosphamide (4-OOH-CP). In aqueous solution, this molecule rapidly 
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generates 4-hydroxycyclophosphamide that further degrades to phosphoramide mustard and 
acrolein. These three latter compounds are all active metabolites of cyclophosphamide in vivo 
[585]. In addition, H2O2 and OH radicals are produced which might contribute to the 
cytotoxic effect of 4-OOH-CP in vitro.  
 
Cisplatin is a synthetic platinum-based drug which covalently binds DNA, resulting in intra- 
and inter-strand crosslinks creating cisplatin-DNA adducts and preventing DNA, RNA and 
protein synthesis [585].  
 
7.1.3.3 The selective use of different DNA-damaging treatments  
We had previously shown that cAMP, as a result of its ability to attenuate DNA replication, 
inhibits cell death induced by S phase-specific cytotoxic drugs [556]. In paper III, we wished 
to examine this effect of cAMP in EBV-infected B lymphocytes, which are defective in AC 
activation. We therefore utilized the S phase-specific cytotoxic compound camptothecin. 
 
In paper I, we aimed to study the possible inhibitory effect of cAMP on DDR signalling per 
se. Therefore, we wished to avoid the presumed inhibitory effect of cAMP on the extent of 
induced DNA damage associated with the use of S phase-specific cytotoxic drugs. To achieve 
this, we used IR and DNA-damaging chemotherapeutic compounds that act in a cell cycle 
phase non-specific manner. With the exception of ciplatin, we used drugs that are common 
constituents of BCP-ALL treatment regimens such as anthracyclins and cyclophosphamide. 
 
In papers I, II and IV, we extensively used IR as a means of introducing DNA DSBs despite 
the rare use of this treatment modatlity in BCP-ALL. The reason for this is that IR represented 
a readily available source of DNA damage that produced highly reproducible results both in 
the BCP-ALL cell line Reh and in primary BCP-ALL cells. The dose-responses to the 
different chemotherapeutic drugs were much more variable, especially within primary BCP-
ALL samples, representing a challenge when working with limited cell material of limited in 
vitro viability. We therefore chose to perform most of the experiments using IR, and 
subsequently confirm the generalizability of some of the key results by using clinically 
relevant chemotherapeutic drugs in selected experiments. 
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7.1.4 Modulation of p53 levels  
7.1.4.1 Knock-down of p53 by transfection 
In order to verify our notion that the inhibitory effect of cAMP on cell death was a 
consequence of the effect of cAMP on p53 levels, we aimed to investigate the effects of 
cAMP in the absence of p53. This was achieved in part by utilizing the lymphoid isogenic cell 
lines TK6 and WTK1 which differ in their p53 status. However, as the bulk of our 
experimental work was performed on Reh cells, we sought to knock-down p53 in this cell line 
by transfection. Good transfection efficiency is generally difficult to achieve in lymphoid 
cells. We used the Amaxa Nucleofector technology, an electroporation-based method in 
which an optimized nucleofector solution and electrical parameters are combined to target 
plasmid DNA into the cell nucleus to trigger rapid and enhanced gene expression. This 
method is also suitable for use with small interfering RNAs (siRNAs). The viability of Reh 
cells after transfection was approximately 80%. For plasmid DNA, a transfection efficiency of 
30-35% was achieved as measured by the expression of green fluorescent protein (GFP) 24 
hours after transfection with the pMax-GFP control plasmid provided by Amaxa. For siRNA 
the transfection efficiency was approximately 90% as measured by the incorporation of 
fluorescein-tagged control siRNA 2 hours after transfection (E. H. Naderi, unpublished 
results). 
 
The pXJ-E6 plasmid encodes the E6 protein from HPV16, one of the HPV strains associated 
with high risk of cervical cancer development. E6 recruits the cellular ubiquitin ligase E6AP, 
facilitating p53 polyubiquitination and proteasomal degradation as described in section 
4.5.4.3. Transfection of Reh cells with pXJ-E6 resulted in a substantial but transient knock-
down of p53 levels with the maximum effect observed approximately 24 hours after 
transfection. Transfection with siRNA against p53 yielded slightly better knock-down, with 
maximum suppression of p53 levels observed after 8 hours. In an effort to circumvent the 
problem of limited transfection efficiency of Reh cells, we aimed to establish stably 
transfected Reh cells using either the pXJ-E6 plasmid or an inducible p53 short hairpin RNA 
(shRNA)-producing plasmid. However, the establishment of such clones expressing sufficient 
amounts of the relevant plasmid product was not successful. 
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7.1.4.2 Activation of p53 by nutlin-3 
Nutlins belong to a group of cis-imidazoline compounds identified in a high-throughput 
screening of synthetic chemicals capable of inhibiting the p53-HDM2 interaction. One of the 
enantiomers of nutlin-3, termed nutlin-3a was demonstrated to be the most potent, with an 
IC50 value of 0.09 μM [444]. Using X-ray crystallography, it has been shown that nutlins bind 
to the p53-binding site of HDM2 [444]. Nutlin-3 has since its discovery become a valuable 
molecular tool in cell biology, capable of causing p53 accumulation and activation in the 
absence of genotoxic stiumuli. In vitro studies have demonstrated that nutlin-3 is able to 
induce apoptosis in virually all the investigated primary haematological malignancies that 
express wt p53, suggesting that downstream defects of the p53-induced apoptotic pathway are 
uncommon events in these cancers. This is contrasted to the situation observed in cell lines 
originating from wt p53-expressing solid tumours in which the cell cycle arrest function 
appears to be universally preserved, while the apoptotic response vary considerably (reviewed 
in [586]). Treatment of Reh cells with 10 μM of the racemic mixture of nutlin-3 enantiomers 
was found to stimulate the accumulation of p53 to a level comparable to that induced by 10 
Gy of IR, and lead to apoptotic cell death. The level of nutlin-3-induced death in Reh cells 
was lower than that observed with 10 Gy of IR, probably reflecting the mere accumulation of 
p53 induced by nutlin-3 in the absence of DNA damage-induced p53 PTMs and activation of 
additional signalling pathways.  
 
7.1.5 Measurement of cell death and apoptosis 
Recently, a “Guideline for the use and interpretation of assays for monitoring cell death in 
higher eukaryotes” was published [587], in which the authors review the plethora of methods 
used in the study of cell death and discuss their strengths and pitfalls. In their conclusion, two 
fundamental questions that need to be addressed in a hierarchical order are highlighted: 1) are 
cells truly dead, and if so, 2) by which subroutine did death occur.  
 
7.1.5.1 Cell death 
As discussed in section 4.3.4, there is still no clearly defined biochemical event that identifies 
a ‘point-of-no-return’ in the process of cell death, and consequently morphological definitions 
still apply [154]. One of these morphological traits easily applicable to in vitro studies is the 
loss of plasma membrane integrity as defined by the incorporation of vital dyes. Propidium 
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iodide (PI) is such a dye, being impermeant to intact plasma membranes, but penetrating the 
damaged membranes of necrotic and late apoptotic cells, intercalating DNA and thus staining 
the cell. In addition, it has the advantage of being a fluorescent molecule, and is therefore 
compatible with flow cytometry analysis [588]. In our experimental settings studying in vitro 
cell culture systems, PI staining quantitated by flow cytometry has been the method of choice 
to establish the presence of cell death. One major advantage of using flow cytometry-based 
methods lies in its detection of changes on a single cell basis. By co-staining procedures, it is 
therefore possible to perform targeted analyses on defined subpopulations of cells. We made 
use of this procedure in studies performed on heterogenous cell populations such as isolated 
BCP-ALL blasts, normal BCPs, and normal peripheral B lymphocytes. By co-staining cells 
with CD19-FITC (fluorescein isothiocyanate) antibodies and PI, we were able to determine 
the fraction of PI-positive cells in the CD19+ subpopulation. 
 
7.1.5.2 Apoptosis 
Having established the appearance of cell death by PI staining, we next aimed to investigate 
the subroutine by which the cell death occurred. For a long time, it has been recognized that 
cells of lymphoid origin are especially prone to undergo apoptosis in response to DNA-
damaging treatment [589]. Consequently, we concentrated our efforts on providing evidence 
that components of the intrinsic apoptotic pathway were activated in the cells. To this end, we 
used several methods based on flow cytometry or immunoblot analysis, the principles of 
which will be briefly accounted for below. 
 
Changes in mitochondrial membrane potential (Δψm) 
Changes in Δψm can be monitored by staining live cells with the fluorochrome 5,5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1). JC-1 is a lipophilic 
dye bearing a delocalized positive charge. In healthy cells, the negative mitochondrial charge 
created by an intact Δψm attracts JC-1, thereby resulting in its accumulation within the 
mitochondria and consequent aggregation. In cells which have lost their Δψm, JC-1 cannot 
accumulate, but remains in its monomeric form in the cytoplasm. Upon excitation, aggregated 
JC-1 emits red fluorescence, whereas monomeric JC-1 emits green fluorescence. Loss of 
Δψm can therefore be monitored by flow cytometry detecting a shift from redhigh/greenlow to 
redlow/greenhigh [590;591].  
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Cleavage of caspase-9, caspase-3, and PARP 
Apoptosis-associated cleavage of caspase-9 and -3 as well as of the caspase-3 substrate 
PARP, can be monitored by the use of antibodies able to recognize the cleaved forms of these 
proteins in conjunction with immunoblot analysis, fluorescence microscopy or flow 
cytometry.  
 
Annexin V labelling 
One of the morphological features of apoptosis is the loss of plasma membrane asymmetry 
with translocation of phosphatidylserine (PS) from the inner to the outer leaflet of the 
membrane. The exposure of PS on the cell surface can be detected by the use of Annexin V, a 
phospholipid-binding protein with high affinity for PS [592;593]. By labelling cells with 
FITC-conjugated Annexin V, cells with exposed PS can be detected by flow cytometry.  
 
TUNEL 
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) is based on the 
principle that cleavage of DNA during apoptosis yields double-stranded low molecular weight 
DNA fragments (mono- and oligonucleosomes) as well as single strand breaks in high 
molecular weight DNA. These breaks can be identified by labelling the free 3’-OH termini 
with the modified nucleotide fluorescein-dUTP catalyzed by the enzyme TdT [594]. The 
appearance of fluorescein-tagged DNA breaks can be detected by flow cytometry or 
fluorescence microscopy.  
 
The specificity of apoptosis detection methods 
None of the above mentioned characteristics of apoptosis are truly specific for apoptosis: 
Δψm dissipation can be transient, caspase activation is involved in non-lethal processes, and 
PS exposure may be reversible (reviewed in [154]). Even TUNEL, which is commonly 
regarded as one of the more apoptosis-specific assays, has its limitations as necrotic cells can 
display extensive DNA degradation [595], and the activation of endogenous endonucleases 
can similarly produce DNA nicks [596]. However, by combining the detection of an 
established cell death marker such as PI with the detection of several of the above-mentioned 
markers of apoptosis, the conclusion that cells in a given context undergo apoptosis can be 
drawn with relative confidence.  
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7.2 General discussion 
7.2.1 Effects of cAMP on the DDR in lymphoid cells 
Previous studies in our laboratory described the mechanism by which cAMP induced a 
transient inhibition of S phase progression by inhibiting DNA replication. Furthermore, it was 
shown that this effect of cAMP resulted in attenuation of the effect of S phase-specific 
cytotoxic drugs when the cells were exposed to these drugs during the cAMP-induced S phase 
arrest [556]. Thus, cell death induced by the topoisomerase I inhibitor camptohecin, the 
alkylating agent hydroxyurea, and the antimetabolite 5-fluorouracil, all of which are regarded 
as highly dependent of ongoing DNA replication for their mode of action [585], was inhibited 
by cAMP. This was in contrast to the inability of cAMP to inhibit cell death induced by the 
tubulin polymerization inhibitor vinblastine, and the microtubule stabilizer paclitaxel, which 
are both considered to be G2/M phase-specific [585]. The above study concluded that cAMP 
inhibited cell death by S phase-specific drugs due to their reduced ability to induce DNA 
damage during S phase arrest, and did not address whether cAMP could directly affect the 
cellular response to DNA damage. The study presented in this thesis was initiated to 
investigate this latter possibility.  
 
To address this question, we made use of IR and DNA-damaging cytotoxic drugs such as 
anthracyclines, cyclophosphamide and cisplatin that are able to induce DNA damage in cells 
independent of ongoing DNA replication (see section 7.1.3). We also changed the 
experimental conditions by exposing cells to cAMP-elevating agents and cytotoxic drugs over 
a prolonged period of time, exceeding the duration of the transient S phase arrest induced by 
cAMP. In paper I, we could demonstrate a profound effect of cAMP on cell death induced by 
all the above-mentioned agents as measured by PI permeability in the BCP-ALL cell line Reh. 
In addition, the generality of this effect was demonstrated by using other lymphoid cell lines 
such as TK6 and EU-3, as well as normal peripheral T and B lymphocytes, and primary BCP-
ALL blasts.   
 
Although it is known that cells of the lymphoid lineage are prone to apoptotic cell death upon 
DNA damage [589], we wished to formally demonstrate that the cell death inhibited by cAMP 
was indeed apoptotic. In paper I, we could demonstrate that IR resulted in loss of Δψm, 
cleavage of procaspase-9 and -3, exposure of PS, cleavage of PARP, and apoptosis-related 
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DNA cleavage as measured by TUNEL. Furthermore, all of these processes were inhibited by 
increasing intracellular cAMP levels. This strongly supports the notion that DNA damage-
induced cell death proceeds through an apoptotic pathway in our cell system, and that cAMP 
inhibits this process.  
 
7.2.2 Mechanisms involved in cAMP-mediated inhibition of DNA damage-
induced apoptosis in lymphoid cells 
7.2.2.1 Effects of forskolin are mediated through AC activation and cAMP production  
Forskolin has been used extensively throughout this study to induce cAMP levels, but as 
forskolin has also been shown to exert effects beyond its ability to activate tmACs [579;580], 
it was important to verify that the observed effects of forskolin could be attributed to elevation 
of intracellular cAMP levels. In paper I, we confirmed this point by showing that the effect of 
a low dose of forskolin could be potentiated by the simultaneous inhibition of cAMP 
degradation by PDEs. In addition, the cAMP analogue 8-CPT-cAMP was found to generally 
mimic the effects of forskolin throughout our experiments.  
 
In paper III, we demonstrated that forskolin is able to induce AC activity in Reh cells, and that 
this leads to cAMP production and activation of PKA. We also showed that EBV infection of 
B lymphocytes leads to an insensitivity of ACs to forskolin treatment, and this was reflected 
in forskolin’s inability to inhibit S phase progression and thus cell death induced by short-
term exposure of cells to camptothecin. We also demonstrated that EBV infection renders B 
lymphocytes insensitive to the inhibitory effect of forskolin on cell death induced by IR or 
long-term camptothecin treatment, and that this defect can be circumvented by treatment of 
cells with 8-CPT-cAMP (E. H. Naderi, unpublished results). Taken together, these findings 
argue in favour of cAMP as the crucial mediator of forskolin’s effect on DNA damage-
induced apoptosis. The mechanistic background for the insensitivity of ACs to forskolin 
treatment in EBV infected cells has not been determined. One possible explanation could be 
provided by the EBV infection-induced overexpression of Epstein-Barr virus-induced 
receptor 2 (EBI2). EBI2 is an orphan, Gαi-associated GPCR which has been demonstrated to 
be constitutively activated in EBV-infected cells [597]. Whether sensitivity to forskolin as a 
growth inhibitor as well as an inhibitor of DNA damage responses can be restored by 
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inhibition of EBI2 activity in EBV-infected cells is currently under investigation in our 
laboratory.  
 
7.2.2.2 cAMP regulates the DDR pathway at the level of p53 protein stability via PKA 
In order to pinpoint the level at which cAMP exerts its effect on DNA damage-induced 
apoptosis, we investigated the effect of cAMP on components of the DDR typically involved 
in the apoptotic signalling induced by DNA DSBs. In paper I, we could show that cAMP did 
not reduce the IR-induced activating phosphorylations of ATM or Chk2; however, it did have 
a profound effect on IR-induced p53 protein levels. Because the cAMP-analogue 8-CPT-
cAMP acts as an agonist of both PKA and EPAC, we wished to address which of these 
effector proteins were involved in mediating the effect of cAMP on p53. To do so, we used 
the EPAC-specific analogue 8-pCPT-2’-O-Me-cAMP, and could show that this compound 
was unable to affect IR-induced p53 accumulation. This result strongly indicates that the 
observed effects of cAMP on p53 levels are mediated by PKA. Accumulation of p53 
following DNA damage is thought to occur primarily as a result of modulation of its protein 
stability [279;280], and to a lesser degree through transcriptional and post-transcriptional 
mechanisms (see section 4.5.2.1). We addressed the mechanisms involved in regulation of 
p53 in paper II and showed that the steady state levels of p53 mRNA were unaffected by both 
IR and cAMP treatment. In contrast, IR was found to profoundly increase the stability of the 
p53 protein. cAMP treatment antagonized this stabilization, restoring the T1/2 of p53 to 
approximately 30 min. 
 
7.2.2.3 The causal relation between cAMP effects on p53 and apoptosis 
In paper I, we demonstrated that in Reh cells exposed to IR, the degree of cAMP-mediated 
inhibition of p53 accumulation correlated with the degree of cAMP-mediated attenuation of 
apoptosis. IBMX (an inhibitor of PDEs) or low doses of forskolin produced minor effects on 
IR-induced p53 accumulation and cell death, whereas the combination of the two, or a single-
agent treatment of cells with higher doses of forskolin or 8-CPT-cAMP led to pronounced 
effects both on p53 levels and cell death. It should be mentioned that most of our immunoblot 
analyses of p53 levels, including those performed for assessment of p53 protein stability, were 
carried out on cells that were harvested 4 hours after IR. At this time point, p53 levels are not 
as efficiently suppressed by 8-CPT-cAMP as by forskolin, which could seem to be in conflict 
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with the consistent observation of a superior effect of 8-CPT-cAMP on cell death. However, 
examination of p53 expression (paper II, Figure 1A) shows that 8-CPT-cAMP and forskolin 
suppresses p53 levels with slightly different kinetics. Whereas 8-CPT-cAMP inhibits 
expression of p53 less efficiently at early time points, it excerts a slightly more potent 
inhibitory effect at later time points (from 8 hours post-IR and onwards). There is thus a good 
correlation between effects on p53 levels and cell death also with regard to forskolin and 8-
CPT-cAMP. 
 
Encouraged by the above-mentioned correlation between p53 levels and cell death 
suppression by cAMP, we aimed to establish a causal relationship between the inhibitory 
effect of cAMP on IR-induced p53 accumulation and its inhibitory effect on cell death. p53-
mediated signalling is generally conceived to play an important role in connecting DDRs to 
the execution of apoptosis in lymphocytes, as demonstrated by severe apoptotic defects of 
lymphoid cells in Trp53 KO mice after exposure to IR [598]. However, because some 
mitogenically activated or transformed lymphocytes have been shown to display a p53-
independent DNA damage-induced apoptosis [598], we considered it important to confirm the 
role of p53 in DNA damage-mediated cell death in Reh cells. To this end, p53 was knocked 
down by transient transfection with HPV E6 or p53 siRNA prior to treatment of cells with 
forskolin and IR. As shown in paper I, this resulted in partial protection agains cell death; 
however, forskolin retained its ability to inhibit the remaining level of cell death (E. H. 
Naderi, unpublished results). We believe this probably reflects the heterogeneity of cells 
produced by transfection due to the incomplete transfection efficiency of Reh cells, as 
accounted for in section 7.1.4.1. Thus, one fraction of cells is successfully transfected, with 
efficient knock-down of p53, and these cells consequently display pronounced apoptotic 
resistance. Another fraction of cells retain sufficient p53 activity to undergo apoptosis in 
response to IR, and these will also retain their sensitivity to cAMP. Although these 
transfection experiments supported the notion that p53 is important for DNA damage-induced 
apoptosis in Reh cells, they did not provide evidence for a causal relationship between cAMP-
induced p53 suppression and cell death inhibition.  
 
To address this question, we first investigated the effects of cAMP on the lymphoblast cell 
line WTK1, a p53-mutated isogenic counterpart of TK6. In paper I, we demonstrated that 
WTK1 cells were highly resistant to IR-induced cell death compared to TK6 cells. 
Importantly, the remaining levels of IR-induced cell death observed in WTK1 cells were not 
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inhibited by cAMP.  Furthermore, we found that in Reh cells, cell death induced by cytotoxic 
compounds that have been demonstrated to work in a p53-indepentent fashion such as 
menadione [599;600] and staurosporine [363;369;601], could not be inhibited by cAMP. 
Finally, in paper II, we showed that nutlin-3 could induce p53 accumulation and cell death in 
Reh cells. In contrast to the potent ability of forskolin to inhibit IR-induced p53 accumulation 
and cell death, it only slightly inhibited nutlin-3-induced p53 accumulation and had no 
inhibitory effect on nutlin-3-induced cell death. Taken together, we believe that our results 
strongly suggest a causal relationship between the observed cAMP-induced p53 suppression 
and cell death inhibition.  
 
7.2.2.4 The effect of cAMP on p53 protein stability is HDM2-dependent 
As discussed in section 4.5.2.1, the main regulatory mechanism for the stability of the p53 
protein is the rate of its proteasomal turnover. The priming of p53 for proteasomal 
degradation is under the control of several E3 ubiquitin ligases of which HDM2 has retained 
its position as the main player, in particular with regards to DDR-associated changes in p53 
degradation [305;417]. Having demonstrated that cAMP affects p53 accumulation at the level 
of protein stability, we proceeded in paper II to show that this effect depended on the presence 
of functional proteasomes. Furthermore, we could demonstrate that cAMP counteracted the 
IR-induced reduction in p53 ubiquitination. To examine whether the effect of cAMP on DNA 
damage-induced p53 accumulation was mediated through HDM2, we made use of the specific 
inhibitor of p53-HDM2 interaction nutlin-3 (see section 7.1.4.2). By exposure of cells to IR in 
the presence of nutlin-3, we could show that cAMP was no longer able to inhibit IR-induced 
p53 accumulation, suggesting that the observed effect of cAMP on p53 levels was indeed 
HDM2-dependent.  
 
7.2.2.5 cAMP promotes p53-HDM2 interaction 
When approaching the question of how cAMP could affect HDM2-mediated p53 
ubiquitination, we hypothesized three possible mechanisms: 1) augmentation of HDM2 
levels, 2) augmentation of p53-HDM2 interaction, and 3) augmentation of HDM2 E3 
ubiquitin ligase activity.  
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Modulation of HDM2 levels 
HDM2 expression is tightly regulated by multiple factors both at a transcriptional and post-
translational level during the DDR [208;323;327] (see section 4.5.2.1.1). In paper II, we used 
immunoblot analysis to assess whether cAMP could influence the levels of HDM2. As 
expected, HDM2 levels were transiently downregulated within 1 hour after IR treatment (E. 
H. Naderi, unpublished results). However, by 2 hours post-IR, HDM2 expression was 
elevated above basal levels. By 4 hours, it had increased approximately 2-fold before levelling 
off. Forskolin did tend to increase IR-induced HDM2 levels by 4 hours, however, by 6 hours, 
forskolin significantly reduced IR-induced HDM2 levels, and by 8 hours forskolin had no 
effect on IR-induced HDM2 levels. Because cAMP was found to exert an inhibitory effect on 
p53 ubiquitination not only at 4 hours post-IR as shown in paper II, but also at 6 and 8 hours 
(S. Naderi, unpublished results), we do not believe that cAMP-induced alterations of IR-
induced HDM2 levels can account for the observed effects of cAMP on p53 ubiquitination. 
  
Modulation of p53-HDM2 interaction 
As discussed in section 4.5.2.1.1, modulation of p53-HDM2 interaction is assumed to play an 
important role in the regulation of p53 levels after DNA damage (reviewed in [305]). In paper 
II we investigated the effect of cAMP on p53-HDM2 interaction by immunoprecipitation of 
p53, followed by immunoblot analysis, to assess the amount of HDM2 that co-
immunoprecipitated with p53. As expected, we found that IR led to dissociation of p53-
HDM2 complexes. However, whereas this dissociation was maintained over time in cells that 
were treated with IR alone, co-treatment of cells with forskolin led to restoration of p53-
HDM2 interaction by 4 and 8 hours. Interestingly, the stimulatory effect of forskolin on p53-
HDM2 association was also observed in non-irradiated cells, providing an explanation for the 
observed repression of basal p53 levels by forskolin (papers I, II, IV).  
 
DNA damage-induced N-terminal p53 phosphorylation has long been in focus as an important 
inhibitor of p53-HDM2 interaction, but the role of these PTMs has in recent years been 
increasingly challenged [305;417] (see section 4.5.2.1.1). In paper II, we assessed the effect of 
IR and forskolin on phosphorylation of p53 on S15, S20 and T18. IR was shown to induce 
phosphorylation at all these sites as expected; however, forskolin inhibited the IR-induced 
phosphorylation of p53 only on S20. Given recent evidence suggesting that p53 
phosphorylation on T18 but not S15 or S20 inhibits its interaction with HDM2, 
[192;193;298;299], we believe that the cAMP-mediated modification of p53 N-terminal 
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phosphorylation is an unlikely mechanism underlying the stiumulatory effect of cAMP on 
p53-HDM2 interaction. After our initial report on the inhibitory effect of cAMP on DNA 
damage-induced accumulation of p53 and apoptosis in Reh and primary BCP-ALL cells 
(paper I), similar results were published on the BCP-ALL cell line Nalm-6 [602]. This report 
claims that cAMP suppresses phosphorylation of p53 on a number of serine residues, 
including S15 and S20, and suggests that the inhibitory effect of cAMP on p53 levels is 
attributable to attenuation of p53 phosphorylation at these sites. However, because the levels 
of phospho-serine p53 were not normalized to the total p53 levels, we do not feel convinced 
that the cAMP-induced reduction in phospho-serine p53 reported in this paper does more than 
reflect the reduction in total p53 levels.  
 
As accounted for in section 4.5.2.1.1, acetylation of p53 has also been implicated in the 
modulation of p53-HDM2 interaction. In addition to reducing the affinity between p53 and 
HDM2 [307], acetylation can directly contribute to the stabilization of p53 by competing with 
ubiquitin moieties for available lysines [308-310]. Recent data from our laboratory 
demonstrates that p53 acetylation is indeed induced by IR in a cAMP-inhibitable manner (S. 
Naderi and M. M. Kloster, unpublished results). The possible role of these modifications for 
cAMP-induced restoration of p53-HDM2 interaction and p53 ubiquitination in Reh cells is 
currently under investigation.  
 
Modulation of HDM2 E3 ubiquitin ligase activity 
The enzymatic activity of HDM2 can be affected by various PTMs [316-318] as well as 
HDM2-interacting proteins [319-322] (see section 4.5.2.1.1). We assessed the ubiquitin ligase 
activity of HDM2 towards p53 in an in vitro ubiquitination assay with HDM2 
immunoprecipitates. Although the experiments have proven technically difficult to perform 
and the results so far have been difficult to interpret, we have no preliminary indications that 
forskolin treatment enhances HDM2 enzymatic activity towards p53 (S. Naderi, unpublished 
results). 
 
In conclusion, our results support a mechanism of cAMP action which involves the promotion 
of p53-HDM2 interaction rather than effects on HDM2 expression levels or enzymatic 
activity.  
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7.2.2.6 Is the inhibitory effect of cAMP on cell death induced by S phase-specific and 
non-S phase-specific DNA-damaging agents mediated by two distinct 
mechanisms? 
The effect of cAMP on cell death induced by DNA-damaging cytotoxic agents has so far in 
the discussion been regarded as proceeding through two distinct mechanisms of action. In 
paper III, the result obtained with short-term treatment of cells with the S phase-specific 
cytotoxic drug camptothecin within the time frame of cAMP-induced S phase arrest, led us to 
assign the inhibitory effect of cAMP on cell death to its ability to inhibit DNA replication and 
thus limit the degree of DNA damage inflicted. In papers I, II and IV we exposed cells to a 
long-term treatment with cAMP-increasing agents in combination with non-S phase-
dependent inducers of DNA damage, and attributed the inhibitory effect of cAMP on cell 
death to its ability to directly inhibit the DDR pathway at the level of p53.  
 
This distinction might be overly simplified. The inhibitory effect of short-term treament of 
cells with forskolin on S phase-specific drug-induced cell death can be recapitulated by the 
DNA polymerase inhibitor aphidicolin (S. Naderi, unpublished results). This strongly 
supports a role for cAMP in limiting the extent of DNA damage induced by camptothecin or 
other S phase-specific cytotoxic drugs. However, it is possible that the forskolin-induced S 
phase arrest does not completely abolish the ability of campothecin to induce DNA damage, 
and additional inhibitory effects of cAMP on DNA damage-induced p53 accumulation might 
therefore contribute to the final inhibition of cell death.  
 
Conversely, it can be speculated that the cAMP-mediated suppression of p53 levels observed 
in papers I, II and IV, could simply reflect reduced levels of DNA damage as a result of the 
inhibition of DNA replication by cAMP. However, throughout these studies, we used S 
phase-independent DNA-damaging agents and therefore assumed that the elevation of 
intracellular cAMP levels did not affect the degree of DNA damage in a significant way. 
Nonetheless, although cell cycle phase non-specific chemotherapeutic drugs do not depend on 
ongoing DNA replication for their mode of action, many are shown to exert maximal 
cytotoxicity during S phase [585]. Therefore, the use of this class of DNA-damaging agents 
could be associated with cAMP-induced inhibition of DNA damage levels. Although we have 
not measured the level of DNA damage in cells in the presence or absence of elevated cAMP, 
several lines of evidence indicate that possible variations in the extent of DNA damage cannot 
alone account for the effect of cAMP on p53 accumulation. First, we have used IR extensively 
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to induce DNA damage. The pattern of sensitivity to DNA damage differ between IR and 
most cytotoxic drugs, as it is the cells in late G2/M phase that are most radiosensitive whereas 
cells in late S phase are most radioresistant (reviewed in [603]). Second, if cAMP were to 
inhibit the level of DNA damage, then short-term elevation of intracellular cAMP levels at the 
time of infliction of DNA damage would be expected to have an inhibitory effect on cell 
death. However, we have observed that short-term exposure of cells to forskolin or 8-CPT-
cAMP around the time of radiation has minimal effect on the resulting cell death (E. H. 
Naderi, unpublished results). Third, in paper I we observed no inhibition of IR-induced 
activation of ATM or Chk2 upon treatment of cells with cAMP-elevating agents, which 
would have been expected if cAMP had a major inhibitory effect on the level of inflicted 
DNA damage. Fourth, we have shown that cAMP also inhibits p53 levels in the absence of 
DNA damage. This is documented in various p53 immunoblots in papers I, II and IV, and is 
also shown to be statistically significant for BCP-ALL blasts in paper IV. This strongly 
suggests that cAMP downregulates p53 levels independently of DNA damage. One possible 
problem with this argument could be the finding that transformed cells have been shown to 
display constitutive DNA damage due to oncogene-driven replication stress [406]. However, 
in paper II we show similar suppression of basal p53 levels in phytohaemagglutinin (PHA)-
stimulated normal peripheral CD4+ T lymphocytes. As oncogene-driven replication stress has 
been shown to be a tumour specific phenomenon, and not a general feature of mitotically 
stimulated cells [406], the downregulation of p53 by cAMP in PHA-stimulated T 
lymphocytes is highly unlikely to be attributable to differences in DNA damage levels.  
 
In conclusion, we believe that cAMP can suppress cell death induced by DNA-damaging 
treatment through two distinct mechanisms: 
1) When cells are treated with S phase-specific drugs during the transient cAMP-induced S 
phase arrest, cAMP limits the extent of DNA damage inflicted. 
 2) cAMP exerts a direct inhibitory effect on the DDR pathway by attenuating the 
accumulation of p53. This is due to cAMP-induced augmentation of the p53-HDM2 
interaction which counteracts DNA damage-associated reduction in p53 ubiquitination and 
consequent proteasomal degradation.  
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7.2.3 Clinical implications of the cAMP effect on p53 and apoptosis using 
BCP-ALL as a model system 
Having demonstrated that cAMP can inhibit p53 accumulation and the consequent apoptotic 
response in various lymphoid cell systems, we wished to examine the possible clinical 
relevance of our findings. As described in section 4.5.4.1, p53 is inevitably activated during 
malignant transformation, possibly due to oncogene-induced p14ARF activation [394] or 
oncogene-induced replication stress with consequent activation of the DDR pathway [406]. 
Due to its ability to induce apoptosis and senescence in transformed cells, normal p53 
function is considered to be a major barrier against malignant development, and is thus 
assumed to be universally suppressed in cancers [4;355]. This can either be achieved through 
direct mutational inactivation, through inhibition of wt p53 levels or activity, or through 
defects in downstream pathways [355]. Most of our experimental work has been performed 
on Reh, which is a BCP-ALL derived cell line. Wt p53 is almost always preserved in BCP-
ALL [604], and furthermore, downstream defects in the p53 pathway appear to be a rare 
phenomenon in haematological malignancies (reviewed in [586]). This would indicate that 
suppression of wt p53 levels or activity is likely to be important in the pathogenesis of BCP-
ALL. Based on our finding in Reh cells that elevated cAMP levels are able to suppress 
induction of wt p53 accumulation in an HDM2-dependent manner with consequent 
suppression of apoptosis, we hypothesized that deregulation of cAMP signalling might be 
utilized as an anti-tumour-suppressive mechanism by BCP-ALL blasts. 
 
7.2.3.1 The effect of cAMP as a malignancy-associated trait 
In order to verify that the observed effects of cAMP in Reh cells were representative of BCP-
ALL, we initiated a pilot study on primary BCP-ALL blasts isolated from paediatric patients 
at initial diagnosis. In papers I and IV, we showed that these primary cancer cells uniformly 
responded to augmented cAMP signalling in a manner similar to what we had previously 
observed in Reh: 1) p53 levels were induced upon treatment with IR or DNA-damaging 
chemotherapeutic drugs commonly used in BCP-ALL treatment, 2) cAMP-elevating agents 
suppressed both basal and DNA damage-induced p53 levels, and 3) cAMP-elevating agents 
potently suppressed DNA damage-induced cell death. In addition, cAMP could significantly 
inhibit spontaneous cell death during in vitro culturing of these blasts, an interesting finding 
that stands in contrast to what we have generally observed in cell lines and in cultured normal 
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peripheral T and B lymphocytes, in which augmented cAMP signalling has either no effect or 
a slightly toxic effect. 
 
To investigate whether the protective effect of cAMP signalling was a general feature of 
BCPs, we isolated normal BCPs from BM aspirates of healthy controls and exposed them to 
cAMP and IR. Due to the limited BCP cell yield from normal BM, only three of the collected 
samples were available for such treatment with subsequent cell death analysis. The results 
presented in paper IV show reproducible results between these three samples: IR yielded 
limited cell death, and forskolin could neither protect cells from spontaneous nor IR-induced 
cell death. Indeed, forskolin had a slight toxic effect on BCPs. Although performed on only 
three samples, the consistency of results is suggestive of a real difference in cAMP-
responsiveness between normal BCPs and transformed BCP-ALL blasts. This finding is also 
supported by a previous report, demonstrating an apoptotic effect of cAMP in CD10+ BCPs 
which was correlated with a decrease in MCL-1 expression [605].  
 
7.2.3.2 Possible implications of cAMP signalling for BCP-ALL development  
The observed protective effect of cAMP elevation on blast survival together with its 
suppressive effect on p53 levels, suggested that augmented intracellular cAMP levels might 
be selected for during the course of malignant transformation. To test this hypothesis, we first 
measured total cellular cAMP levels in BCP-ALL blasts and compared it to that of normal 
BCPs isolated from healthy BM donors (paper IV). We found no indications of elevated 
cAMP levels in the leukaemic blasts compared to untransformed BCPs. In light of the tight 
spatiotemporal control of physiological cAMP signalling described in section 4.7.3, the lack 
of such differences in gross cAMP content might not be unexpected. Nonetheless, given our 
finding that cAMP exerts an inhibitory effect on p53 expression in BCP-ALL blasts, together 
with the published studies describing increased cAMP levels in tumour materials [542;543], 
we found it important to explore the possibility of substantial transformation-related changes 
in intracellular cAMP concentrations. 
 
Because there was no indication of constitutively upregulated cAMP levels in BCP-ALL 
blasts, we considered the possibility that cAMP-augmenting signals might be provided to the 
blasts by the BMME. Similar to solid tumours that are known to exist in interdependence with 
their surrounding tumour stroma (see section 4.1.3), it is well established that leukaemic 
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blasts in vivo exist in a tight interplay with cells of the BMME, being provided with signals 
conveyed through secreted factors, cell-cell and cell-matrix interactions [606;607]. Such 
signalling has also been implicated in the development of treatment resistant subclones 
(reviewed in [606;607]). To investigate whether interaction with BM stromal cells could 
recapitulate the observed effects of cAMP on BCP-ALL blasts, we co-cultured the blasts on a 
confluent layer of a BM-derived stromal cell line or primary stromal cells. In paper IV, we 
show that such co-culturing can indeed protect BCP-ALL blasts against spontaneous and 
DNA damage-induced cell death. Furthermore, we demonstrate that this effect is in large part 
dependent on cell-cell interactions, because much of the protective effect is lost when blasts 
are physically separated from the stromal cells by porous well inserts. The observation that 
stromal cells suppress the expression of p53 in BCP-ALL blasts, an event also shown to occur 
upon elevation of cAMP levels, indicates that stromal cells might utilize cAMP signalling to 
exert their pro-survival effect on BCP-ALL blasts. Preliminary results with PKA inhibitors 
suggest that cAMP-induced PKA activity is implicated in the protective signalling provided 
by stromal cells to BCP-ALL cells. 
 
There is also a possibility that cAMP levels per se are not elevated in transformed cells, but 
that signalling events downstream of cAMP might be aberrantly activated. As described in 
section 4.7.4.1, constitutive upregulation of RIα and the relative increase in the ratio of PKAI 
to PKAII has been implicated in malignant transformation (reviewed in [549;550]). In 
accordance with this, the BCP-ALL cell line Reh has been shown to expresses only the PKAI 
isoform [608]. This together with our demonstration that PKA inhibition can potentiate DNA 
damage-induced cell death in BCP-ALL blasts, warrants further investigation into the relative 
expression of PKA isoforms in primary BCP-ALL blasts.  
 
The suggestion that the transformation process of BCPs favours the selection of enhanced 
cAMP signalling to quench the transformation-related activation of p53, should be weighed 
against the possible negative effect of cAMP on tumour progression due to its growth-
inhibitory effect. Indeed, cAMP has been shown to exert an anti-proliferative effect on cells 
of the lymphoid lineage [554;609;610] including Reh [554;555;611]. Assuming that cAMP 
also inhibits the proliferation of primary BCP-ALL blasts, it may be suggested that this effect 
of cAMP might counteract the selection of augmented cAMP signalling as a p53-neutralizing 
event. However, one could envision a scenario in which the BM normally provides BCPs with 
stimuli generating a certain level of cAMP sufficient for the execution of various cell 
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physiological processes, but not enough to compromise their proliferative capacity. Once 
faced with oncogenic transformation, these same signalling pathways might be taken 
advantage of by providing sufficient cAMP levels to suppress oncogene-induced p53 
accumulation, and thus become part of an essential transformation-related survival pathway.  
 
7.2.3.3 Possible implications of cAMP signalling for BCP-ALL treatment  
The possibility that cAMP can be incorporated in a transformation-related survival pathway 
can potentially be problematic during treatment of the leukaemia, as it would compromise the 
induction of p53 by DNA-damaging treatment modalities. In support of this, our results 
presented in papers I and IV clearly demonstrate the ability of cAMP to inhibit chemotherapy- 
and radiation-induced p53 accumulation and cell death in BCP-ALL blasts. Furthermore, in 
paper IV, we demonstrate that stromal co-culture can limit radiation-induced p53 
accumulation and cell death, an effect that tends to be reversed by PKA inhibitors. These 
findings suggest a role for PKA inhibitors in the potentiation of conventional BCP-ALL 
treatment. The observation that the normal BCPs used in our study do not show enhanced 
survival upon augmentation of cAMP levels, indicates the possible presence of a therapeutic 
window for such treatment, allowing for the suppression of a survival pathway which is active 
in the leukaemic blasts but not in their normal counterparts.  
 
The idea of manipulating the cAMP pathway as part of cancer treatment is not new. As briefly 
reviewed in section 4.7.4.1, deregulation of several of the signalling components of the cAMP 
pathway have been implicated in cancer development. Regarding reported effects of elevated 
cAMP levels in experimental settings, the results on spontaneous and DNA damage-induced 
apoptosis appear to be highly cell type-specific. In the haematopoietic system, transformed 
cells of the myeloid lineage have in some studies been shown to be sensitive to cAMP-
induced apoptosis [612;613], whereas other studies have demonstrated cAMP-mediated 
protection against both spontaneous and chemotherapy-induced apoptosis [545;546]. These 
latter reports agree with our findings in lymphoid cells, but whether the mechanisms of action 
involved are similar is uncertain, as non of the above mentioned papers have examined the 
regulation of p53 by cAMP signalling.  
 
Regarding transformed lymphoid cells, however, our results seem to generally contrast the 
published data assigning a pro-apoptotic role for cAMP signalling. PDE inhibitors have been 
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demonstrated to induce both spontaneous apoptosis and to synergize with chlorambucil in B-
CLL [614;615] leading to clinical trials assessing their possible therapeutic potential. Gene 
expression analysis of clinical DLBCL material has demonstrated overexpression of PDE4B 
in fatal/refractory cases, and this has been interpreted as an indication that PDE-induced 
reduction of cAMP levels would be of advantage to the cancer cells, rendering them resistant 
to chemotherapy [616]. These reports of pro-apoptotic effects of cAMP signalling, in 
combination with the already established anti-proliferative effect of cAMP, has encouraged 
speculations into the possible therapeutic use of cAMP-augmenting agents such as PDE 
inhibitors in various lymphoid cancers [541]. B-CLL and DLBCL are both lymphoid 
malignancies of a more mature phenotype than BCP-ALL. Therefore, the conclusion that 
cAMP augmentation might be useful in the treatment of these diseases should not 
automatically discourage the principle of inhibition of cAMP signalling as a potential 
therapeutic approach in BCP-ALL.  
 
Regarding cAMP and ALL, one report demonstrates that cAMP elevation can potentiate 
glucocorticoid-induced cell death in the T lymphoblast cell line CEM as well as in Reh, and 
consequently, cAMP-inducing therapy was suggested to have possible clinical potential also 
in ALL [617]. Glucocorticoid-induced apoptosis in lymphocytes has been shown to proceed 
through a p53-independent pathway [243;372;598], which could explain why cAMP appears 
to have opposing effects on glucocorticoid- and DNA damage-induced cell death. We have 
not reproduced the above-mentioned finding that cAMP augments glucocorticoid-induced 
apoptosis in Reh cells, nor have we examined these effects in the material of primary BCP-
ALL blasts. If indeed our suggestion to combine PKA inhibition with conventional BCP-ALL 
treatment should be translated into clinical use, the possible interference of PKA inhibition 
with glucocorticoid treatment would be important to clarify, as such effects might necessitate 
careful attention to the relative timing of PKA inhibition with respect to chemotherapy and 
glucocorticoid administration. 
 
7.2.3.4 Clinical relevance of cell systems 
When hypothesizing potential clinical implications of laboratory-based results, it is important 
to evaluate the relevance of the cell systems that have been used. Performing experiments on 
primary cells isolated from patients and healthy volunteers certainly brings research one step 
closer to the bedside compared to cell line-based assays; however, the impact of the 
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unphysiological in vitro settings as well as the selection of cell material must be critically 
considered. Regarding the latter point, the cellular origin of BCP-ALL blasts is not definitely 
determined. Depending on the subtype, both HSCs and early B lineage-committed CD19+ 
progenitor cells have been proposed to be the target for the initial genetic hits that produce the 
‘cancer stem cells’ driving the disease (reviewed in [568;569]). These very rare cells then give 
rise to progeny that are arrested prematurely during their differentiation, implying that the 
bulk of leukaemic cells found in the patient’s BM display a phenotype which is more 
differentiated than their transformed cells of origin. As all patients included in our study were 
diagnosed with either B-II (common-B) or B-III (pre-B) subtypes of BCP-ALL, they shared 
the CD10+CD19+ phenotype with the analyzed population of normal BCPs. However, as 
discussed in section 7.1.1.2, the normal BCP cell population comprises a wider spectrum of 
BCP stages, including cells with more mature phenotypes, than the ALL blasts. With respect 
to our speculations into the possible clinical relevance of our findings, there are thus at least 
two important notes of caution that deserve mentioning. First, the concern that we have 
studied the progeny population of cancer cells rather than the very few cells that are probably 
responsible for driving the leukaemia. Secondly, the concern that by comparing the 
responsiveness of the blasts with a heterogenous and probably more differentiated population 
of CD10+CD19+ normal BCPs, we might not be describing a shift in cAMP responsiveness 
resulting from the malignant transformation, but rather a difference arising as a result of B 
lymphocyte maturation. 
 
These potential problems regarding the relevance of our cell systems cannot easily be 
circumvented. The exact nature of ‘cancer stem cells’ for paediatric BCP-ALL is not 
determined [569;618] and their isolation and study is therefore difficult. Furthermore, even 
though ‘cancer stem cell’-directed therapy might be appealing in theory, experimental or 
clinical evidence to prove its superiority over conventional therapy is still pending [619]. 
With respect to our BCP populations, further isolation procedures could have been performed 
to enrich for cells at developmental stages matching more closely those present in BCP-ALL 
samples. Such procedures would have led to additional loss of cell material, and were 
therefore not carried out.  
 
Consequently, bearing the concerns regarding the clinical transfer value of our in vitro 
findings in mind, we nonetheless conclude that our findings on differences in cAMP 
sensitivity of primary BCP-ALL blasts and normal BCPs deserve further attention, and that 
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they lend encouraging support to our hypothesis on the possible role of cAMP in BCP-ALL 
development and treatment. 
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8 CONCLUSIONS 
In this thesis, we have demonstrated that cAMP is an important modulator of DNA damage 
responses in lymphoid cells. The data presented show that: 
 
1) cAMP inhibits DNA damage-induced apoptosis in a variety of lymphoid cells. The 
inhibitory effect of cAMP on apoptosis depends on its ability to attenuate p53 
accumulation. 
 
2) The inhibitory effect of cAMP on p53 accumulation depends on attenuation of p53 protein 
stabilization as a consequence of its augmented interaction with HDM2, resulting in 
maintenance of p53 ubiquitination and proteasomal degradation.  
 
3) cAMP can potently inhibit both basal and DNA damage-induced p53 levels and cell death 
in cultured primary BCP-ALL blasts. This is in contrast to the lack of protective effect of 
cAMP on cell death in normal BCPs. Consequently, we have hypothesized a possible role 
for cAMP signalling in a transformation-associated survival pathway engaged to quench 
oncogene-driven p53 activation. Furthermore, we have proposed that such signalling 
could contribute to resistance against DNA damage-inducing therapy. Our preliminary 
results suggest that PKA inhibitors can be utilized to potentiate the effect of such agents. 
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9 FUTURE PERSPECTIVES 
In light of the results presented in this thesis, we wish to pursue the following lines of 
investigation:  
 
1) Further characterize the mechanisms involved in cAMP-mediated augmentation of p53-
HDM2 interaction. In particular, we intend to explore the possible effect of cAMP on p53 
acetylation levels. 
 
2) Explore the molecular basis for the observed differential effects of cAMP on BCP-ALL 
blasts and normal BCPs. In particular, we intend to investigate whether there are 
differences in expression levels of RI and RII subunits of PKA between these two cell 
types. 
 
3) Validate our hypothesis that the pro-survival effect of BM stromal cells on BCP-ALL 
blasts is in part mediated through cAMP signalling. As we have indications that cell-cell 
interactions are of importance, the possible involvement of stroma-bound ligands for AC-
associated GPCRs as well as gap junction-mediated cAMP transfer will be investigated. 
 
4) Further explore the therapeutic potential of PKA inhibitors. We wish to extend our 
findings indicating a role for PKA inhibition in potentiation of IR-induced cell death to 
DNA-damaging chemotherapeutic compounds commonly used in treatment of BCP-ALL. 
In case of promising in vitro results, we aim to test the feasibility of PKA inhibition as an 
addition to conventional BCP-ALL treatment in vivo. 
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Errata 
The following corrections of the originally submitted manuscript have been approved by the 
evaluation committee and implemented in the final printed version. 
Pages 7-9: Change the order of references 1 and 2, with corresponding changes in the reference 
list. 
Page 18: Figure legend of figure 6: add a full stop at the end.   
Page 20: 2nd line: correct “C. elegance” to “C. elegans”. 
Page 21:  Figure legend of figure 7: remove a double space before “The figure shows…”. 
Page 21:  Figure legend of figure 7: insert a space to correct “C.elegans” to “C. elegans”. 
Page 22:  Last sentence: change “revieved by…” to “revieved in…”. 
Page 24:  First sentence: remove hyphen in “BH-3-only” to “BH3-only”. 
Page 35:  First sentence: remove a space after the oblique, i.e. “kinase/ mitogen” to 
“kinase/mitogen”. 
Page 43:  5th and 6th lines: remove space in “NF- κB” to “NF-κB”. 
Page 46:  8th line: remove double space in “targeted  by” to “targeted by”. 
Page 46:  3rd paragraph, 6th line: remove hyphen in “CBP-/p300” to “CBP/p300”. 
Page 49:  4th line: change “or” to “of”.  
Pages 51-52: Expand “IR” as “ionizing radiation” at first and not second mention, i.e. page 51, 2nd 
paragraph, 15th line should read: “protected from ionizing radiation (IR)-induced 
apoptosis”, whereas page 52, 1st paragraph, 8th/9th line should read: “… come from 
whole body IR of mice”. 
Page 54: 2nd paragraph, 23rd line: change “INK4A” to “p16INK4A”. 
Page 103: 2nd paragraph, last sentence: correct “ovserved” to “observed”. 
Page 106:  3rd line in the heading: correct “mechanims” to “mechanisms” with corresponding 
correction in the index. 
Page 107:  3rd line: remove double space before “Second, if cAMP…”. 
Page 108: 1st paragraph, last line: add left-out word to change “tumour-suppressive” to “anti-
tumour-suppressive”. 
Page 113:  12th line: add left-out word to specify “blasts” as “ALL-blasts”. 

